

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/29038 A2

- (51) International Patent Classification⁷: **C12N 15/00**
- (21) International Application Number: **PCT/US01/31377**
- (22) International Filing Date: **4 October 2001 (04.10.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/237,862 **4 October 2000 (04.10.2000)** **US**
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US **60/237,862 (CIP)**
Filed on **4 October 2000 (04.10.2000)**
- (71) Applicant (for all designated States except US): **CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HERRMANN, John, L. [US/US]; 78 Barnshed Lane, Guilford, CT 06437 (US). RASTELLI, Luca [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US). SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US).**
- (74) Agent: **ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/29038 A2

(54) Title: **NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME AND ANTIBODIES DIRECTED AGAINST THESE PROTEINS**

(57) Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

BEST AVAILABLE COPY

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME AND ANTIBODIES DIRECTED AGAINST THESE PROTEINS

FIELD OF THE INVENTION

5 The invention generally relates to nucleic acids and polypeptides encoded thereby, and antibodies directed against the polypeptides.

BACKGROUND OF THE INVENTION

 The invention generally relates to nucleic acids and polypeptides encoded therefrom.
10 More specifically, the invention relates to nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

SUMMARY OF THE INVENTION

15 The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, and NOV6 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide
20 sequences.

 In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, and 11. In some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid
25 sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, and 12. The nucleic acid
30 can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, and 11.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7, 9, and 11) or a complement of said oligonucleotide.

Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8, 10, and 12). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic

acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, Cancer, 5 Leukodystrophies, Breast cancer, Ovarian cancer, Prostate cancer, Uterine cancer, Hodgkin disease, Adenocarcinoma, Adrenoleukodystrophy, Cystitis, incontinence, Von Hippel-Lindau (VHL) syndrome, hypercalcaemia, Endometriosis, Hirschsprung's disease, Crohn's Disease, Appendicitis, Cirrhosis, Liver failure, Wolfram Syndrome, Smith-Lemli-Opitz syndrome, Retinitis pigmentosa, Leigh syndrome; Congenital Adrenal Hyperplasia, Xerostomia; tooth 10 decay and other dental problems; Inflammatory bowel disease, Diverticular disease, fertility, Infertility, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic 15 purpura, obesity, Diabetes Insipidus and Mellitus with Optic Atrophy and Deafness, Pancreatitis, Metabolic Dysregulation, transplantation recovery, Autoimmune disease, Systemic lupus erythematosus, asthma, arthritis, psoriasis, Emphysema, Scleroderma, allergy, ARDS, Immunodeficiencies, Graft versus host, Alzheimer's disease, Stroke, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Multiple sclerosis, Ataxia- 20 telangiectasia, Behavioral disorders, Addiction, Anxiety, Pain, Neurodegeneration, Muscular dystrophy, Lesch-Nyhan syndrome, Myasthenia gravis, schizophrenia, and other dopamine-dysfunctional states, levodopa-induced dyskinesias, alcoholism, epileptic seizures and other neurological disorders, mental depression, Cerebellar ataxia, pure; Episodic ataxia, type 2; Hemiplegic migraine, Spinocerebellar ataxia-6, Tuberous sclerosis, Renal artery stenosis, 25 Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Renal tubular acidosis, IgA nephropathy, and/or other pathologies and disorders of the like.

The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment 30 of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By

way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

The invention further includes a method of using antibodies that are specific for a NOVx polypeptide to treat a disease. The method includes treating a patient with an effective amount of the antibody to block the mechanism of their pathology. Pathologies that are blocked by the use of NOVX antibodies include metastatic potential and invasion in kidney and gastric tumors; cell growth and cell survival in colon, breast, liver and gastric tumors; cell growth and cell survival in colon, breast, liver and gastric tumors; metastasis in breast and brain tumors; metastasis and chemotherapy resistance in colon, gastric, ovarian and lung tumors; and angiogenesis and tumor growth in liver cancer.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

5 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references
10 mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX
20 polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE A. Sequences and Corresponding SEQ ID Numbers

25

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1	GMAC034209 A	1	2	UNC5-like
2	CG-SC29263825	3	4	Fat 2 (FAT2) cadherin related tumor suppressor like
3	CG-SC 17661211	5	6	orphan GPCR-like
4	CG-SC28471525	7	8	Slit-like
5	AC133 antigen	9	10	AC133 antigen-like
6	NM 012445	11	12	Spondin 2-like

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX
5 nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

NOV1 is homologous to a UNC5-like family of proteins. NOV1 could be used to treat metastatic potential and invasion. Therapeutic targeting of NOV1 with a monoclonal antibody is anticipated to limit or block the extent of metastatic potential and invasion in kidney,
10 gastric, and various other tumors.

NOV2 is homologous to the Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor-like family of proteins. Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor has homology to the b-catenin binding regions of classical cadherin cytoplasmic tails and also ends with a PDZ domain-binding motif. Protocadherin regulates branching
15 morphogenesis in the kidneys and lungs. Therefore, NOV2 has a role in cell growth and cell survival. Therapeutic targeting of NOV2 with a monoclonal antibody is anticipated to limit or block the extent of cell growth and cell survival in colon, breast, liver, gastric, and various other tumors.

NOV3 is homologous to a family of Orphan GPCR-like proteins. Because of its high
20 homology to GPCRs and its containing GPCR 7 transmembrane domains, NOV3 is thought to be involved with cell growth and cell survival. Therapeutic targeting of NOV3 with a monoclonal antibody is anticipated to limit or block the extent of cell growth and cell survival in colon, breast, liver, gastric, and various other tumors.

NOV4 is homologous to the Slit-like family of proteins. NOV4 blocks Natriuretic
25 peptide receptor proteins, possibly a receptor with ATP binding and Kinase activity. NOV4 is thought to be involved with metastatic potential. Therapeutic targeting of NOV4 with a monoclonal antibody is anticipated to limit or block the extent of metastasis and invasion in breast, brain, and various other tumors.

NOV5 is homologous to the AC133 Antigen-like family of proteins. NOV5 is thought
30 to be involved in metastatic potential and chemotherapy resistance. Therapeutic targeting of AC133 with a monoclonal antibody is anticipated to limit or block the extent of metastasis and chemotherapy resistance in colon, gastric, ovarian, lung, and various other tumors.

NOV6 is homologous to the Spondin 2-like family of proteins. It is thought that NOV6 is involved with liver cancer. Therapeutic targeting of NOV6 with a monoclonal antibody is

anticipated to limit or block the extent of angiogenesis and tumor growth in liver, and various other cancers.

The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis. Antibodies specific for NOVX can be used to treat certain pathologies as detailed above.

Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

NOV1

A disclosed NOV1 nucleic acid of 2881 nucleotides (also referred to as GMAC034209_A) encoding a novel UNC5-like protein is shown in Table 1A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 87-89 and ending with a TGA codon at nucleotides 2784-2786. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 1A. The start and stop codons are in bold letters.

Table 1A. NOV1 nucleotide sequence (SEQ ID NO:1).

<p> AGCTGGGGCTCCGGGCTGAGGCGCTAAAGCCGCCCTCCCGCCCGGGGCCCCGCGCCCGGCCCCCGCCT GCCCGCCCCCGGCCATGGCCGTCCGGCCCGGCTGTGGCCAGCGCTCCTGGGCATAGTCCTCCGCGCTTGGC TCCGCGGCTCGGGTCCCCAGCAGAGTGCCACCGTGGCCAACCCAGTGCTGGTGCCAACCCGGACCTGCTTC CCCATTCCTGGTGGAGCCCGAGGATGTGTACATCGTCAAGAACCAAGCCAGTGCTGCTTGTGTGCAAGGCCG TGCCCGCCACGCAGATCTTCTTCAAGTGCAACGGGGAGTGGGTGCGCCAGGTGGACCACGTGATCGAGCGCA GCACAGACGGGAGCAGTGCTGAGCCGACCATGGAGGTCCGCATTAATGTCTCAAGGCAGCAGGTGAGAAAG TGTTCGGGCTGGAGGAATACTGGTGCCAGTGCGTGGCATGGAGCTCCTCGGGCACCACCAAGAGTCAGAAGG CCTACATCCGCATAGCCAGATTGCGCAAGAACTTCGAGCAGGAGCCGCTGGCCAAGGAGGTGTCCCTGGAGC AGGCGATCGTGCTGCGCTGCCGTCCACCGAGGGCATCCCTCCAGCCGAGGTGGAGTGGCTCCGGAACGAGG ACCTGGTGGACCCGTCCTGGACCCCAATGTATACATCACGCGGGAGCACAGCCTGGTGGTGCGACAGGCC GCCTTGCTGACACGCCAACTACACCTGCGTGCCCAAGAACATCGTGCCACGTGCGCCGAGCGCCTCCGCTG CTGTCATCGTCTACGTGAACGGTGGGTGGTTCGACGTGGACCGAGTGGTCCGCTGTCAGCGCCAGCTGTGGGC GCGGCTGGCAGAAACGGAGCCGAGCTGCACCAACCCGGCGCCTCTCAACGGGGGCGCTTCTGTGAGGGGC AGAATGTCCATGACCGCACCGTCTCCTCTCTGCTTGTCTCTGTGGACGGCAGCTGGAGCCCGTGGAGCAAGT GGTCCGGCTGTGGGCTGGACTGCACCCACTGGCGGAGCCGTGAGTGCTCTGACCCAGCACCCCGCAACGGAG GGGAGGAGTGCCAGGGCACTGACCTGGACACCCGCAACTGTACCACTGACCTCTGTGTACACAGTGCTTCTG GCCCTGAGGACGTGGCCCTCTATGTGGGCCTCATCGCGTGGCGCTCTGCCTGGTCTGCTGCTGCTTGTCTC TCATCCTCGTTTATGCGGAAGAAGGAGGGCTGGACTCAGATGTGGCTGACTCGTCCATTTCTACCTCAG GCTTCAGCCCGTCAGCATCAAGCCAGCAAGCAGACAACCCCATCTGCTCACCATCCAGCCGGACCTCA GCACCACCACCACTACAGGGCAGTCTCTGTCCCGCAGGATGGGCCAGCCCCAAGTTCCAGCTACCA ATGGGCACCTGCTCAGCCCCCTGGGTGGCGGCGGCCACACTGCACCACAGCTCTCCACCTCTGAGGCCG AGGAGTTCGTCTCCCGCCTCTCCACCCAGAACTACTTCGCTCCCTGCCCCGAGGCACCAACATGACCT ATGGACCTTCAACTTCTCGGGGGCGGCTGATGATCCCTAATACAGGTATCAGCCTCCTCATCCCCCAG ATGCCATACCCCGAGGGAAGATCTATGAGATCTACCTCACGCTGCACAAGCCGGAAGACGTGAGGTTGCC TAGCTGGCTGTACAGCCCTCTGAGTCCCATCGTGTAGCTGTGGACCCCTGGCGTCTGCTCAGCCGGCCAG TCATCCTGGCTATGGACCACTGTGGGGAGCCAGCCCTGACAGCTGGAGCCTGCGCCTCAAAAAGCAGTCTG GCGAGGGCAGCTGGGAGCAGGATGTCTGCACCTGGGCGAGGAGGCGCCCTCCACCTCTACTACTGCCAGC TGGAGGCCAGTGCTGCTACGTCTTACCGAGCAGCTGGGCCGCTTGGCCCTGGTGGGAGAGGCCCTCAGCG </p>

```

TGGCTGCCGCAAGCGCCTCAAGCTGCTTCTGTTTGGCCGGTGGCCTGCACCTCCCTCGAGTACAACATCC
GGGTCTACTGCCTGCATGACACCCACGATGCACTCAAGGAGGTGGTGCAGCTGGAGAAGCAGCTGGGGGGAC
AGCTGATCCAGGAGCCACGGGTCTGCACTTCAAGGACAGTTACCACAACCTGCGCCTATCCATCCACGATG
TGCCCAGCTCCCTGTGGAAGAGTAAGCTCCTTGTGAGTACCAGGAGATCCCCTTTTATCACATCTGGAATG
GCACGCAGCGGTACTTGCACTGCACCTTCACCTGGAGCGTGTGAGCCCCAGCACTAGTGACCTGGCCTGCA
AGCTGTGGGTGTGGCAGGTGGAGGGCGACGGGCAGAGCTTCAGCATCAACTTCAACATCACCAGGACACAA
GGTTTGCTGAGCTGCTGGCTCTGGAGAGTGAAGCGGGGTCCCAGCCCTGGTGGGCCCCAGTGCCTTCAAGA
TCCCCTTCCTCATTCGGCAGAAGATAATTTCCAGCCTGGACCCACCTGTAGGCGGGGTGCCACTGGCGGA
CTCTGGCCAGAACTCCACTGGACAGCCATCTCAGCTTCTTGCCTCCAAGCCCAGCCCCACAGCCATGA
TCCTCAACCTGTGGGAGGCGCGGCACTTCCCCAACGGCAACCTCAGCCAGCTGGCTGCAGCAGTGGCTGGAC
TGGGCCAGCCAGACGCTGGCCTCTTCACAGTGTGGAGGCTGAGTGTGAGGCCGGCCAGGCCCGACACCTA
CACTCTCACCAGCTTGGCACCACCAAGGACAGGAGAAGCCGGACAGGGGCCCTTCCCCACACGGGGGAG
A

```

In a search of public sequence databases, the NOV1 nucleic acid sequence, located on chromosome 13 has 1718 of 1725 bases (99%) identical to a *Homo sapiens* sequence similar to transmembrane receptor Unc5H1 from *Rattus norvegicus*. (gb:GENBANK-ID: gi|14781377|ref|XM_030300.1|). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.

In all BLAST alignments herein, the "E-value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject ("Sbjct") retrieved from the NOV1 BLAST analysis, e.g., *Homo sapiens* sequence similar to transmembrane receptor Unc5H1 from *Rattus norvegicus*, matched the Query NOV1 sequence purely by chance is 0.0. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.

The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of one assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g.,

<http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/>. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low-

complexity sequence that is performed to prevent artifactual hits. The filter substitutes any low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNNNN") or the letter "X" in protein sequences (e.g., "XXXXXXXXXX"). Low-complexity regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. (Wootton and Federhen, Methods Enzymol 266:554-571, 1996).

The disclosed NOV1 polypeptide (SEQ ID NO:2) encoded by SEQ ID NO:1 has 899 amino acid residues and is presented in Table 1B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV1 is likely to be localized in the plasma membrane.

TaqMan data for NOV1 can be found below in Example 1. It indicates overexpression of NOV1 in kidney and gastric tumors.

Table 1B. Encoded NOV1 protein sequence (SEQ ID NO:2).

```
MAVRPGLWPALLGI VLA A WLRGSGAQQSATVANPVPGANPDLLPHFLVEPEDVYIVKNKPVLLVCKAVPATQ
IFFKCNGEWVRQVDH VIERSTDGSSGSEPTMEVRINVSROQVEKVFGL E EYWCQCVAWSSSGTTKSQKAYIRI
ARLRKNFEQEPLAKEVSLEQGI VLP CRPPEGIPPAEVEWLRNEDLVDP SLDPNVYITREHSLVVRQARLADT
ANYTCVAKNIVARRRSASA A VIVVNGGWSTWTEWSVCSASCGRGWQKR SR SCTNPAPLNGGAFCEGQNVHD
RTVSSLLVSV DGSWSPWSKWSACGLDCTHWR SRECS DPAPRNGGECQGTDL DTRNCTSDLCVHSASGPE DV
ALYVGLI A VAVCLV LLLVL I LVYCRKKEGLSDVADSSILTS GFQPVSIKPSKADNPHLLTIQPD LSTTTT
YQGS LCPRODGPSPKFQLTNGHLLSPLGGGRHTLHHSSPTSEAEFFVSRLSTQNYFRSLPRGTSNMTYGT FN
FLGGR LMI PNTGISLLI PPD AI PRGKI YEI YLTLHKPEDVRLPLAGCQTL LSPIVSCGPPGVLLTRPVILAM
DHCGEPSPD SWSLRLKKQSC EGSWEQDVLHLGEEAPSHLYYCQLEASACYVFTEQLGRFALVGEALSVA AAK
RLKLLLFAPVACTSLEYNIRVYCLHDTHDALKEVVQLEKQLGGQLIQEP RVLHFKDSYHNRLRSIHDVPSSL
WKS KLLVSYQEIPFYHIWNGTQRYLHCTFTLERVSPSTSD LACKLWVWQVEGDGQSFSINFNITKDTRFAEL
LALESEAGVPALVGPSAFKIPFLIRQKI ISSLDPPCRRGADWRTLAQKLHLD SHLSFFASKPSPTAMILNLW
EARHFPNGNLSQLAAAVAGLGQPDAGLFTVSEAE C
```

A search of sequence databases reveals that the NOV1 amino acid sequence has 812 of 900 amino acid residues (90%) identical to, and 828 of 900 amino acid residues (91%) similar to the 898 amino acid residue transmembrane receptor Unc5H1 [Rattus norvegicus] (GenBank Acc. No.: gi|11559980|ref|NP_071542.1|) (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.

The disclosed NOV1 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 1C.

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11559980 ref NP_071542.1	transmembrane receptor Unc5H1 [Rattus norvegicus]	898	812/900 (90%)	828/900 (91%)	0.0
gi 14424612 gb AAH09333.1 AAH09333 (BC009333)	Similar to transmembrane receptor Unc5H1 [Homo sapiens]	544	506/542 (93%)	506/542 (93%)	0.0
gi 6678505 ref NP_033498.1	UNC-5 homolog (C. elegans) 3 [Mus musculus]	931	490/913 (53%)	631/913 (68%)	e-161
gi 15296526 ref XP_042940.2	unc5 (C.elegans homolog) c [Homo sapiens]	931	483/913 (52%)	625/913 (67%)	e-160
gi 4507837 ref NP_03719.1	unc5 (C.elegans homolog) c; homolog of C. elegans transmembrane receptor Unc5 [Homo sapiens]	931	482/913 (52%)	624/913 (67%)	e-158

5

10

- 15

25

			70	80	90	100	110	120	
	NOV1		LP	HL	FL	VE	PE	DV	I
	gi 11559980 ref		LP	HL	FL	VE	PE	DV	I
5	gi 14424612 gb		LP	HL	FL	VE	PE	DV	I
	gi 6678505 ref		LP	HL	FL	VE	PE	DV	I
	gi 15296526 ref		LP	HL	FL	VE	PE	DV	I
	gi 4507837 ref		LP	HL	FL	VE	PE	DV	I
10			130	140	150	160	170	180	
	NOV1		EV	RI	NV	SR	QQ	VE	K
	gi 11559980 ref		EV	RI	NV	SR	QQ	VE	K
	gi 14424612 gb		EV	RI	NV	SR	QQ	VE	K
15	gi 6678505 ref		EV	RI	NV	SR	QQ	VE	K
	gi 15296526 ref		EV	RI	NV	SR	QQ	VE	K
	gi 4507837 ref		EV	RI	NV	SR	QQ	VE	K
20			190	200	210	220	230	240	
	NOV1		EQ	GI	VL	PC	RP	PE	GI
	gi 11559980 ref		EQ	GI	VL	PC	RP	PE	GI
	gi 14424612 gb		EQ	GI	VL	PC	RP	PE	GI
25	gi 6678505 ref		EQ	GI	VL	PC	RP	PE	GI
	gi 15296526 ref		EQ	GI	VL	PC	RP	PE	GI
	gi 4507837 ref		EQ	GI	VL	PC	RP	PE	GI
30			250	260	270	280	290	300	
	NOV1		AK	NI	VA	RR	RS	SA	AA
	gi 11559980 ref		AK	NI	VA	RR	RS	SA	AA
	gi 14424612 gb		AK	NI	VA	RR	RS	SA	AA
	gi 6678505 ref		AK	NI	VA	RR	RS	SA	AA
	gi 15296526 ref		AK	NI	VA	RR	RS	SA	AA
35	gi 4507837 ref		AK	NI	VA	RR	RS	SA	AA
40			310	320	330	340	350	360	
	NOV1		GO	NV	HD	RT	V	SS	L
	gi 11559980 ref		GO	NV	HD	RT	V	SS	L
	gi 14424612 gb		GO	NV	HD	RT	V	SS	L
	gi 6678505 ref		GO	NV	HD	RT	V	SS	L
	gi 15296526 ref		GO	NV	HD	RT	V	SS	L
45	gi 4507837 ref		GO	NV	HD	RT	V	SS	L
50			370	380	390	400	410	420	
	NOV1		RN	CT	SD	LC	MT	AS	GP
	gi 11559980 ref		RN	CT	SD	LC	MT	AS	GP
	gi 14424612 gb		RN	CT	SD	LC	MT	AS	GP
	gi 6678505 ref		RN	CT	SD	LC	MT	AS	GP
	gi 15296526 ref		RN	CT	SD	LC	MT	AS	GP
	gi 4507837 ref		RN	CT	SD	LC	MT	AS	GP
55			430	440	450	460	470	480	
	NOV1		TS	GF	QP	VS	IK	PS	KA
	gi 11559980 ref		TS	GF	QP	VS	IK	PS	KA
	gi 14424612 gb		TS	GF	QP	VS	IK	PS	KA
60	gi 6678505 ref		TS	GF	QP	VS	IK	PS	KA
	gi 15296526 ref		TS	GF	QP	VS	IK	PS	KA
	gi 4507837 ref		TS	GF	QP	VS	IK	PS	KA
65			490	500	510	520	530	540	
	NOV1		GG	RT	TL	HH	SS	PT	SE
	gi 11559980 ref		GG	RT	TL	HH	SS	PT	SE
	gi 14424612 gb		GG	RT	TL	HH	SS	PT	SE
	gi 6678505 ref		GG	RT	TL	HH	SS	PT	SE
70	gi 15296526 ref		GG	RT	TL	HH	SS	PT	SE

gi 4507837 ref		NLRKIKVYNTSGAVSPQDDLSEFTSKLS PQMTQSLLENEALSLKNQSLARQNDPSCTAFGS	535
		550 560 570 580 590 600	
5	NOV1	FNFLGGRLMIPNTGISLLTPPDAIPRGKIYEIYLTLLHHPEDVRLPLAGCQTLLSPVIVSCG	562
	gi 11559980 ref	FNFLGGRLMIPNTGISLLTPPDAIPRGKIYEIYLTLLHHPEDVRLPLAGCQTLLSPVIVSCG	562
	gi 14424612 gb	FNFLGGRLMIPNTGISLLTPPDAIPRGKIYEIYLTLLHHPEDVRLPLAGCQTLLSPVIVSCG	208
	gi 6678505 ref	FNSLGGHLIIPNSGVSLIPAGAIPOGRVYEMVTVVHRKENMRPPEMDSOTLLTPVVSCG	595
	gi 15296526 ref	FNSLGGHLIIPNSGVSLIPAGAIPOGRVYEMVTVVHRKETMRPPEMDDSOTLLTPVVSCG	595
10	gi 4507837 ref	FNSLGGHLIIPNSGVSLIPAGAIPOGRVYEMVTVVHRKETMRPPEMDDSOTLLTPVVSCG	595
		610 620 630 640 650 660	
	NOV1	PPGVLLTRPVILAMDHCGEPPSPDSWSLRLLKKQSCGGSWEQDVIHLGEEAPSHLYYCQLEA	622
15	gi 11559980 ref	PPGVLLTRPVILAMDHCGEPPSPDSWSLRLLKKQSCGGSWEQDVIHLGEEAPSHLYYCQLEA	621
	gi 14424612 gb	PPGVLLTRPVILAMDHCGEPPSPDSWSLRLLKKQSCGGSWEQDVIHLGEEAPSHLYYCQLEA	267
	gi 6678505 ref	PPGALLTRPVILTMHHCADPNTEDWKILKNQAAGGOWE-DVVVVGEENFTTPCYIQIDA	654
	gi 15296526 ref	PPGALLTRPVILTMHHCADPNTEDWKILKNQAAGGOWE-DVVVVGEENFTTPCYIQIDA	654
20	gi 4507837 ref	PPGALLTRPVILTMHHCADPNTEDWKILKNQAAGGOWE-DVVVVGEENFTTPCYIQIDA	654
		670 680 690 700 710 720	
	NOV1	SACYVFTEQLGRFALVGEALSVAALKRLKLLFAPVACTSLEYNIRVYCLDTHDALKEV	682
25	gi 11559980 ref	SACYVFTEQLGRFALVGEALSVAALKRLKLLFAPVACTSLEYNIRVYCLDTHDALKEV	681
	gi 14424612 gb	SACYVFTEQLGRFALVGEALSVAALKRLKLLFAPVACTSLEYNIRVYCLDTHDALKEV	327
	gi 6678505 ref	EACHILTENLSTYALVGSTTKAAAKRLKLATFGLCCSLEYNIRVYCLDTHDALKEV	714
	gi 15296526 ref	EACHILTENLSTYALVGSTTKAAAKRLKLATFGLCCSLEYNIRVYCLDTHDALKEV	714
30	gi 4507837 ref	EACHILTENLSTYALVGSTTKAAAKRLKLATFGLCCSLEYNIRVYCLDTHDALKEV	714
		730 740 750 760 770 780	
	NOV1	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	742
35	gi 11559980 ref	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	741
	gi 14424612 gb	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	387
	gi 6678505 ref	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	774
	gi 15296526 ref	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	774
40	gi 4507837 ref	VOLEKOLGGQLIQEPRVLHFKDSYHNLRLSIHDVPSLWKSLLVSYQEIPIFYHIWNGTQ	774
		790 800 810 820 830 840	
	NOV1	RYLHCTFTLERVSPSTSLACKLWVWQVEGCGQSESNFNITKOTRFAELLALAESEAGVP	802
45	gi 11559980 ref	RYLHCTFTLERVSPSTSLACKLWVWQVEGCGQSESNFNITKOTRFAELLALAESEAGVP	801
	gi 14424612 gb	RYLHCTFTLERVSPSTSLACKLWVWQVEGCGQSESNFNITKOTRFAELLALAESEAGVP	447
	gi 6678505 ref	RNLHCTFTLERVSLNTVELVCKLCVRQVEGEGQIFOLNCTVSEPTGIDLPLDIPANTIT	834
	gi 15296526 ref	RNLHCTFTLERVSLNTVELVCKLCVRQVEGEGQIFOLNCTVSEPTGIDLPLDIPANTIT	834
50	gi 4507837 ref	RNLHCTFTLERVSLNTVELVCKLCVRQVEGEGQIFOLNCTVSEPTGIDLPLDIPANTIT	834
		850 860 870 880 890 900	
	NOV1	ALVGPFAFKIPFLIRQKITSSLDPPCRRGADWRITLAOKLHLDSHLSFPASKPSPTAMILN	862
55	gi 11559980 ref	ALVGPFAFKIPFLIRQKITSSLDPPCRRGADWRITLAOKLHLDSHLSFPASKPSPTAMILN	861
	gi 14424612 gb	ALVGPFAFKIPFLIRQKITSSLDPPCRRGADWRITLAOKLHLDSHLSFPASKPSPTAMILN	507
	gi 6678505 ref	TWTGPSAFSIPFLPIRQKITSSLDAPOTRGHDWRMLAHKLNLDRLNYPATKSSPTGVILN	894
	gi 15296526 ref	TWTGPSAFSIPFLPIRQKITSSLDAPOTRGHDWRMLAHKLNLDRLNYPATKSSPTGVILN	894
60	gi 4507837 ref	TWTGPSAFSIPFLPIRQKITSSLDAPOTRGHDWRMLAHKLNLDRLNYPATKSSPTGVILN	894
		910 920 930	
	NOV1	LWEARHFPNGNLSOLAAAVAGLGQPDAGLFTVSEAE	899
65	gi 11559980 ref	LWEARHFPNGNLSOLAAAVAGLGQPDAGLFTVSEAE	898
	gi 14424612 gb	LWEARHFPNGNLSOLAAAVAGLGQPDAGLFTVSEAE	544
	gi 6678505 ref	LWEAQNFPGNLSMLAAVLEEMGRHETVVSIAAEGQY	931
	gi 15296526 ref	LWEAQNFPGNLSMLAAVLEEMGRHETVVSIAAEGQY	931
	gi 4507837 ref	LWEAQNFPGNLSMLAAVLEEMGRHETVVSIAAEGQY	931

The presence of identifiable domains in NOV1, as well as all other NOVX proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro>).

- 5 DOMAIN results for NOV1 as disclosed in Tables 1E-1L, were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Table 1E and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (!) and "strong" semi-conserved residues are indicated by grey shading or by the sign (+). The "strong" group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

- 10 Tables 1E-1L list the domain description from DOMAIN analysis results against NOV1. This indicates that the NOV1 sequence has properties similar to those of other proteins known to contain this domain.

Table 1E. Domain Analysis of NOV1

gnl|Smart|smart00218, ZU5, Domain present in ZO-1 and Unc5-like netrin receptors; Domain of unknown function. (SEQ ID NO:42)
CD-Length = 51 residues, 100.0% aligned
Score = 49.7 bits (117), Expect = 7e-07

- 20 Query: 495 TSNMTYGTFFNFGGRLMIPNTGISLLIPDAIPRGKIYEIYLT LHKPEDVRLPLAGCQTL 554
| + |||+ |||| | + | + ||| |||+ | | | + | || + ||
Sbjct: 1 PSFLVSGTFDARGGRLRGPRTGVRLIIPPGAIPQGETRYTCYLVVHDKLSTPPPLEEGETL 60
- 25 Query: 555 LSPIVSCGPPGVLLTRPVILAMDHCGEPPSPDSWSLRLKKQSCGE 598
|||+| ||| | | ||||| + || | | + | + |
Sbjct: 61 LSPVVECGPHGALFLRPVILEVPHCASLRPRDWEIVLLRSENGG 104

Table 1F. Domain Analysis of NOV1

gnl|Smart|smart00082, LRRCT, Leucine rich repeat C-terminal domain.
(SEQ ID NO:43)
CD-Length = 104 residues, 100.0% aligned
Score = 152 bits (383), Expect = 1e-37

- 30 Query: 495 TSNMTYGTFFNFGGRLMIPNTGISLLIPDAIPRGKIYEIYLT LHKPEDVRLPLAGCQTL 554
| + |||+ |||| | + | + ||| |||+ | | | + | || + ||
Sbjct: 1 PSFLVSGTFDARGGRLRGPRTGVRLIIPPGAIPQGETRYTCYLVVHDKLSTPPPLEEGETL 60
- Query: 555 LSPIVSCGPPGVLLTRPVILAMDHCGEPPSPDSWSLRLKKQSCGE 598
|||+| ||| | | ||||| + || | | + | + |
Sbjct: 61 LSPVVECGPHGALFLRPVILEVPHCASLRPRDWEIVLLRSENGG 104

Table 1G. Domain Analysis of NOV1

gnl|Pfam|pfam00791, ZU5, ZU5 domain. Domain present in ZO-1 and Unc5-like netrin receptors Domain of unknown function. (SEQ ID NO:44)
 CD-Length = 104 residues, 100.0% aligned
 Score = 150 bits (378), Expect = 4e-37

Query: 495 TSNMTYGTFFNFGGRLMIPNTGISLLIPDAIPRGKIYEIYLTTLHKPEDVRLPLAGCQTL 554
 + + |||+ |||| | ||+ |+||| |||+| | || +| || +||
 5 Sbjct: 1 SGFLVSGTFDARGGRLRGPRTVRLIIPGAIPQGTRYTCYLVVHDKLSTPPPLEEGETL 60

Query: 555 LSPIVSCGPPGVLLTRPVILAMDHCGEPPSPDSWSLRLKKQSCEG 598
 |||+| ||| | | ||||| + || | | | + |
 10 Sbjct: 61 LSPVVECGPHGALFLRPVILEVPHCASLRPRDWELVLLRSENGG 104

Table 1H. Domain Analysis of NOV1

gnl|Smart|smart00005, DEATH, DEATH domain, found in proteins involved in cell death (apoptosis).; Alpha-helical domain present in a variety of proteins with apoptotic functions. Some (but not all) of these domains form homotypic and heterotypic dimers.. (SEQ ID NO:45)
 CD-Length = 96 residues, 91.7% aligned
 Score = 61.6 bits (148), Expect = 2e-10

Query: 806 GPSAFKIPFLIRQKIISSLDPPCRRGADWRTLAQKLHL-DSHLSFFASKPS-----PTAM 859
 | | + | |+| || | ||| |+|| | ++ ++ +
 15 Sbjct: 1 PPGAASLTETREKLAKLLDHD--LGDDWRELARKLGLSEADIDQIETESPRDLAEQSYQ 58

Query: 860 ILNLWEARHFPNGNLSQLAAAVAGLGQPD 889
 +| ||| | | | | + +|+ ||
 20 Sbjct: 59 LLRLWEQREGKNATLGTLLLEALRKMGRDDA 88

Table 1I. Domain Analysis of NOV1

gnl|Smart|smart00209, TSP1, Thrombospondin type 1 repeats; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta. (SEQ ID NO:46)
 CD-Length = 51 residues, 84.3% aligned
 Score = 56.2 bits (134), Expect = 8e-09

Query: 245 WSTWTEWSVCSASCGRGWQKRSRSCNTPAPLNGGAFCEGQNVHDR 289
 | |+||| || +|| | |+| | ||| | | + |
 25 Sbjct: 1 WGEWSEWSPCSVTCGGGVQTRTRCCNPPP--NGGGPCTGPDTETR 43

Table 1J. Domain Analysis of NOV1

gnl|Smart|smart00209, TSP1, Thrombospondin type 1 repeats; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta. (SEQ ID NO:46)
 CD-Length = 51 residues, 98.0% aligned
 Score = 49.7 bits (117), Expect = 7e-07

Query: 302 WSPWSKWSACGLDCTH-WRSRECSDFAPRNGGEECGGTDLDTRNCTSDLC 350
 | ||+|| | + | ++| || ||| | | | +|| | |
 Sbjct: 1 WGEWSEWSPCSVTCGGGVQTRTRCCNPPPNGGGPCTGPDTETRACNEQPC 50

Table 1K. Domain Analysis of NOV1

gnl|Pfam|pfam00531, death, Death domain (SEQ ID NO:47)
 CD-Length = 83 residues, 90.4% aligned
 Score = 52.8 bits (125), Expect = 9e-08

Query: 818 QKIISLDPPCRRGADWRTLAQKLHL-DSHLSFFASKP---SPTAMILNLWEARHFPNG 872
 + ||| | ||| ||+|| | + + + ||| +|+||| | |
 5 Sbjct: 1 RELCKLLDDP--LGRDWRRLARKLGLSEEEIDQIEHENPRLASPTYQLLDLWEQRGGKNA 58
 Query: 873 NLSQLAAAVAGLGQPD 889
 | |+ |+ ||
 10 Sbjct: 59 TVGTLLEALRKMRDDA 75

Table 1L. Domain Analysis of NOV1

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:48)
 CD-Length = 86 residues, 79.1% aligned
 Score = 44.3 bits (103), Expect = 3e-05

Query: 159 EVSLEQGIVLPCRPEGIPPAEVEWLRNEDLVDPSLDPNVYITRE---HSLVVRQARLAD 215
 | + +| | || | | + + +| + + |
 15 Sbjct: 5 TVKEGESVTLSCAS-GNPPPTVTWYKQ-GGKLLAESGRFSVSRSGGNSTLTISNVTPE 62
 Query: 216 TANYTCVAKN 225
 + ||| | |
 Sbjct: 63 SGTYTCAATN 72

20 Murine netrin-3 protein binds to netrin receptors of the DCC (deleted in colorectal cancer) family [DCC and neogenin] and the UNC5 family (UNC5H1, UNC5H2 and UNC5H3). *C elegans* Unc5 and murine unc5hr homolog are involved in cell migration during cerebellum development, inducing repulsion in axon guidance through its cytoplasmic tail, and are expressed in brain, fetal heart.

25 The disclosed NOV1 nucleic acid of the invention encoding a UNC5 -like protein includes the nucleic acid whose sequence is provided in Table 1A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 1A while still encoding a protein that maintains its UNC5-like activities and physiological functions, or a fragment of such a nucleic acid. The
 30 invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar
 35 phosphate backbones are modified or derivatized. These modifications are carried out at least

in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 30% percent of the bases may be so changed.

5 The disclosed NOV1 protein of the invention includes the UNC5-like protein whose sequence is provided in Table 1B or 1E. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 1B or 1E while still encoding a protein that maintains its UNC5-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 48% percent of the residues may be so changed.

The invention further encompasses antibodies and antibody fragments, such as F_{ab} or (F_{ab})₂, that bind immunospecifically to any of the proteins of the invention.

15 The above defined information for this invention suggests that this UNC5-like protein (NOV1) may function as a member of a "UNC5 family". Therefore, the NOV1 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration *in vivo* and *in vitro* of all tissues and cell types composing (but not limited to) those defined here. NOV1 could be used to treat metastatic potential and invasion. Therapeutic targeting of NOV1 with a monoclonal antibody is anticipated to limit or block the extent of metastatic potential and invasion in kidney and gastric tumors.

25 NOV1 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV1 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV1 protein has multiple hydrophilic regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies can also be used to treat certain pathological conditions as detailed above.

A disclosed NOV2 nucleic acid of 14536 nucleotides (also referred to as CG-SC29263825 GenBank #AF231022) encoding a novel protocadherin Fat 2 (FAT2) cadherin related tumor suppressor like protein is shown in Table 2A. An open reading frame was
5 identified beginning with an ATG initiation codon at nucleotides 14-16 and ending with a TAG codon at nucleotides 13061-13063. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 2A, and the start and stop codons are in bold letters.

Table 2A. NOV2 nucleotide sequence (SEQ ID NO:3).

GGAGT¹TTTCCACCATGACTATTGCCCTGCTGGGTTT²TGCCATATTCTTGCTCCATTGTGCGACCTGTGAGAA
GCCTCTAGAAGGGATTCTCTCCTCCTCTGCTTGGCACTT³CACACACTCCCATTACAATGCCACCATCTATGA
AAATTCTTCTCCCAAGACCTATGTGTGAGAGCTTCGAGAAAATGGGCATCTACCTCGCGGAGCCACAGTGGGC
AGTGAGGTACCGGATCATCTCTGGGGATGTGGCCAATGTATT⁴AAAACTGAGGAGTATGTGGTGGGCAACTT
CTGCTTCTTAAGAATAAGGACAAAGAGCAGCAACACAGCTCTTCTGAACAGAGAGGTGCGAGACAGCTACAC
CCTCATCAT⁵TCCAAGCCACAGAGAAGACCTTGGAGTTGGAAGCTTTGACCCGTGTGGTGGTCCACATCTCTGGA
CCAGAATGACCTGAAGCCTCTCTTCTCTCCACCTTCGTACAGAGTCAACATCTCTGAGGACATGCCCTTGAA
GAGCCCCATCTGCAAGGTGACTGCCACAGATGCTGATCTAGGCCAGAATGCTGAGTTCTATATGCCTTTAA
CACAAGGTCAAGATGTTT⁶GCCATCCATCCCAACAGCGGTGTGGTCACTGTGGCTGGGAAGCTTAACGTAC
CTGGCGAGGAAAGCATGAGCTCCAGGTGCTAGCTGTGGACCGCATGCGGAAAATCTCTGAGGGCAATGGGTT
TGGCAGCCTGGCTGCACTTGTGGTTCATGTGGAGCCTGCCCTCAGGAAGCCCCAGCCATTGCTTCGGTGGT
GGTGACTCCACCAGACAGCAATGATGGTACCACCTATGCCACTGTACTGGTTCGATGCAATAGCTCAGGAGC
TGAAGTGGAGTCAGTGGAAGTTGTGGTGGTGACCTTGGAAAGCACTTCAAAGCCATCAAGTCTTATGCCCG
GAGCAATGAGTTCACTTGGTGTCTGTCAAAGACATCACTGGATGGAGTACCTTCATGGGTTCAACCTCAG
CCTCCAGGCCAGGAGTGGGAGCGGCCCTTATTTTATCCAGATCAGGGGCTTTCACCTACCACCTTCCAA
ACTGTCTTCCCTCAAATTCGAGAAGGCTGTTTACAGAGTGCAGCTTAGTGAGTTTCCCTCCTGGCAGCCG
CGTGGTGTATGGTGTAGAGTCACCCCAGCCTTCCCCAACCTGCAGTATGTTCTAAAGCCATCTTCAGAGAATGT
AGGATTTAACTTAATGCTCGAAGTGGGTTGATCACCACCACAAAGCTCATGGACTTCCACGACAGAGCCCA
CTATCAGCTACACATCAGAACCTCACCGGCCAGGCCCTCCACCGTGGTGGTCAATGACATTGTGGACTGCAA
CAACCATGCCCCCTCTTCAACAGGTCTTCTATGATGGTACCTTGGATGAGAACATCCCTCCAGGCACCAG
TGTTTTGGCTGTGACTGCCACTGACCGGGATCATGGGGAAAATGGATATGTCACTATTCCATTGCTGGACC
AAAAGCTTTGGCATTTTCTATTGACCCCTACTTGGGGATCATCTCCACCTCCAAACCATGGACTATGAAT
CATGAAAAGAATTTATACCTTCCGGGTAAAGAGCATCAGACTGGGGATCCCCTTTTCGCCGGGAGAAGGAAGT
GTCCATTTTCTTCACTCAGGAACTTGAATGACAACCAAGCCATGTTTGAAGAAGTCACTGTACAGGGTC
TATCCGCCAAGACTGGCCAGTAGGGAAATCGATAATGACTATGTGAGCCATAGATGTGGATGAGCTTCAGAA
CCTAAATACGAGATGTATCAGGCAATGAATAGAGTATTTGATCTAAATCATTTCTCCGGAGTGATATC
CCTCAAACGCCCTTTTATCAATCTTACTGTGGTCAACCCACCAAGTTATTCCTGAAGATTACAGCCTCAG
TGGCAAAAACATGATGCCTCACCCAACTTTGAATATTACTGTGGTGAAGGACCTCATTTTGAAGTTCTCTGT
AACATGTGATAAAAAGGGGTATTGACACAATTCAAAAGACTATCTCCACTTTATTGGGCTTCAGAACCA
GGAGTCCAGTGATGAGGAATCACTTCTTTAAGCACATATCAGATTAATCATTACACCCACAGTTTGAGGA
CCACTTCCCCCAATCCATTGATGTCTTGGAGAGTGTCCCTATCAACACCCCTTGGCCCGCTAGCAGCCAC
TGACCTGATGCTGGTTTAAATGGCAAACTGGTCTATGTGATTGCAGATGGCAATGAGGAGGGCTGCTTTGA
CATAGAGCTGGAGACAGGGCTGCTCACTGTAGCTGCTCCCTTGGACTATGAAGCCACCAATTTCTACATCCT
CAATGTAACAGTATATGACCTGGGCACACCCAGAGTCTCCTGGAAGCTGCTGACAGTGAATGTGAAGA
CTGGAATGACAACGACCCAGATTTCTCCCGGTGGGTACCAAGTTAACCATCTCGGAGGACACAGAAGTTGG
AACCACAATTGCAGAGCTGACAACCAAGATGCTGACTCGGAAGACAATGGCAGGGTTTCGTACACCCTGCT
AAGTCCCACAGAGAAGTTCTCCCTCACCTCTCACTGGGGAAGTGGTTGTTACAGGACACCTGGACCGCA
ATCAGAGCCTCGGTACATACTCAAGGTGGAGGCCAGGGATCAGCCAGCAAAGGCCACAGCTCTTCTCTGT
CACTGACCTGATAATCAATTGGAGGATGTCAACGACAACCTCTCCCACTGCATCAGAAACAAACAGGCT
GAAGGTTCCAGAGGACCTGCCCCCGGACTGTCTTGACATTCTCGGATGCCTCTGATCCTGACCTGGGCCC
CGCAGGTGAAGTGCATATGTTCTGATGGATGGCGCCCATGGGACCTTCCGGGTGGACCTGATGACAGGGGC
GCTCATTTCTGGAGAGAGAGCTGGACTTTGAGAGGCGAGCTGGGTACAATCTGAGCCTGTGGGCGAGTATGG
TGGGAGGCCCTAGCCCGCAGGACTCTCTGCCATGTGGAGGTGATCGTCTGGATGTGAATGAGAATCTCCA
CCCTCCCCACTTTGCTCTCTCGTGACCAGGGCCAGGTGCAGGAGAACAGCCCCCTCGGGAACCTCAGGTGAT
TGATGTGGCTGCCAGGACGATGACAGTGGCTTGGATGGGGAGCTCCAGTACTTCTGCGTGTGGCACTGG
ACTCGAGCCTTCAGCATCAACCAAGATACAGGAATGATTCACTCTGGCACCCTGGACCCGAGAAATTTGC
ATCTTACTACTGGTTGACGGTATTAGCAGTGGACAGGGGTTCTGTGCCCTCTCTTCTGTAAGTGAAGTCTA
CATCGAGGTTACGGATGCCAATGACAACCCACCCAGATGTCCAAGCTGTGTTTACCCCTCCATCCAGGA
GGATGCTCCCGTGGGCACCTCTGTGCTTCACTGGATGCCTGGGACCCAGACTCCAGCTCCAAAGGGAAGCT
GACCTTCAACATCACCAGTGGGAATACATGGGATTCTTTATGATTACCCCTGTTACAGGTCTCTATCTAC

AGCCAGCAGCTGGACAGAGAGAACAAGGATGAACACATCCTGGAGGTGACTGTGCTGGACAATGGGGAACC
 CTCACGTGAAGTCCACCTCCAGGGTGGTGGTAGGCATCTTGGACGTCAATGACAATCCACCTATATTCTCCCA
 CAAGCTCTTCAATGTCCGCTTCCAGAGAGGCTGAGCCCTGTGTCCCTGGGCTGTGTACAGGCTGGTGGC
 TTCAGACCTGGATGAGGGTCTTAATGGCAGAGTACCTACAGTATCGAGGACAGCTATGAGGAGGCTTTCAG
 TATCGACCTGGTTCACAGGTGTGGTTTATCCAACAGCACTTTACAGCTGGAGAGTACAACATCCTAACGAT
 CAAGGCAACAGACAGTGGGCAGCCACCACTCTCAGCCAGTGTCCGGCTACACATTGAGTGGATCCCTTGGCC
 CCGGCCGTCTCCATCCCTCTGGCCTTTGATGAGACCTACTACAGCTTTACGGTTCATGGAGACGGACCCCTGT
 GAACCACATGGTGGGGTTCATCAGCGTAGAGGGCAGACCCGACTCTTCTGGTTCAACATCTCAGGTGGGGA
 TAAGGACATGGACTTTGACATTGAGAAGACCACAGGCAGCATCGTCATTGCCAGGCCTCTTGATACCAGGAG
 AAGGTCGAACATAAATTGACTGTTGAGGTGACAGATGGGTCCCGCACCATTGCCACACAGGTCCACATCTT
 CATGATTGCCAAGATTAAACCACCATCGGCCCAAGTTTCTGAAACTCGTTATGAAGTCAGAGTTCGCCAGGA
 CACCGTCCCAAGGTTAGAGTCTCTGCGAGTCCAGGCCATAGATCAAGACAAGGGCAAAAGCCTCATCTATAC
 CATACATGGCAGCCAAGACCCAGGAAGTCCAGCCTCTTCCAGCTGGACCCAAGCAGTGGTGTCTCTGTTAAC
 GGTGGGAAATTTGGACCTCGGCTCGGGCCCTCCAGCACACACTGACAGTCATGGTCCGAGACCAGGAAAT
 ACCTATCAAGAGGAACCTTCGTGTGGGTGACCATTCATGTGAGGATGGAAACCTCCACCCACCCGCTTTCAC
 TCAGCTCCATTATGAGGCAAGTGTCTGACACCATAGCCCGGCACAGAGCTGCTGAGGTCCGAGCCAT
 GGATGCTGACCGGGAGTCAATGCTGAGGTCCACTACTCCCTCTGAAAGGGAAACAGCGAAGGTTTCTTCAA
 CATCAATGCCCTGCTAGGCATCATTACTTAGCTCAAAGCTTGATCAGGCAATCATGCCCCACATACTCT
 GACAGTGAAGGAGAAATCAAGGCTCCCAACATGGCATGACCTGGCTACAGTGTATTCATGTCTATTC
 CTCAGATAGGAGTGGCCCATCTTTCAAATCTGAGTACTTTGTAGAGATCCCTGAATCAATCCCTGTGG
 TTCCCAATCCTCTTGTCTCTGCTAGAGCCCTCTGAAGTTACCTATGAGTTAAGAGAGGGAAATAAGGA
 TGGAGTCTTCTATGAACCTCATATTCTGGCCTTATTTCCACCCAGAAGAAATGGACCATGAGAAATCTC
 GTCTTACCAGCTGAAATCCGAGGCAGCAATATGGCAGGTGCATTACTGATGTCTGTTGGTGGTGGACAT
 AATTGATGAAATGCAATGCTCCTATGTTCTTAAAGTCAACTTTTGTGGGCCAAATTAGTGAAGCAGCTCC
 ACTGTATAGTATGATCATGGATAAAACACAAACCCCTTTGTGATTACATGCTCTGACAGTCAAGAAAGC
 TAATTCCTTGTGGTCTATAAAATTTTGGAGCCGAGGCTTGAAGTTTTCAAAATGATCCAGCATGGG
 AACCTAACCATTTGATCAGAGATGGATTATGAGAGCATGCCCTCTTCCAATCTGTGTCTATGTCCATGA
 CCAAGGAAGCCCTGTATTTTGCACCCAGACCTGCCAAGTTCATTCATGTCTGAGATGTGAATGATTC
 CCTCCAGATTTCTCAGAACAGATATATGAGGTAGCAATAGTCCGGCCTATCCATCCAGGCATGGAGCTTCT
 CATGGTGGCGGCCAGCGATGAAGACTCAGAAGTCAATTATAGCATCAAAACTGGCAATGCTGATGAAGCTGT
 TACCATCCATCCTGTCACTGGTAGCATATCTGTGCTGAATCCTGCTTCTTGGGACTCTCTCGGAAGCTCAC
 CATCAGGGCTTCTGATGGCTTGTATCAAGACACTGCGCTGGTAAATTTCTTTGACCCAAGTCTTGACAA
 AAGCTTGCAGTTTGTATCAGGATGTCTACTGGGCAGCTGTGAAGGAGAACTTGACAGGACAGAAAGGCATGGT
 GATTCCTGGTGGCCAGGGCAATCATTGGAATGACACCCCTTCTACTTTCTCTTGAATGGCACAGATATGTT
 TCATATGGTCCAGTCAAGGCTGTGTTGACAGCAAGAGGTGTGGCTTTGACCGGGAGCAGCAGGACACTCA
 TGAGTTGGCAGTGAAGTGAGGGACAATCGGACACCTCAGCGGTGGCTCAGGGTTTGGTCTGAGTCTCTAT
 TGAGGATGTCAATGACAAATCCCCCAAAATTAAGCATCTGCCCTATTACACAATCATCAAGATGGCAGAGA
 GCCAGGGGATGTCTCTTTCAGGTATCTGCCACTGATGAGGACTTGGGGACAATGGGGCTGTTACATATGA
 ATTTGACAGAAGATTACACATATTTCCGAATTGACCCCTATCTTGGGGACATATCACTCAAGAAACCTTTGA
 TTATCAAGCTTTAAATAAATATCACCTCAAAGTCAATTGCTCGGGATGGAGGAACGCCATCCCTCCAGAGTGA
 GGAAGAGGTACTTGTCACTGTGAGAAATAAATCCAACCCACTGTTTTCAGAGTCTTATTACAAAGTCAGAGT
 ACCTGAAAATATCACCTCTATACCCCAATTTCTCCACACCCAGGCCCGGAGTCCAGAGGGACTCCGGCTCAT
 CTACAACATTGGTGGAGGAAGAACCCTTGATGCTGTTCAACCACTGACTTCAAGACTGGTGTCTTAACAGTAAC
 AGGGCTTTTGGACTATGAGTCCAAGACCAAACTGTGTTTCAAGTCAAGAGCCACGGATACAGCTCTGGGGTC
 ATTTTCTGAAGCCACAGTGAAGTCTAGTGGAGGATGTCAATGATAACCTCCCACTTTTCCCAATTTGGT
 CTATACCACTTCCATCTCAGAAGCTTGTCTGCTCAGACCCCTGTGATCCAATGTTGGCTTCTGACCAGGA
 CTAAGGGCGGAACCGTGACGTCTCTTATCAGATTGTGGAGGATGGCTCAGATGTTTCCAAGTCTTCCAGAT
 CTGAGGAGCAGAGGGGAGATGTCCACAGTTCAAGAACTGGATTATGAAGCCCAACAACTCTTATGTTGAA
 AGTCAGGGCCATGGATAAAGGAGATCCCCACTCACTGGTGAAACCTTGTGGTGTCAATGTGTCTGATAT
 CAATGACAACCCCCAGAGTTGAGACAACCTCAATATGAAGCCAATGTCAGTGAACCTGGCAACCTGTGGACA
 CCTGGTTCTTAAAGTCCAGGCTATTGACCTGACAGCAGAGACACCTCCCGCTGGAGTACCTGATTCTTTC
 TGGCAATCAGGACAGGCATCTTCTATTAAAGCTCATCGGGAATAATTTCTATGTTCAACCTTTGCAAAAA
 GCACCTGGACTCTTCTTACAATTTGAGGGTAGGTGCTTCTGATGGAGTCTTCCGAGCACTGTGCTGTGTA
 CATCAACACTACAATGCCAACAAGTACAGCCAGAGTTCAGCAGCACCTTTATGAGGCAGAAATAGCAGA
 GAATGCAATGGTTGGAACCAAGGTGATTGATTGTCTAGCCATAGACAAAGATAGTGGTCCCTATGGCACTAT
 AGATTATACTATCATCAATAAATAGCAAGTGAGAAGTCTCCATAAACCCTAATGGCCAGATTGCCACTCT
 GCAGAAACTGGATCGGGAAAATTCACAGAGAGAGTCAATGCTATTAAGGTGATGGCTCGGGATGGAGGAGG
 AAGAGTAGCCTTCTGCACGGTGAAGATCATCTCACAGATGAAAATGACAACCCCCACAGTTCAAAGCATC
 TGAGTACACAGTATCCATTCAATCCAATGTCAGTAAAGACTCTCCGGTTATCCAGGTGTTGGCTATGATGC
 AGATGAAGGTGAGAACGAGATGTCACTACTCAGTGAACCCAGAGGACCTAGTTAAAGATGTCTTGAAT
 TAACCCAGTCACTGGTGTGGTCAAGGTGAAGACAGCCTGGTGGGATGGAAAATCAGACCTTGACTTCTT
 CATCAAGCCCAAGATGGAGGCCCTCTCTCACTGGAACCTCTGGTGCCAGTACGACTTCAGGTGGTTCTAA
 AAAAGTATCCTTACCGAAATTTCTGAACCTTTGTATACTTTCTCTGCACCTGAAGACCTTCCAGAGGGGTC
 TGAAATTTGGGATTTGTTAAAGCAGTGGCAGCTCAAGATCCAGTCATCTACAGTCTAGTGGGGGCACTACACC
 TGAGAGCAACAAGGATGGTGTCTTCTCCCTAGACCCAGACACAGGGGTCATAAAGGTGAGGAAGCCCATGGA
 CCACGAATCCACCAAAATTTGATACCAGATTGATGTGATGGCATTGCTTTCAGAACTGATGTGGTGTCTT
 GGTCTCTGTCAACATCCAAGTGGGAGACGTCAATGACAATAGGCCTGTATTTGAGGCTGATCCATATAAGGC
 TGTCTCTCACTGAGAATATGCCAGTGGGGACCTCAGTCATTCAAGTGAAGTGCATTGACAAGGACACTGGGAG
 AGATGGCCAGGTGAGCTACAGGCTGTCTGCAGACCTGGTAGCAATGTCATGAGCTCTTGGCATTGACAG

TGAGAGTGGTTGGATCACCACACTCCAGGAACCTTGACTGTGAGACCTGCCAGACTTATCATTTTCATGTGGT
GGCCTATGACCACGACAGACCATCCAGCTATCCTCTCAGGCCCTGGTTTCAGGTCTCCATTACAGATGAGAA
TGACAATGCTCCCGATTGCTTCTGAAGAGTACAGAGGATCTGTGGTTGAGAACAGTGAGCCTGGCGAAT
GGTGGCGACTCTAAAGACCCTGGATGCTGACATTTCTGAGCAGAACAGGCAGGTACCTGCTACATCACAGA
GGGAGACCCCTGGGCCAGTTTGGCATCAGCCAAGTTGGAGATGAGTGGAGGATTCTCTCAAGGAAGACCCT
GGACCGCAGCATACAGCCAAGTACTTGCTCAGAGTACAGCATCTGATGGCAAGTTCCAGGCTTCGGTAC
TGTGGAGATCTTTGCTCTGGACGTCAATGATAACAGCCCACAGTGTTCACAGCTTCTCTATACTGGCAAGGT
TCATGAAGATGTAATTCAGGACACTTCATTTTGAAGTTTCTGCCACAGACTTGGACACTGATACCAATGC
TCAGATCACATATTCTCTGCATGGCCCTGGGGCGCATGAATTCAAGCTGGATCCTCATACAGGGGAGCTGAC
CACACTACTGCCCTAGACCGAGAAAGGAAGGATGTGTTCAACCTTGTGTTGCAAGGCGACGGATGGAGGTGG
CCGATCGTGCCAGGCAGACATCACCTCCATGTGGAGGATGTGAATGACAATGCCCGCGGTTCTTCCCGAG
CCACTGTGCTGTGGCTGTCTTCGACAACACCACAGTGAAGACCCTGTGGCTGTAGTATTTGCCCGGGATCC
CGACCAAGGCGCCAATGCCAGGTGTTTACTCTCTGCCGATTTCAGCCGAAGGCCACTTTCCATCGACGC
CACCACGGGGGTGATCCGCCTGGAAAAGCCGCTGCAGGTTCAGGCCACAGGCACCACTGGAGCTCACGGTCCG
TGCTCTGACCTGGGCACCCCAATACCGCTGTCCACGCTGGGCACCGTCACAGTCTCGGTGGTGGGCTAGA
AGACTACCTGCCCGTGTTCCTGAACACCGAGCACAGCGTGCAGGTGCCCGAGGACGCCCCACCTGGCACGGA
GGTGTGTCAGCTGGCCACCTCACTCGCCCGGCGCAGAGAAGACCGGTACCGCGTGGTTCAGCGGGAACGA
GCAAGGCAGGTTCGCGCTGGATGCTCGCACAGGGATCCTGTATGTCAACGCAAGCTTGGACTTTGAGACAAG
CCCCAAGTACTTCTGTCCATTGAGTGCAGCCGAAGAGCTCCTCTTCCCTCAGTGACGTGACCACAGTCAT
GGTCAACATCACTGATGTCAATGAACACCGGCCCAATTCGCCCAAGATCCATATAGCACAAAGGCTCTTAGA
GAATGCCCTTGTGGGTGACGTCACTCTCAGGTATCAGCGACTGATGAAGATGGACCCCTAAATAGTGACAT
TACCTATGACCTCATAGGAGGGAACAGCTTGGGCACTTCACCATTCACCCAAAAGGGGAGCTACAGGT
GGCCAAGGCCCTGGACCGGGAACAGGCCTCTAGTTATTCCCTGAAGCTCCGAGCCACAGACAGTGGGCAGCC
TCCACTGCATGAGGACACAGACATCGCTATCCAAGTGGCTGATGTCAATGATAACCCACCGAGATTCTTCCA
GCTCAACTACAGCACCACTGTCCAGGAGAACTCCCCCATTTGGCAGCAAGTCTGTCAGCTGATCCTGAGTGA
CCCAGATTCTCCAGAGAATGGCCCCCTACTCGTTTGAATCACCAGGGGAACAACGGCTCTGCCTTCCG
AGTGACCCGGATGGATGGCTGGTGAATGCTGAGGGCCTAAGCAGGAGGGCTCAGGAATGGTATCAGCTTCA
GATCCAGGCGTCAGACAGTGGCATCCTTCCCTCTCGTCTTTGACGTCTGTCCGTGTCCATGTTCACAGAGCA
GAGCCACTATGACCTTCTGCTCTCCCACTGGAGATCTTCATCACTGTGGAGAGGATGAGTTCCAGGGTGG
CATGGTGGGTAAGATCCATGCCACAGACCGAGACCCCGAGGACAGCTGACCTATAGCCTGGCAGAAAGGGA
GACCTTGGGCAGGCCTTCTCAGTGGGTGCGCTGATGGCAAGATTATCGCCGCGGAGGCTGCTCGTGG
CCACTACTCGTTCAACGTACCGGTACCGATGGGACCTTACCACGACTGCTGGGGTCCATGTGTACGTGTG
GCATGTGGGGCAGGAGGCTCTGCAGCAGGCCATGTGGATGGGCTTCTACCAGCTCACCCCGAGGAGCTGGT
GAGTGACCACTGGCGGAACCTGCAGAGGTTCTCAGCCATAAGCTGGACATCAACCGGGCTAACATTCACCT
GGCCAGCCTCCAGCCTGCAGAGGCGGTGGTGGTGTGGATGTGCTCCTGGTCTTTGAGGGGCATTCTGGAAC
CTTCTACAGATTTTCAGGAGCTAGCATCCATCACTCACTCAGCCAAAGGAGATGGAGCATTCAGTGGGGT
TCAGATGCGGTGAGTATGCCCATGGTGGCTGCCAGGGGCCAACCTGCCAGGGTCAAATCTGCCATAACAC
AGTGATCTGGACCCCAAGGTTGGGGCCACGTACAGCACCGCCAGGCTCAGCATCTAACCCCGCGGCACCA
CCTGCAGAGGAGCTGCTCCTGCAATGGTACTGCTACAAGGTTTCAGTGGTCAGAGCTATGTGCGGTACAGGGC
CCAGCGGCTGGAACTGGCACATCCATTTCTATCTGAAAACACTCCAGCCACAGGCCATTCTTCTATTAC
CAATGAAGCAGCGTCCGTCTCCCTGAAGCTGGCCAGTGGAGTCCCCAGCTGGAATACCAGTGTCTGTGGGTG
TTTCTATGGAACCTTTCTCCAGCGCCATGTGAATGACCAGAGTGGCACTCCATCTGGTGGAGGAGAT
GGACGCTTCCATTGCGCTGATGGTTGACAGCATGGGCAACACCTCCCTTGTGGTCCCAGAGAACTGCCGTGG
TCTGAGGCCCGAAAGGCACCTCTTGCTGGGCGGCCTCATTCTGTTGCAATCTTCTCGAATGTCTCCAGGG
CTTTGAAGGCTGCTGGATGCTGTGCTGGTCAACGAAGAGGCTCTAGATCTGCTGGCCCCGCGCAAGAGCT
GGCAGGCTTGTGGAGACACAAGCCCTCACCCAGTGTGCTCCACAGTGACTACTGCAGCCAGAACACATG
CCTCAATGTGGGAGTGTCTATGGACCCATGGGGCAGGCTATGTCTGCAAATGTCCCCACAGTTCTCTGG
GAAGCACTGTGAACAAGGAAGGAGAACTGTACTTTTGCAACCTGCTGGAAGGTGGAACCTGCATCCTCTC
CCCCAAGGAGCTTCTGTAACTGCCCTCATCCTTACACAGGAGACAGGTGTGAATGGAGGCGAGGGGTG
TTCAGAAGGACACTGCTAGTCACTCCGAGATCCAAAGGGGGGACTGGGGGCAGCAGGAGTTACTGATCAT
CACAGTGGCCGTGGCGTTTATTATCATAAGCACTGTGCGGCTTCTCTTCTACTGCCCGCTTGCAAGTCTCA
CAAGCCTGTGGCCATGGAGGACCCAGACCTCTGGCCAGGAGTGTGGTGTGACACCCAAAGCCATGCTGTC
CATCGAGCTCAACCCATTGAGTGCCAGCTCCTGCAACAACCTCAACCAACCGGAACCCAGCAAGGCCCTGTG
TCCAAATGAATCTGTCAATTTGGACCCAATTCTAAGCAACGCGCCAGTGGTCTGCAGTGTGCCCCCCAGACT
CCCGCCAGCTGCGGTCCCTTCCCACTCTGACAATGAGCCTGTCTAAGAGAACCTGGTCCAGCGAGGAGAT
GGTGTACCTTGGCGGAGCCATGGTCTGGCCCCCTACTTACTCCAGGAACGAACGCTGGGAATACCCCACTC
CGAAGTGACTCAGGGCCCTCTGCGGCCCTCGGCTCACCGCACTCAACCCAGTCTGTATGCCAGAGCCTAA
TGGCCTCTATGGGGCTTCCCTTCCCCCTGGAGATGGAACAAGCGGGCACCTCTCCACCCCGTTACAG
CAACAGACTCTGGAAGATCTGATGCCCTCTGCGCCCCCTAGTCCCCGGGAGCGCTGGTGGCCCCCTGCT
CAATGAGTACACGGCCATCAGTACTACCACTCGCAGTTCGGCAGGGAGGGGGAGGGCCCTGCTGGCAGA
CGGGGGCTACAAGGGGGTGGTATGCGCCTCAGCCGAGCTGGGCCCTCTATGCTGTCTGTGAGGTGGAGGG
GGCACCTCTTGACGGCCAGGGCCAGCCCGGGTGGCCCCCACTATGAGGGCTCTGACATGGTGGAGAGTGA
TTATGGCACTGTGAGGAGTCACTGTCTAGCTTCCCATTCACAGAGCAAGGCAGGCGGGAGGCCAAGACT
GGACTTGGCTTATTTCTTCTGTCTCGTAGGGGGTGAAGTTGAGTGTGGCTGGGAGAGTGGGAGGGAAGCCCT
CAGCCAGGCTGTTGCTCCCTGAAATGTGCTCTTCAATCCCCACCTAGTCCCTGAGGGTGGAGGGAAGCT
GAGGATAGAGCTCCAGAAACAGCACTAGGGTCCAGGAGAGGGGCATTCTAGAGCAGTGACCTGGAAGAAC
CAGGAACCTGATCTCTGGGTGGCGCAGACAGGAGGGCTCCCTGATCTGCCGGCTCTCAGTCCCCGGG
GCAAAGCCTGATTGACTGTGCTGGCTCAACTTCAACAGATGCAATCTCATACCTGCCACAGCTCCATTTT
GGAGGCAGGCAGGTTGGTGCCTGACAGACAACCACTACGCGGCCGTACAGAGGAGCTCTAGAGGGCTGCT


```

GGCATCCTCTAGGGGCTGAGAGGTGAGCAGCAGGGGAGCGGGCACAGTCCCCTGCCCCCTGCCTCAGTCG
AGCACTCACTGTGTCTTTGTCAAGTGTCTGCTCCACGTCAGGCACTGTGCTTTGCACCGGGGAGAAAATGGT
GATGGAGGGCAACAAGGACTCCGAGGAGCACCACAGGCCTCGGGCCCCAGAGGTCCCGCTCCTCAGCCTAC
ACGCAGAGGAACGGGCCCACCTCAGAGTCACACCCTGGCTGCCAGTCAGGGCCCTGCCAGGAGTCTACACAG
CTCTGAACCTTCTTTGTTAAAGAATTGAGACCTCATGGAACCTGCGGTTCTTCATCCCAAGTTTCCAGGGCA
CTTTTGGCCAAAGGAAGGAAGGAACCTAATTTCTCATTTTAAAAATTCTTAGGCACCTTTTGGACCTTGCTGTC
TGGATGAGTTTCTCAATGGGATTTTCTTCCCTAGACACAAGGAAGTCTGAACCTCTATTTAGGGCCGGTT
GGAAGCAGGAGCTGACCGCAGTGTCCAGGCTGGACACCTGCCATTGCCCTCCTCCTCCACTGCAGACGCCTG
CCCATCAAGTATTACCTGCAGCGACTCAACCTATGATGAGGGTCAATGTGGGCACATGTCTACACATGT
GGGTGCCCATGGATAGTACGTGTGTACACATGTGTAGAGTGTATGTAGCCAGGAGTGGTGGGACAGAGAAGC
CTCTGTGGCCTTTGGTGACCTCACCCTCCCTCCACCCAGTCCCTCCCTCTGGTCCACTGCCCTTTTCATAT
GTGTTGTTTCTGGAGACAGAAGTCAAAGGAAGAGCAGTGGAGCCTTGCCACAGGGCTGCTGCTTCATGCG
AGAGGGAGATGTGTGGCGAGAGCAATTTGTGTGAGTGGTTTGTGGCTGTGTGTGTGACTGTGAGTGTGAG
TGACAGATACATAGTTTCATTGGTCAATTTTTTTTTTTTAAACAATAAAGTATCTTTTTTACTGTT

```

The disclosed NOV2 nucleic acid sequence, localized to the q33 region of human chromosome 5, has 14536 of 14536 bases (100%) identical to a protocadherin Fat 2 (FAT2) cadherin related tumor suppressor (GENBANK-ID: AF231022) (E = 0.0).

- 5 A NOV2 polypeptide (SEQ ID NO:4) encoded by SEQ ID NO:3 has 4349 amino acid residues and is presented using the one-letter code in Table 2B. Signal P, Psort and/or Hydropathy results predict that NOV2 does not contain a signal peptide and is likely to be localized in the plasma membrane, and is a Type Ia membrane protein.

Table 2B. Encoded NOV2 protein sequence (SEQ ID NO:4).

```

MTIALLGFAIFLLHCATCEKPLEGILSSSAWHFTHSHYNATIYENSSPKTYVESFEKMGIIYLAEPQWAVRYR
IISGDVANVFKEEYVVGNFCLRIRTKSSNTALLNREVRDSYTLIIQATEKTLELEALTRVVVHILDQNDL
KPLFSPPSYRVTIISEDMPKSPICKVTATDADLGQNAEFYAFNTRSEMFAIHPTSGVVTVAGKLNVTWRGK
HELQVLAVDRMRKISEGNGFGSLAALVVHVEPALRKPPAIASVVVTPPDSNDGTTYATVLVDANSSGAEVES
VEVVGDPGKHKFAIKSYARSNEFSLVSVKDINWMEYLHGFNLSLQARSGSGPYFYSQIRGFHLPPSKLSSL
KFEKAVYRVQLSEFSPPGSRVVMVRVTPAFPNLQYVLKPSSENVGFKLNARTGLITTTKLMDFDHRAHYQLH
IRTPGQASTVVVIDIVDCNNHAPLFNRSSYDGTLDENIPPGTSLAVTATDRDHGENGVVTSIAGKALP
FSIDPYLGIISTSKPMDYELMKRIYTFRVRASDWGSPFRREKEVSI FLQLRNLDNDQPMFEEVNCTGSIRQD
WPVGKSIMTMSAIDVDELQNLKYEIVSGNELEYFDLNFHSGVISLKRPFINLTAGQPTSYSLKITASDGKNY
ASPTTLNITVVKDPHFVPTVCDKTVLTQFTKTI LHF IGLQNQESSDEEFTSLSTYQINHYTPQPEDHFPQ
SIDVLESVPINTPLARLAATDPDAGFNGKLVYVIADGNEEGCFDIELETGLLTVAAPLDYEATNFYILNVT
YDLGTPQKSSKLLTVNVKWDNDNAPRFPFGGYQLTISEDTEVGTTIAELTTKDADSEDNNGRVRVYLLSPT
KPSLHPLTGELVVTGHLDRSEPRYILKVEARDQPSKGHQLFSVTDLIITLEDVNDNSPQCITEHNRKLVPE
DLPPGTVLTFLDASDPDLGPAGEVRVYVMDGAHGTFRVLDLMTGALILERELEDFERRAGYNLSLWASDGGRL
ARRTLCHVEVIVLDVNENLHPPHFASFVHQQGVQENSPSGTQVIIVAAQDDDSGLDGELOQFLRAGTGAAFP
SINQDTGMIQTLAPLDREFASYWLTVLAVDRGSVPLSSVTEVYIEVTDANDNPPQMSQAVFYPSIQEDAPV
GTSVLQLDADPDSSSKGKLTFNITSGNYMGFFMIHPVTGLLSTAQQLDRENKDEHILEVTVLNDGEP SLKS
TSRVVVGILDVNDNPPIFSHKLFNVRLPERLSPVSPGPVYRLVASDLDEGLNGRVITYSIEDSYEEAFSIDLV
TGUVSSNSTFTAGEYNILTIKATDSGQPPLSASVRLHIEWIPWPRPSSIPLAFDETYYSFTVMETDPVNHMV
GVISVEGRPGLFWFNISGGDKDMDFDIEKTGSIIVARPLDTRRRSNYNLTVEVTDGSRITATQVHIFMIAN
INHHRPQFLETRYEVVRPQDTPVPGVELLRVQAIDQDKGKSLIYTIHGSQDPGSASLFLQDLPSSGVLVTGKL
DLGSGPSQHTLTVMVRDQEIPIKRNFWVVTIHVEDGNLHPPRPTQLHYEASVPDTIAPGTELLQVRAMADR
GVNAEVHYSLLKGNSEGFFNINALLGIITLAQKLDQANHAPHTLTVKAEQDQSPQWHDLATVIHVVYPSDRS
APIFSKSEYFVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVFMSNSYSLISTQKKLDHEKISSYQL
KIRGSNLMAGAFDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMIMDKNNNPFVHISDSDKEANSLL
VYKILEPEALKFFKIDPSMGTLTIVSEMDYESMSPSQFCVYVHDQGSVPLFAPRPAQVIHVRDVNDSPPRF
SEQIYEVAIVGPIHPGMELLMVRASDEDESVNYSIKTGNABAVTIHPVTGSI SVLNPAFLGLSRKLTIRAS
DGLYQD TALVKISLTQVLDKSLQFDQVYWA AVKENLQDRKALVILGAQGNHNLNDTLSYFLLNGTDMFHMVQ
SAGVLTATRGVAFDREQDTHELAVEVRDNRTPQRAVQGLVRVSI EDVNDNPPKFKHLPYTTIIQDGTPEGDV
LPQVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDYQALNKYHLKVIARDGGTTPSLQSEEEVL
VTVRNKSNPLFQSPYYKVRVPENITLYTPI LHTQARSPEGLRLIYNIVEEPEPLMFTTDFKTGVLTVTGPLD
YESKTKHVFTVRATD TALGSFSEATVEVLVEDVNDNPPTPSQLVYTTISI SEGLPAQTPVIQLLASDQDSGRN
RDVSYQIVEDGSDVSKFPQINGSTGEMSTVQELDYBAQOHFVKVRAMDKGDPPLTGETLVVVNVSDINDNP

```

```

PEFRQPYEAVNSELATCGHLVLKVQAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMFNLCCKHLD
SYNLRVGASDGVFRATVPVYINTTNANKYSPFQQHLYEAEAEANAMVGTKVIDLLAIDKDSGPYGTIDYTI
INKLASEKFSINPNGQIATLQKLDRENSTERVIAIKVMARDGGGRVAFCTVKIILTDENDNPPQFKASEYTV
SIQSNVSKDSPVIQVLAYDADEGQNADVTSVNPEDLVKDVIENPVTGVVVKVDSLVLGLENQTLDFFIKAQ
DGGPPHWNLSLVPVRLQVVPKKVSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTTPESENK
DGVFSLDPDTGVIKVRKPMDEHSTKLYQIDVMAHCLQNTDVSLSVSVNIQVGDVNDNRPFVFEADPYKAVLTE
NMPVGTSTVQVTAIDKDTGRDQVSYRLSADPGSNVHELFAIDSESGWITTLQELDCETCQTYHFHVAYDH
GQTIQLSSQALVQVSI TDENDNAPRFASEEYRGSVVENSEPGEVLVATLKTLDADI SEQNQVTCYITEGDPL
GQFGISQVGDEWRISSRKTLDRHTAKYLLRV TASDGKFQASVTVEI FVLVDVNDNSPQCSQLLYTGKVHEDV
FPGHFILKVSATDLDTDTNAQITYSLHGPGAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQ
ADITLHVEDVNDNAPRFFPSHCAVAVFDNTTVKTPVAVVFARDPDQGANAQVVYSLPDSAEHGHSIDATTGV
IRLEKPLQVRPQAPLELTVRASDLGTP IPLSTLGTVTVS VVGLEDYLPVFLNTEHSVQVPEDAPPGETVLQ
ATLTRPGA EKTGYRVVSGNEQGRFRLDARTGILYVNASLD FETSPKYFLSIECSRKSSSSSLSDVTTVMVNIT
DVNEHRPQFPQDPYSTRVLENALVGDVILT SATDEDEGPLNSDITYSLIGGNQLGHFTIHPKKGELQVAKAL
DREQASSYSLKL RATDSGQPLHEDTDIAIQVADVNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDPSP
ENGPPYSFRITKGNNGSAFRVTPDGLVLTAEGLSRR AQEWYQLQIQASDSGIPPLSSLT SVRVHVTQSHYA
PSALPLEIFITVGEDEFQGGMVGKI HATDRDPQDTLTYS LAEEETLGRHFSVGAPDGKIIAAQGLPRGHYSF
NVTVSDGTPTTTAGVHVYVWHVGQEALQQAMWGMGYQLTPEELVSDHWRNLQRFSLHKLDIKRANIHSLAQ
PAEAVAGVDVLLVFEGHSGTFYEFQELASIIITHSAKEMEHSVGVQMR SAMPMPVPCQGPTCQGQICHNTVHLD
PKVGPTYSTARLSILT PRHLQ RSCSCNGTATRFSGQSYVRYRAPAARNWHIHFY LKTLQQAILLFTNETA
SVSLKLASGVPQLEYHCLGGFYGNLSSQRHVNDHEWHSILVEEMDASIRLMVDSMGNTSLVVPENCRLRPE
RHL LGLL LLLHSSSNVSQGFEGCLDAVVVNEEALDLLAPGKT VAGLLETQALTQCCLHSDYCSQNTCLNGG
KCSWTHGAGYVCKC PPFQSGKHCEQGRENCTFAPCLEGGTCILSPKGASCNCPPHYTGDRCEMEARGCSEGH
CLVTPEIQRGDWGQQELLII TVAVAFIIISTVGLLFYCRCKSHKPVAMEDPDL LARSVGVDTQAMPAIELN
PLSASSCNLNLQPEPSKASVPNELVTFGPNSKQRPVVCVPPRLPPAAVPSHSDNEPVIKRTWSSEEMVYPG
GAMVWPPTYSRNERWEYPHSEVTQGPLPPSAHRHSTPVVMPEPNGLYGGFFFPLEMENKRAPLP PRYSNQNL
EDLMP SRPPSPRERLVAPCLNEYTAISYYHSQFRQGGGGPCLADGGYKGVGMRLSRAGPSYAVCEVEGAPLA
GQGQPRVPNPNYEGSDMVESDYGSCEEVMF

```

The disclosed NOV2 amino acid sequence has 4349 of 4349 amino acid residues (100%) identical to, and 4349 of 4349 amino acid residues (100%) similar to, the 4349 amino acid residue Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor protein from human protocadherin Fat 2 (FAT2) cadherin related tumor suppressor (GENBANK-ID: AF231022) (E = 0.0).

TaqMan data for NOV2 is displayed below in Example 1, and SAGE data is shown below in Example 2. The TaqMan data shows overexpression of NOV2 in ovarian cancer cell lines, breast and lung cancers and high expression in cerebellum. Sage analysis agrees for Cerebellum and weaker for Ovaries.

NOV2 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 2C.

Table 2C. BLAST results for NOV2					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect

gi 13787217 ref NP_001438.1	FAT tumor suppressor 2 precursor; multiple epidermal growth factor-like domains 1; cadherin family member 8; FAT tumor suppressor (Drosophila) homolog 2; protocadherin FAT2 [Homo sapiens]	4349	4305/4349 (98%)	4306/4349 (98%)	0.0
gi 7407144 gb AAF61928.1 AF231022_1 (AF231022)	protocadherin Fat 2 [Homo sapiens]	4349	4307/4349 (99%)	4307/4349 (99%)	0.0
gi 12621132 ref NP_075243.1	MEGF1 [Rattus norvegicus]	4351	3524/4351 (80%)	3878/4351 (88%)	0.0
gi 4885229 ref NP_05236.1	FAT tumor suppressor precursor; homolog of Drosophila tumor suppressor Fat precursor; cadherin-related tumor suppressor homolog precursor; homolog of Drosophila Fat protein precursor; homolog of Drosophila Fat protein; cadherin family member 7 precursor	4590	1828/4089 (44%)	2623/4089 (63%)	0.0
gi 14733833 ref XP_041971.1	FAT tumor suppressor 2 precursor [Homo sapiens]	2991	2963/2991 (99%)	2963/2991 (99%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 2D.

5

Table 2D. ClustalW Analysis of NOV2

- 1) NOV2 (SEQ ID NO:4)
- 2) gi|13787217|ref|NP_001438.1| FAT tumor suppressor 2 precursor (SEQ ID NO:18)

- 2) gi|7407144|gb|AAF61928.1|AF231022_1 (AF231022) protocadherin Fat 2 (Homo sapiens) (SEQ ID NO:19)
 3) gi|12621132|ref|NP_075243.1|MEGF1 [Rattus norvegicus] (SEQ ID NO:20)
 4) gi|4885229|ref|NP_005236.1|FAT tumor suppressor precursor (SEQ ID NO:21)
 5) gi|14733833|ref|XP_041971.1|FAT tumor suppressor 2 precursor [Homo sapiens] (SEQ ID NO:22)

10	NOV2	10	20	30	40	50	60	
	gi 13787217 ref	MTIALLGFAIFLLHCA	TCERPLEGILSSSA	HHFTHSHYNATIYENS	SPKTYVESPEKMG	59		
	gi 7407144 gb A	MTIALLGFAIFLLHCA	TCERPLEGILSSSA	HHFTHSHYNATIYENS	SPKTYVESPEKMG	59		
	gi 12621132 ref	MTIALLGFAIFLLHCA	TCERPLEGILSSSA	HHFTHSHYNATIYENS	SPKTYVESPEKMG	59		
15	gi 4885229 ref	MGRHLALLLLLL	LLFQHFQSDGSQRLE	QTPLOFTHLEYNVTQ	ENSAKTYVGHFVKMG	60		
	gi 14733833 ref	-----	-----	-----	-----	1		
20	NOV2	70	80	90	100	110	120	
	gi 13787217 ref	IVLAEPQAVVRYRIIS	GDVANVFKTEEVVGN	FCFLRIRTKSSNTALL	NREVRDSYTLIK	119		
	gi 7407144 gb A	IVLAEPQAVVRYRIIS	GDVANVFKTEEVVGN	FCFLRIRTKSSNTALL	NREVRDSYTLIK	119		
	gi 12621132 ref	IVLAEPQAVVRYRIIS	GDVANVFKTEEVVGN	FCFLRIRTKSSNTALL	NREVRDSYTLIK	119		
25	gi 4885229 ref	IVLAEPQAVVRYRIIS	GDVANVFKTEEVVGN	FCFLRIRTKSSNTALL	NREVRDSYTLIK	120		
	gi 14733833 ref	-----	-----	-----	-----	1		
30	NOV2	130	140	150	160	170	180	
	gi 13787217 ref	QATEKLELEALTRVV	VHILDNDLKPLFSP	PSYRVITISED	MPLKSPICKVTATD	ADLQG	179	
	gi 7407144 gb A	QATEKLELEALTRVV	VHILDNDLKPLFSP	PSYRVITISED	MPLKSPICKVTATD	ADLQG	179	
	gi 12621132 ref	QATEKLELEALTRVV	VHILDNDLKPLFSP	PSYRVITISED	MPLKSPICKVTATD	ADLQG	179	
35	gi 4885229 ref	QATEKLELEALTRVV	VHILDNDLKPLFSP	PSYRVITISED	MPLKSPICKVTATD	ADLQG	179	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	
40	NOV2	190	200	210	220	230	240	
	gi 13787217 ref	NAEFYAFNRSEMF	FAIHPTSGVVT	VAGKLVTRGKHE	LOQLAVDRMRKIS	EGNGFGSL	239	
	gi 7407144 gb A	NAEFYAFNRSEMF	FAIHPTSGVVT	VAGKLVTRGKHE	LOQLAVDRMRKIS	EGNGFGSL	239	
	gi 12621132 ref	NAEFYAFNRSEMF	FAIHPTSGVVT	VAGKLVTRGKHE	LOQLAVDRMRKIS	EGNGFGSL	239	
45	gi 4885229 ref	NAEFYAFNRSEMF	FAIHPTSGVVT	VAGKLVTRGKHE	LOQLAVDRMRKIS	EGNGFGSL	239	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	
50	NOV2	250	260	270	280	290	300	
	gi 13787217 ref	AALVVHVEPALRK	PPATASVVVTP	PPDSNDGTYATV	LVLDANGSSG	EEVESVEVVGDDPG	297	
	gi 7407144 gb A	AALVVHVEPALRK	PPATASVVVTP	PPDSNDGTYATV	LVLDANGSSG	EEVESVEVVGDDPG	297	
	gi 12621132 ref	AALVVHVEPALRK	PPATASVVVTP	PPDSNDGTYATV	LVLDANGSSG	EEVESVEVVGDDPG	297	
55	gi 4885229 ref	AALVVHVEPALRK	PPATASVVVTP	PPDSNDGTYATV	LVLDANGSSG	EEVESVEVVGDDPG	297	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	
60	NOV2	310	320	330	340	350	360	
	gi 13787217 ref	KHFKAITSYARSN	EEFLSVKNDINM	EMYLHGFNL	SLQARS	SGGPFYYSQIRGFHLEPSKI	357	
	gi 7407144 gb A	KHFKAITSYARSN	EEFLSVKNDINM	EMYLHGFNL	SLQARS	SGGPFYYSQIRGFHLEPSKI	357	
	gi 12621132 ref	KHFKAITSYARSN	EEFLSVKNDINM	EMYLHGFNL	SLQARS	SGGPFYYSQIRGFHLEPSKI	357	
65	gi 4885229 ref	KHFKAITSYARSN	EEFLSVKNDINM	EMYLHGFNL	SLQARS	SGGPFYYSQIRGFHLEPSKI	357	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	
70	NOV2	370	380	390	400	410	420	
	gi 13787217 ref	SS--LKFEKAVYRV	CLSEFSPPGSR	VVMVRVTPAG	FNLYVLKPSSEN	VGFKLNARTGLI	415	
	gi 7407144 gb A	SS--LKFEKAVYRV	CLSEFSPPGSR	VVMVRVTPAG	FNLYVLKPSSEN	VGFKLNARTGLI	415	
	gi 12621132 ref	SS--LKFEKAVYRV	CLSEFSPPGSR	VVMVRVTPAG	FNLYVLKPSSEN	VGFKLNARTGLI	415	
75	gi 4885229 ref	SS--LKFEKAVYRV	CLSEFSPPGSR	VVMVRVTPAG	FNLYVLKPSSEN	VGFKLNARTGLI	415	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	
	NOV2	430	440	450	460	470	480	
	gi 13787217 ref	TTTKLVDFH	QRAHYQLHRTSP	QOASTVVVIDIV	DCNNHAPFN	RSSYGGTLDENIPPGT	475	
	gi 7407144 gb A	TTTKLVDFH	QRAHYQLHRTSP	QOASTVVVIDIV	DCNNHAPFN	RSSYGGTLDENIPPGT	475	
	gi 12621132 ref	TTTKLVDFH	QRAHYQLHRTSP	QOASTVVVIDIV	DCNNHAPFN	RSSYGGTLDENIPPGT	475	
	gi 4885229 ref	TTTKLVDFH	QRAHYQLHRTSP	QOASTVVVIDIV	DCNNHAPFN	RSSYGGTLDENIPPGT	475	
	gi 14733833 ref	-----	-----	-----	-----	-----	1	

	gi 4885229 ref	STILEPVKROQAHPFELVYITSDRRASTVLLVVLGANSNPPEFTGTAKAAFDENVBIST	480
	gi 14733833 ref	-----	1
5	NOV2	SVLAVTATDRDHGENGYVTYSIAGPKATPFSIDPLGHIISTSKPMYELMKRIYTFVRVA	535
	gi 13787217 ref	SVLAVTATDRDHGENGYVTYSIAGPKATPFSIDPLGHIISTSKPMYELMKRIYTFVRVA	535
	gi 7407144 gb A	SVLAVTATDRDHGENGYVTYSIAGPKATPFSIDPLGHIISTSKPMYELMKRIYTFVRVA	535
	gi 12621132 ref	SVLAVTATDRDHGENGYVTYSIAGPKATPFSIDPLGHIISTSKPMYELMKRIYTFVRVA	535
10	gi 4885229 ref	TIMSLSAVDPDDEGENGYVTYSIANLNHVPFAIDHETGAVTSENIDYELMFRVYTLRRA	540
	gi 14733833 ref	-----	1
15	NOV2	SDWGSPPFRREKEVSDPLQLRLNLDNQPMPEEVNCTGSIROQMPVGKSIMTMSAIDVDELQ	595
	gi 13787217 ref	SDWGSPPFRREKEVSDPLQLRLNLDNQPMPEEVNCTGSIROQMPVGKSIMTMSAIDVDELQ	595
	gi 7407144 gb A	SDWGSPPFRREKEVSDPLQLRLNLDNQPMPEEVNCTGSIROQMPVGKSIMTMSAIDVDELQ	595
	gi 12621132 ref	SDWGSPPFRREKEVSDPLQLRLNLDNQPMPEEVNCTGSIROQMPVGKSIMTMSAIDVDELQ	595
20	gi 4885229 ref	SDWGLPYRRREVEVLATITLNNLNLDNTPLEKINCGRTPRDLGVGEQITIVSAIDADELO	600
	gi 14733833 ref	-----	1
25	NOV2	NLKYEIVSGNELEYFDLNHFSGVISLKRPFNLTAQPTSYSLKITASDGKNYASPTTLN	655
	gi 13787217 ref	NLKYEIVSGNELEYFDLNHFSGVISLKRPFNLTAQPTSYSLKITASDGKNYASPTTLN	655
	gi 7407144 gb A	NLKYEIVSGNELEYFDLNHFSGVISLKRPFNLTAQPTSYSLKITASDGKNYASPTTLN	655
	gi 12621132 ref	NLKYEIVSGNELEYFDLNHFSGVISLKRPFNLTAQPTSYSLKITASDGKNYASPTTLN	655
30	gi 4885229 ref	LVCYQTEAGNEIDFLSLNPNSSVLSLKRSLMDGLGAKVSPHSLRITATDGENFATILYLN	660
	gi 14733833 ref	-----	1
35	NOV2	ITVVKDPHSEVPVQCDKTGVLTQFTKTLHFISLQNOSSDEEFTSLSTVQINHYTPQFE	715
	gi 13787217 ref	ITVVKDPHSEVPVQCDKTGVLTQFTKTLHFISLQNOSSDEEFTSLSTVQINHYTPQFE	715
	gi 7407144 gb A	ITVVKDPHSEVPVQCDKTGVLTQFTKTLHFISLQNOSSDEEFTSLSTVQINHYTPQFE	715
	gi 12621132 ref	ITVVKDPHSEVPVQCDKTGVLTQFTKTLHFISLQNOSSDEEFTSLSTVQINHYTPQFE	715
	gi 4885229 ref	ITVVAAS-HKLVNMLQCEETGVAKMLAKTLOANKIFNQ--GEVEDIFFDSHYNATIPQER	717
	gi 14733833 ref	-----	1
40	NOV2	DHFPQSIDVLESVPINTPLARLAATDPDAGFNGKLVVYVADGNEEGCFDIELETGLLIWA	775
	gi 13787217 ref	DHFPQSIDVLESVPINTPLARLAATDPDAGFNGKLVVYVADGNEEGCFDIELETGLLIWA	775
	gi 7407144 gb A	DHFPQSIDVLESVPINTPLARLAATDPDAGFNGKLVVYVADGNEEGCFDIELETGLLIWA	775
45	gi 12621132 ref	DHFPQSIDVLESVPINTPLARLAATDPDAGFNGKLVVYVADGNEEGCFDIELETGLLIWA	775
	gi 4885229 ref	STLPTGIQVKEQNPVCSWIFNNSDLDGTFNGKLVYVAGGNEBSCPMIDMETGMKIL	777
	gi 14733833 ref	-----	1
50	NOV2	APLDYEATNFEYLLNVTVYDLGTPQKSSWKLLTVNVKQWNDNAPRFPFGGYQLTISEDTEV	835
	gi 13787217 ref	APLDYEATNFEYLLNVTVYDLGTPQKSSWKLLTVNVKQWNDNAPRFPFGGYQLTISEDTEV	835
	gi 7407144 gb A	APLDYEATNFEYLLNVTVYDLGTPQKSSWKLLTVNVKQWNDNAPRFPFGGYQLTISEDTEV	835
	gi 12621132 ref	APLDYEATNFEYLLNVTVYDLGTPQKSSWKLLTVNVKQWNDNAPRFPFGGYQLTISEDTEV	835
55	gi 4885229 ref	SPLDRETTDKYTLNITVYDLGTPQKAAWRLHVVVVDANDNPEELQESVFEVSEDKEV	837
	gi 14733833 ref	-----	1
60	NOV2	GTTIAELTIKDADSEDNGRVRYTLLSPTEKFSLHPITGSLVVTGHLDRSEPPRYILKVEA	895
	gi 13787217 ref	GTTIAELTIKDADSEDNGRVRYTLLSPTEKFSLHPITGSLVVTGHLDRSEPPRYILKVEA	895
	gi 7407144 gb A	GTTIAELTIKDADSEDNGRVRYTLLSPTEKFSLHPITGSLVVTGHLDRSEPPRYILKVEA	895
	gi 12621132 ref	GTTIAELTIKDADSEDNGRVRYTLLSPTEKFSLHPITGSLVVTGHLDRSEPPRYILKVEA	895
65	gi 4885229 ref	HSEITQVEATDKDLGFNGHVTYSILEADDTFSIDSVTGVANTARPLDRBLQEHSLKTEA	897
	gi 14733833 ref	-----	1
70	NOV2	RDQFSKGHQLFSVTDLIITLEDVNDNSPQCITEHNRKLVPEDLFPSTVLTFLDASDPDLG	955
	gi 13787217 ref	RDQFSKGHQLFSVTDLIITLEDVNDNSPQCITEHNRKLVPEDLFPSTVLTFLDASDPDLG	955
	gi 7407144 gb A	RDQFSKGHQLFSVTDLIITLEDVNDNSPQCITEHNRKLVPEDLFPSTVLTFLDASDPDLG	955
	gi 12621132 ref	RDQFSKGHQLFSVTDLIITLEDVNDNSPQCITEHNRKLVPEDLFPSTVLTFLDASDPDLG	955
	gi 4885229 ref	RDQARREFQLFSTVVVXVSLSDVNDNPPTTFIPNVKRVKREDLFPSTVIMMLEADDPDLG	957
	gi 14733833 ref	-----	1
75	NOV2	PAGEVRYVLMUGAHGTERVDLMTGALILEREELDFERRAGYNLSLWASDCSRPLARTLCH	1015

5	gi 13787217 ref	PAGEVRYVLMDCAHGTRFVDMTGALILRELDERRAGYNLSLWASDGGRIPLARRTLCH	1015
	gi 7407144 gb A	PAGEVRYVLMDCAHGTRFVDMTGALILRELDERRAGYNLSLWASDGGRIPLARRTLCH	1015
	gi 12621132 ref	PAGEVRYVLMDCAHGTRFVDMTGALILRELDERRAGYNLSLWASDGGRIPLARRTLCH	1015
	gi 4885229 ref	QSCQVRYSLDHCENSDVDKLSGAVRIVQGLDFKKQVYNLVRRKDKKRPVSLGSLCH	1017
	gi 14733833 ref	-----	1
10	NOV2	1030 1040 1050 1060 1070 1080	
	gi 13787217 ref	VEVIVLDVNENLHPPHFAFVHCGQVQENSFSGTQVIVVAAQDDSGLDGELQYFLRAGT	1075
	gi 7407144 gb A	VEVIVLDVNENLHPPHFAFVHCGQVQENSFSGTQVIVVAAQDDSGLDGELQYFLRAGT	1075
	gi 12621132 ref	VEVIVLDVNENLHPPHFAFVHCGQVQENSFSGTQVIVVAAQDDSGLDGELQYFLRAGT	1075
	gi 4885229 ref	VEVIVLDVNENLHPPHFAFVHCGQVQENSFSGTQVIVVAAQDDSGLDGELQYFLRAGT	1075
15	gi 14733833 ref	VEVIVLDVNENLHPPHFAFVHCGQVQENSFSGTQVIVVAAQDDSGLDGELQYFLRAGT	1077
		-----	1
20	NOV2	1090 1100 1110 1120 1130 1140	
	gi 13787217 ref	GLAASFINSQDTGMICTLAPLDREFASYYNLTVLAVDRGSVPLSSVTEVYIEVTDANDNPP	1135
	gi 7407144 gb A	GLAASFINSQDTGMICTLAPLDREFASYYNLTVLAVDRGSVPLSSVTEVYIEVTDANDNPP	1135
	gi 12621132 ref	GLAASFINSQDTGMICTLAPLDREFASYYNLTVLAVDRGSVPLSSVTEVYIEVTDANDNPP	1135
	gi 4885229 ref	GLAASFINSQDTGMICTLAPLDREFASYYNLTVLAVDRGSVPLSSVTEVYIEVTDANDNPP	1135
25	gi 14733833 ref	GLAASFINSQDTGMICTLAPLDREFASYYNLTVLAVDRGSVPLSSVTEVYIEVTDANDNPP	1137
		-----	1
30	NOV2	1150 1160 1170 1180 1190 1200	
	gi 13787217 ref	QMSQAVFYPSIQEDAPVGTSLVQLDAMDPPSSSGKLTFTNITSGNMGFFMIHPVTGLLS	1195
	gi 7407144 gb A	QMSQAVFYPSIQEDAPVGTSLVQLDAMDPPSSSGKLTFTNITSGNMGFFMIHPVTGLLS	1195
	gi 12621132 ref	QMSQAVFYPSIQEDAPVGTSLVQLDAMDPPSSSGKLTFTNITSGNMGFFMIHPVTGLLS	1195
	gi 4885229 ref	QMSQAVFYPSIQEDAPVGTSLVQLDAMDPPSSSGKLTFTNITSGNMGFFMIHPVTGLLS	1195
35	gi 14733833 ref	QMSQAVFYPSIQEDAPVGTSLVQLDAMDPPSSSGKLTFTNITSGNMGFFMIHPVTGLLS	1197
		-----	1
40	NOV2	1210 1220 1230 1240 1250 1260	
	gi 13787217 ref	TAQQLDRENKDEHILEVTVDNGEPSSLKSTSRVVVGILDVNDNPPHFSHKLFNVRLPER	1254
	gi 7407144 gb A	TAQQLDRENKDEHILEVTVDNGEPSSLKSTSRVVVGILDVNDNPPHFSHKLFNVRLPER	1254
	gi 12621132 ref	TAQQLDRENKDEHILEVTVDNGEPSSLKSTSRVVVGILDVNDNPPHFSHKLFNVRLPER	1254
	gi 4885229 ref	TAQQLDRENKDEHILEVTVDNGEPSSLKSTSRVVVGILDVNDNPPHFSHKLFNVRLPER	1254
45	gi 14733833 ref	TAQQLDRENKDEHILEVTVDNGEPSSLKSTSRVVVGILDVNDNPPHFSHKLFNVRLPER	1257
		-----	1
50	NOV2	1270 1280 1290 1300 1310 1320	
	gi 13787217 ref	LSP-----VSPGPVYRLVASDLDDEGLNGRVTVYSIEDSDEE-AFSDILVTGVVSSNSTFAA	1308
	gi 7407144 gb A	LSP-----VSPGPVYRLVASDLDDEGLNGRVTVYSIEDSDEE-AFSDILVTGVVSSNSTFAA	1308
	gi 12621132 ref	LSP-----VSPGPVYRLVASDLDDEGLNGRVTVYSIEDSDEE-AFSDILVTGVVSSNSTFAA	1308
	gi 4885229 ref	LSP-----VSPGPVYRLVASDLDDEGLNGRVTVYSIEDSDEE-AFSDILVTGVVSSNSTFAA	1308
55	gi 14733833 ref	LSP-----VSPGPVYRLVASDLDDEGLNGRVTVYSIEDSDEE-AFSDILVTGVVSSNSTFAA	1317
		-----	1
60	NOV2	1330 1340 1350 1360 1370 1380	
	gi 13787217 ref	GEYNILTIKATDSCQPPLASVRLHIEWIPWRPSSIPLAFDETYYSFTVMEIDPVNHMV	1368
	gi 7407144 gb A	GEYNILTIKATDSCQPPLASVRLHIEWIPWRPSSIPLAFDETYYSFTVMEIDPVNHMV	1368
	gi 12621132 ref	GEYNILTIKATDSCQPPLASVRLHIEWIPWRPSSIPLAFDETYYSFTVMEIDPVNHMV	1368
	gi 4885229 ref	GEYNILTIKATDSCQPPLASVRLHIEWIPWRPSSIPLAFDETYYSFTVMEIDPVNHMV	1368
65	gi 14733833 ref	GEYNILTIKATDSCQPPLASVRLHIEWIPWRPSSIPLAFDETYYSFTVMEIDPVNHMV	1377
		-----	10
70	NOV2	1390 1400 1410 1420 1430 1440	
	gi 13787217 ref	GVISVEGRPGLFWFNISGGDKDMDFDIKTTGSIVIARPLDTRRRSNYNLTVEVTDGSRIT	1428
	gi 7407144 gb A	GVISVEGRPGLFWFNISGGDKDMDFDIKTTGSIVIARPLDTRRRSNYNLTVEVTDGSRIT	1428
	gi 12621132 ref	GVISVEGRPGLFWFNISGGDKDMDFDIKTTGSIVIARPLDTRRRSNYNLTVEVTDGSRIT	1428
	gi 4885229 ref	GVISVEGRPGLFWFNISGGDKDMDFDIKTTGSIVIARPLDTRRRSNYNLTVEVTDGSRIT	1428
75	gi 14733833 ref	GVISVEGRPGLFWFNISGGDKDMDFDIKTTGSIVIARPLDTRRRSNYNLTVEVTDGSRIT	1437
		-----	70
80	NOV2	1450 1460 1470 1480 1490 1500	
	gi 13787217 ref	IATQVHIFMIANINHHRPQFLSTRYEVVRPQDTVPGVLLRVQAIDQDKGKSLIYTHGS	1488
	gi 7407144 gb A	IATQVHIFMIANINHHRPQFLSTRYEVVRPQDTVPGVLLRVQAIDQDKGKSLIYTHGS	1488
	gi 12621132 ref	IATQVHIFMIANINHHRPQFLSTRYEVVRPQDTVPGVLLRVQAIDQDKGKSLIYTHGS	1488
	gi 4885229 ref	IATQVHIFMIANINHHRPQFLSTRYEVVRPQDTVPGVLLRVQAIDQDKGKSLIYTHGS	1488
85	gi 14733833 ref	IATQVHIFMIANINHHRPQFLSTRYEVVRPQDTVPGVLLRVQAIDQDKGKSLIYTHGS	1496
		-----	130

		1510	1520	1530	1540	1550	1560	
	NOV2	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					1548	
5	gi 13787217 ref	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					1548	
	gi 7407144 gb A	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					1548	
	gi 12621132 ref	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					1548	
	gi 4885229 ref	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					1555	
	gi 14733833 ref	QDPGSASLFQLDPSGVLTVGKLDLGGSPSQHTLTVMVRDQETPIKRNFWVVTIHVEDG					190	
10		1570	1580	1590	1600	1610	1620	
	NOV2	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	1605
	gi 13787217 ref	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	1605
	gi 7407144 gb A	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	1605
15	gi 12621132 ref	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	1605
	gi 4885229 ref	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	1615
	gi 14733833 ref	NLHPPRFTQLHYEASVPDTIAPGTELLQVRANDADRGVNAEVHYSLLKGNS					EGFFNI	247
20		1630	1640	1650	1660	1670	1680	
	NOV2	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					1665	
	gi 13787217 ref	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					1665	
	gi 7407144 gb A	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					1665	
25	gi 12621132 ref	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					1665	
	gi 4885229 ref	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					1675	
	gi 14733833 ref	NALLGIITLAQKLDQANHAPHTLTVKAEDQGSQWHDLATVIHVYPSDRSAPIFSKSEY					307	
30		1690	1700	1710	1720	1730	1740	
	NOV2	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					1725	
	gi 13787217 ref	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					1725	
	gi 7407144 gb A	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					1725	
	gi 12621132 ref	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					1725	
	gi 4885229 ref	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					1735	
35	gi 14733833 ref	FVEIPESIPVGSPIILLVSAMSPSEVTYELREGNKDGVSFMSYSGLISTQKKLDHEKISS					367	
40		1750	1760	1770	1780	1790	1800	
	NOV2	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					1785	
	gi 13787217 ref	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					1785	
	gi 7407144 gb A	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					1785	
	gi 12621132 ref	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					1785	
	gi 4885229 ref	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					1795	
45	gi 14733833 ref	YQLKIRGSNMAGFTDVMVVVDIIDENDNAPMFLKSTFVGQISEAAPLYSMINDKNNNPF					427	
50		1810	1820	1830	1840	1850	1860	
	NOV2	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					1845	
	gi 13787217 ref	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					1845	
	gi 7407144 gb A	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					1845	
	gi 12621132 ref	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					1845	
	gi 4885229 ref	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					1855	
	gi 14733833 ref	VIHASDSDKEANSLLVYKILEPEALKFFKIDPSNGTLTIVSENDYESMPFQFCVYVHDC					487	
55		1870	1880	1890	1900	1910	1920	
	NOV2	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					1901	
	gi 13787217 ref	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					1901	
	gi 7407144 gb A	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					1901	
60	gi 12621132 ref	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					1901	
	gi 4885229 ref	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					1915	
	gi 14733833 ref	GSPVLFAPRPAQVVIHVVDVNDSPPRFSEQIYEVAVIGPIHPCMELLMVRASDEDS					543	
65		1930	1940	1950	1960	1970	1980	
	NOV2	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					1961	
	gi 13787217 ref	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					1961	
	gi 7407144 gb A	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					1961	
	gi 12621132 ref	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					1961	
70	gi 4885229 ref	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					1975	
	gi 14733833 ref	EVNYSIKTGNADAVTIHPVTGSISVLNPAFLGLSRKLTIRASDGLYQDTALVKISLTQV					603	
75		1990	2000	2010	2020	2030	2040	
	NOV2	LDKSLQPDQDVYAAVAKENLQDRKALVILGAQGNHLNDTLSYFLLNGTDMFHMVQSAGVL					2021	
	gi 13787217 ref	LDKSLQPDQDVYAAVAKENLQDRKALVILGAQGNHLNDTLSYFLLNGTDMFHMVQSAGVL					2021	
	gi 7407144 gb A	LDKSLQPDQDVYAAVAKENLQDRKALVILGAQGNHLNDTLSYFLLNGTDMFHMVQSAGVL					2021	
	gi 12621132 ref	LDKSLQPDQDVYAAVAKENLQDRKALVILGAQGNHLNDTLSYFLLNGTDMFHMVQSAGVL					2021	

		gi 4885229 ref	KESHKFAQDVYSAVVKENSTRAFLAVTAIGSSPINEPSEYHILNPDRRFCTGRTSGVL	2035
		gi 14733833 ref	LKSLQFDQDVYNAAVKENLQDRKALVILGAQGNHLDNLTLSYFLNGTDMFEMVQSAGVL	663
		<div>2050 2060 2070 2080 2090 2100</div> <div>..... </div>		
5		NOV2	QTRGVAFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	2081
		gi 13787217 ref	QTRGVAFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	2081
		gi 7407144 gb A	QTRGVAFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	2081
		gi 12621132 ref	QTRGGTFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	2081
10		gi 4885229 ref	STGTGTFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	2095
		gi 14733833 ref	QTRGVAFDREQQDTHLAVEVRDNRTPQ RVAQGLVRVSIEDVNDNPPKFKHLPYYTIIQD	723
		<div>2110 2120 2130 2140 2150 2160</div> <div>..... </div>		
15		NOV2	GTEPGDVLFOVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDDYQALN-KYH	2140
		gi 13787217 ref	GTEPGDVLFOVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDDYQALN-KYH	2140
		gi 7407144 gb A	GTEPGDVLFOVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDDYQALN-KYH	2140
		gi 12621132 ref	GTEPGDVLFOVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDDYQALN-KYH	2140
20		gi 4885229 ref	DTVEVGDIYRYVTAVDRISSRNGEYVHYLKEHEHFCIGF-LGRIISLKKPFDDYQALN-KYH	2154
		gi 14733833 ref	GTEPGDVLFOVSATDEDLGTNGAVTYEFAEDYTYFRIDPYLGDISLKKPFDDYQALN-KYH	782
		<div>2170 2180 2190 2200 2210 2220</div> <div>..... </div>		
25		NOV2	LKVIARDGGTPSLQSEEEVLVTVRNKSNDLFSQSPYKVRVPENITLYTPILHTQARSPEG	2200
		gi 13787217 ref	LKVIARDGGTPSLQSEEEVLVTVRNKSNDLFSQSPYKVRVPENITLYTPILHTQARSPEG	2200
		gi 7407144 gb A	LKVIARDGGTPSLQSEEEVLVTVRNKSNDLFSQSPYKVRVPENITLYTPILHTQARSPEG	2200
		gi 12621132 ref	LKVIARDGGTPSLQSEEEVLVTVRNKSNDLFSQSPYKVRVPENITLYTPILHTQARSPEG	2200
30		gi 4885229 ref	WTVVARDGGNPAFSAVIVIPITVMNKAMPVFKKPFYSAGTASBITQVHSFVHVQARSPEG	2214
		gi 14733833 ref	LKVIARDGGTPSLQSEEEVLVTVRNKSNDLFSQSPYKVRVPENITLYTPILHTQARSPEG	842
		<div>2230 2240 2250 2260 2270 2280</div> <div>..... </div>		
35		NOV2	LRLIYNIVEEPEPLMLFTTDFKGTGLVTVTGPLDYESKTKHVFTVRATDTALGSFSEATVEV	2260
		gi 13787217 ref	LRLIYNIVEEPEPLMLFTTDFKGTGLVTVTGPLDYESKTKHVFTVRATDTALGSFSEATVEV	2260
		gi 7407144 gb A	LRLIYNIVEEPEPLMLFTTDFKGTGLVTVTGPLDYESKTKHVFTVRATDTALGSFSEATVEV	2260
		gi 12621132 ref	LRLIYNIVEEPEPLMLFTTDFKGTGLVTVTGPLDYESKTKHVFTVRATDTALGSFSEATVEV	2260
		gi 4885229 ref	LKVFYSITDGDPPSCFTIN-NTGVLENVIAPIIDFBAHPAKKLSIRATDSIT-AHARVFMOT	2274
		gi 14733833 ref	LRLIYNIVEEPEPLMLFTTDFKGTGLVTVTGPLDYESKTKHVFTVRATDTALGSFSEATVEV	902
		<div>2290 2300 2310 2320 2330 2340</div> <div>..... </div>		
40		NOV2	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	2320
		gi 13787217 ref	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	2320
		gi 7407144 gb A	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	2320
45		gi 12621132 ref	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	2320
		gi 4885229 ref	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	2334
		gi 14733833 ref	LVEDVNDNPPPTFSQQLVYTTTISSEGLPAQTPVVIQLLASDQDSGRNRDVSQIIVEDGSDVSK	962
		<div>2350 2360 2370 2380 2390 2400</div> <div>..... </div>		
50		NOV2	FFQINGSTGEMSTVQELDYEAQQHFHVKVRAMDKGDPPLTGETLVVNVSDINDNPPPEFR	2380
		gi 13787217 ref	FFQINGSTGEMSTVQELDYEAQQHFHVKVRAMDKGDPPLTGETLVVNVSDINDNPPPEFR	2380
		gi 7407144 gb A	FFQINGSTGEMSTVQELDYEAQQHFHVKVRAMDKGDPPLTGETLVVNVSDINDNPPPEFR	2380
		gi 12621132 ref	FFQINGSTGEMSTVQELDYEAQQHFHVKVRAMDKGDPPLTGETLVVNVSDINDNPPPEFR	2380
55		gi 4885229 ref	HFEVDSSTGLISLRLTLDYEQSROHTAFVRAVDCGMFT-SSDVIITVDVTDINCNPPPEFR	2394
		gi 14733833 ref	FFQINGSTGEMSTVQELDYEAQQHFHVKVRAMDKGDPPLTGETLVVNVSDINDNPPPEFR	1022
		<div>2410 2420 2430 2440 2450 2460</div> <div>..... </div>		
60		NOV2	QPQYEANVSELATCGHLVLKVAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMEN	2440
		gi 13787217 ref	QPQYEANVSELATCGHLVLKVAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMEN	2440
		gi 7407144 gb A	QPQYEANVSELATCGHLVLKVAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMEN	2440
		gi 12621132 ref	EPQYEANVSELATCGHLVLKVAIDPDIIGTSRLEYLILSGNQDRHFFINSSSGIISMEN	2440
65		gi 4885229 ref	QQIYEANVSELATCGHLVLKVAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMEN	2454
		gi 14733833 ref	QPQYEANVSELATCGHLVLKVAIDPDSRDTSRLEYLILSGNQDRHFFINSSSGIISMEN	1082
		<div>2470 2480 2490 2500 2510 2520</div> <div>..... </div>		
70		NOV2	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	2500
		gi 13787217 ref	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	2500
		gi 7407144 gb A	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	2500
		gi 12621132 ref	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	2500
		gi 4885229 ref	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	2514
		gi 14733833 ref	LCKKHLDSYNLRVGASDGVFRATVPVYINTTNANKYSPEFQOHLYEABLAENAMVGTKV	1142
		<div>2530 2540 2550 2560 2570 2580</div> <div>..... </div>		
75		NOV2	IDLLAIDKDSGPGYGTIDYTIINKLASEKPSINPNGOIAFLQKLDRENSTERVIAIKVMAR	2560

5	gi 13787217 ref	IDLLA-DKDSGPGYGTIDYTIINKLASEKFSINPNQGIATLQKLDRENSTERVIAIKVMAR	2560
	gi 7407144 gb A	IDLLAIDKDSGPGYGTIDYTIINKLASEKFSINPNQGIATLQKLDRENSTERVIAIKVMAR	2560
	gi 12621132 ref	IELLAIDKDSGPGYGTIDYTIINKLAGERFFINFRGQIATLQKLDRENSTERVIAIKVMAR	2560
	gi 4885229 ref	MEVKTIDSDSGYGTIDYTIINKLAGERFFINFRGQIATLQKLDRETPAEKVISVRLMAK	2574
	gi 14733833 ref	IDLLAIDKDSGPGYGTIDYTIINKLASEKFSINPNQGIATLQKLDRENSTERVIAIKVMAR	1202
10	NOV22590.....2600.....2610.....2620.....2630.....2640.....	
	gi 13787217 ref	DGGGRVAFCTVKIILTDENDHPPQFKASEYTVSIQSNVSKDSPVIQVLAAYDADEGQNADV	2620
	gi 7407144 gb A	DGGGRVAFCTVKIILTDENDHPPQFKASEYTVSIQSNVSKDSPVIQVLAAYDADEGQNADV	2620
	gi 12621132 ref	DGGGRVAFCTVKIILTDENDHPPQFKASEYTVSIQSNVSKDSPVIQVLAAYDADEGQNADV	2620
	gi 4885229 ref	DGGGRVAFCTVKIILTDENDHPPQFKASEYTVSIQSNVSKDSPVIQVLAAYDADEGQNADV	2633
15	gi 14733833 ref	DGGGRVAFCTVKIILTDENDHPPQFKASEYTVSIQSNVSKDSPVIQVLAAYDADEGQNADV	1263
20	NOV22650.....2660.....2670.....2680.....2690.....2700.....	
	gi 13787217 ref	TYSVN-PEDLVKDVIEINPVTVGVVVKVDSLVLGLENQTLDDFFIKAQDGGPPHNSLVVPVRL	2679
	gi 7407144 gb A	TYSVN-PEDLVKDVIEINPVTVGVVVKVDSLVLGLENQTLDDFFIKAQDGGPPHNSLVVPVRL	2679
	gi 12621132 ref	TYSVN-PEDLVKDVIEINPVTVGVVVKVDSLVLGLENQTLDDFFIKAQDGGPPHNSLVVPVRL	2680
	gi 4885229 ref	TYSVN-PEDLVKDVIEINPVTVGVVVKVDSLVLGLENQTLDDFFIKAQDGGPPHNSLVVPVRL	2693
25	gi 14733833 ref	TYSVN-PEDLVKDVIEINPVTVGVVVKVDSLVLGLENQTLDDFFIKAQDGGPPHNSLVVPVRL	1321
30	NOV22710.....2720.....2730.....2740.....2750.....2760.....	
	gi 13787217 ref	QVVPKKSLSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTPESNKGDV	2739
	gi 7407144 gb A	QVVPKKSLSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTPESNKGDV	2739
	gi 12621132 ref	QVVPKKSLSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTPESNKGDV	2739
	gi 4885229 ref	QVVPKKSLSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTPESNKGDV	2740
35	gi 14733833 ref	QVVPKKSLSLPKFSEPLYTFSAPEDLPEGSEIGIVKAVAAQDPVIYSLVRGTPESNKGDV	1381
40	NOV22770.....2780.....2790.....2800.....2810.....2820.....	
	gi 13787217 ref	FSLDPDGTGVIVKVKPMHDHESKLYQIDVMAHCLQN-TDVVSLVSVNIQVGDVNDNRPVFE	2798
	gi 7407144 gb A	FSLDPDGTGVIVKVKPMHDHESKLYQIDVMAHCLQN-TDVVSLVSVNIQVGDVNDNRPVFE	2798
	gi 12621132 ref	FSLDPDGTGVIVKVKPMHDHESKLYQIDVMAHCLQN-TDVVSLVSVNIQVGDVNDNRPVFE	2798
	gi 4885229 ref	FSLDPDGTGVIVKVKPMHDHESKLYQIDVMAHCLQN-TDVVSLVSVNIQVGDVNDNRPVFE	2800
45	gi 14733833 ref	FSLDPDGTGVIVKVKPMHDHESKLYQIDVMAHCLQN-TDVVSLVSVNIQVGDVNDNRPVFE	1440
50	NOV22830.....2840.....2850.....2860.....2870.....2880.....	
	gi 13787217 ref	ADPYKAVLTENNMPVGTSVIQVTAIDKDTGRDQGVSYRLSADPGSNVHFLFAIDSESGWIT	2858
	gi 7407144 gb A	ADPYKAVLTENNMPVGTSVIQVTAIDKDTGRDQGVSYRLSADPGSNVHFLFAIDSESGWIT	2858
	gi 12621132 ref	ADPYKAVLTENNMPVGTSVIQVTAIDKDTGRDQGVSYRLSADPGSNVHFLFAIDSESGWIT	2858
	gi 4885229 ref	ADPYKAVLTENNMPVGTSVIQVTAIDKDTGRDQGVSYRLSADPGSNVHFLFAIDSESGWIT	2860
55	gi 14733833 ref	ADPYKAVLTENNMPVGTSVIQVTAIDKDTGRDQGVSYRLSADPGSNVHFLFAIDSESGWIT	1500
60	NOV22890.....2900.....2910.....2920.....2930.....2940.....	
	gi 13787217 ref	TLQELDCETCQTYHFHVAYDHGQTIQLSSQALVQVSTIDENDNAPRFASEEYRGSVVEN	2918
	gi 7407144 gb A	TLQELDCETCQTYHFHVAYDHGQTIQLSSQALVQVSTIDENDNAPRFASEEYRGSVVEN	2918
	gi 12621132 ref	TLQELDCETCQTYHFHVAYDHGQTIQLSSQALVQVSTIDENDNAPRFASEEYRGSVVEN	2918
	gi 4885229 ref	TLQELDCETCQTYHFHVAYDHGQTIQLSSQALVQVSTIDENDNAPRFASEEYRGSVVEN	2920
65	gi 14733833 ref	TLQELDCETCQTYHFHVAYDHGQTIQLSSQALVQVSTIDENDNAPRFASEEYRGSVVEN	1550
70	NOV22950.....2960.....2970.....2980.....2990.....3000.....	
	gi 13787217 ref	SEPGLVATLKTLDADISEQNRQVTCYITEGDPDLCQFQISQVGDENRISRRKTLDRHTA	2978
	gi 7407144 gb A	SEPGLVATLKTLDADISEQNRQVTCYITEGDPDLCQFQISQVGDENRISRRKTLDRHTA	2978
	gi 12621132 ref	SEPGLVATLKTLDADISEQNRQVTCYITEGDPDLCQFQISQVGDENRISRRKTLDRHTA	2978
	gi 4885229 ref	SEPGLVATLKTLDADISEQNRQVTCYITEGDPDLCQFQISQVGDENRISRRKTLDRHTA	2980
75	gi 14733833 ref	SEPGLVATLKTLDADISEQNRQVTCYITEGDPDLCQFQISQVGDENRISRRKTLDRHTA	1620
80	NOV23010.....3020.....3030.....3040.....3050.....3060.....	
	gi 13787217 ref	KYLLRVATSDGKFQASVTVEIFVLDVNDNSPQCSQLLYTGKVHEDVFPGHFILKVSATDL	3038
	gi 7407144 gb A	KYLLRVATSDGKFQASVTVEIFVLDVNDNSPQCSQLLYTGKVHEDVFPGHFILKVSATDL	3038
	gi 12621132 ref	KYLLRVATSDGKFQASVTVEIFVLDVNDNSPQCSQLLYTGKVHEDVFPGHFILKVSATDL	3038
	gi 4885229 ref	KYLLRVATSDGKFQASVTVEIFVLDVNDNSPQCSQLLYTGKVHEDVFPGHFILKVSATDL	3040
85	gi 14733833 ref	KYLLRVATSDGKFQASVTVEIFVLDVNDNSPQCSQLLYTGKVHEDVFPGHFILKVSATDL	1680

		3070	3080	3090	3100	3110	3120	
	NOV2	DTDTNAQITYSLHGP	GAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQAL	3098				
5	gi 13787217 ref	DTDTNAQITYSLHGP	GAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQAL	3098				
	gi 7407144 gb A	DTDTNAQITYSLHGP	GAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQAL	3098				
	gi 12621132 ref	DTDTNAQITYSLHGP	GAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQAL	3100				
	gi 4885229 ref	DIRSNAEITYLLSS	GAEFKLDPHTGELTSTPLDRSEQAVYHLVVRATDGGGRSCQAS	3112				
	gi 14733833 ref	DTDTNAQITYSLHGP	GAHEFKLDPHTGELTTLTALDRERKDVFNLVAKATDGGGRSCQAL	1740				
10		3130	3140	3150	3160	3170	3180	
	NOV2	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	3158				
	gi 13787217 ref	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	3158				
	gi 7407144 gb A	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	3158				
15	gi 12621132 ref	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	3160				
	gi 4885229 ref	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	3172				
	gi 14733833 ref	ITLHVEDVNDNAPRFF	PSHCAVAFDNTTVKTPVAVVFARDPDQGANACVVYSLPDSAEQ	1800				
20		3190	3200	3210	3220	3230	3240	
	NOV2	HFSIDATTGVIRLEK	PLQVRPQAPLELTVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	3218				
	gi 13787217 ref	HFSIDATTGVIRLEK	PLQVRPQAPLELTVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	3218				
	gi 7407144 gb A	HFSIDATTGVIRLEK	PLQVRPQAPLELTVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	3218				
	gi 12621132 ref	QFSIDATTGVIRLEK	PLQVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	3220				
25	gi 4885229 ref	QFSIDATTGVIRLEK	PLQVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	3232				
	gi 14733833 ref	HFSIDATTGVIRLEK	PLQVRPQAPLELTVRASDLGTPPLSTLGTVTVSVVGLDYLVPVF	1860				
30		3250	3260	3270	3280	3290	3300	
	NOV2	LNTHEHSVQVPEDAP	PGTEVLQLATLTR--	PGA	EKTGYRVVSGNEQGRFLDARTGILYVN	3276		
	gi 13787217 ref	LNTHEHSVQVPEDAP	PGTEVLQLATLTR--	PGA	EKTGYRVVSGNEQGRFLDARTGILYVN	3276		
	gi 7407144 gb A	LNTHEHSVQVPEDAP	PGTEVLQLATLTR--	PGA	EKTGYRVVSGNEQGRFLDARTGILYVN	3276		
	gi 12621132 ref	LNTHEHSVQVPEDAP	PGTEVLQLATLTR--	PGA	EKTGYRVVSGNEQGRFLDARTGILYVN	3278		
35	gi 4885229 ref	EYREYGATVSEDD	ILVCTEVLQVTAAS	RDIEANAGITYSLISGNEHCKPESLDSKTCVAFPI	3292			
	gi 14733833 ref	LNTHEHSVQVPEDAP	PGTEVLQLATLTR--	PGA	EKTGYRVVSGNEQGRFLDARTGILYVN	1918		
40		3310	3320	3330	3340	3350	3360	
	NOV2	ASLDFETSPKYFLSI	ECSRKSSSSLS	SDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	3336			
	gi 13787217 ref	ASLDFETSPKYFLSI	ECSRKSSSSLS	SDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	3336			
	gi 7407144 gb A	ASLDFETSPKYFLSI	ECSRKSSSSLS	SDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	3336			
	gi 12621132 ref	ASLDFETSPKYFLSI	ECSRKSSSSLS	SDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	3338			
	gi 4885229 ref	ENLDDYSSHEVYLT	VAADGGG	PSLSDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	3352			
45	gi 14733833 ref	ASLDFETSPKYFLSI	ECSRKSSSSLS	SDVTVMVNITDVNEHRPQFPQDFYSTRVLENALV	1978			
50		3370	3380	3390	3400	3410	3420	
	NOV2	GDVILTVSATDEDG	PLNSDITYSLIGGNOLGHFTIHPKKGELQVAKALDREQASSYSLKL	3396				
	gi 13787217 ref	GDVILTVSATDEDG	PLNSDITYSLIGGNOLGHFTIHPKKGELQVAKALDREQASSYSLKL	3396				
	gi 7407144 gb A	GDVILTVSATDEDG	PLNSDITYSLIGGNOLGHFTIHPKKGELQVAKALDREQASSYSLKL	3396				
	gi 12621132 ref	GDVILTVSATDEDG	PLNSDITYSLIGGNOLGHFTIHPKKGELQVAKALDREQASSYSLKL	3398				
	gi 4885229 ref	BQSVITVMADADG	PSNSHITHYSIIDSGSSFTIDFVRSEVAVKILDREITISGVALTV	3412				
	gi 14733833 ref	GDVILTVSATDEDG	PLNSDITYSLIGGNOLGHFTIHPKKGELQVAKALDREQASSYSLKL	2038				
55		3430	3440	3450	3460	3470	3480	
	NOV2	RATDSGQPPPLHED	TDIAIQVADVNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDSF	3456				
	gi 13787217 ref	RATDSGQPPPLHED	TDIAIQVADVNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDSF	3456				
	gi 7407144 gb A	RATDSGQPPPLHED	TDIAIQVADVNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDSF	3456				
	gi 12621132 ref	RATDSGQPPPLHED	TEVAEVEVDNNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDSF	3458				
60	gi 4885229 ref	QASDNGSPPRVNT	ITVNIDVSDVNDNAPVFSRGNYSVIIQENKPVGFSVLQVATDEDS	3472				
	gi 14733833 ref	RATDSGQPPPLHED	TDIAIQVADVNDNPPRFFQLNYSTTVQENSPIGSKVLQILSDPDSF	2098				
65		3490	3500	3510	3520	3530	3540	
	NOV2	ENGPPYSFRITKGN	NGSAFRVTPDGNLVTAEGLSRAQEWYQLQIQASDSGIPPLSSLT	3516				
	gi 13787217 ref	ENGPPYSFRITKGN	NGSAFRVTPDGNLVTAEGLSRAQEWYQLQIQASDSGIPPLSSLT	3516				
	gi 7407144 gb A	ENGPPYSFRITKGN	NGSAFRVTPDGNLVTAEGLSRAQEWYQLQIQASDSGIPPLSSLT	3516				
	gi 12621132 ref	ENGPPYSFRITKGN	NGSAFRVTPDGNLVTAEGLSRAQEWYQLQIQASDSGIPPLSSLT	3518				
70	gi 4885229 ref	HNGPPPEFTITV	TGNDEKAFVNNPQGVLTSSATKKRKKDHVLLQVVAENGKFPOLSSLT	3532				
	gi 14733833 ref	ENGPPYSFRITKGN	NGSAFRVTPDGNLVTAEGLSRAQEWYQLQIQASDSGIPPLSSLT	2158				
75		3550	3560	3570	3580	3590	3600	
	NOV2	VRVHVTEQSHYAP	SALPLEIFTVGEDEFQGGMVGKIHA	TDRDPQDTLITYSLAEETLGR	3576			
	gi 13787217 ref	VRVHVTEQSHYAP	SALPLEIFTVGEDEFQGGMVGKIHA	TDRDPQDTLITYSLAEETLGR	3576			
	gi 7407144 gb A	VRVHVTEQSHYAP	SALPLEIFTVGEDEFQGGMVGKIHA	TDRDPQDTLITYSLAEETLGR	3576			
	gi 12621132 ref	VRVHVTEQSHYAP	SALPLEIFTVGEDEFQGGMVGKIHA	TDRDPQDTLITYSLAEETLGR	3578			

	gi 4885229 ref	TDRVLEESLVPPAH LPLSIFITSSGSEYSSGVTCKIHATDQDVYDTLTYSIDP--QMDN 3590
	gi 14733833 ref	VRVHVTEQSHYAPSALPLEIFITVGEDBDFQGGVMGKIHATDRDPQDITLTYSLAEBETLCR 2218
5	NOV2	<div> <div>361036203630364036503660</div> <div>..... </div> </div>
	gi 13787217 ref	HFSVGAPDGKIIAAQGLPRGHYSFNVTVSDGTFTTTAGVHVYVWHVQGQALQQAAMWNGFY 3636
	gi 7407144 gb A	HFSVGAPDGKIIAAQGLPRGHYSFNVTVSDGTFTTTAGVHVYVWHVQGQALQQAAMWNGFY 3636
10	gi 12621132 ref	YFTVGASDGKIIASQGLPHGRYSFNVTVSDGTFTTTAGVHVYVWHVMEFEVPOAMVWLGPH 3638
	gi 4885229 ref	LFSVSATGGKLIATKKLDICQMLNVSVDGKFTTADLVVLIROVLIQEMLNHTLATRAFA 3650
	gi 14733833 ref	HFSVGAPDGKIIAAQGLPRGHYSFNVTVSDGTFTTTAGVHVYVWHVQGQALQQAAMWNGFY 2278
15	NOV2	<div> <div>367036803690370037103720</div> <div>..... </div> </div>
	gi 13787217 ref	QLTPBELVSDHWRNLQRFLSHKLDIKRANIHLASLQPAEAVAGVDVLLVFEGHSGTFFYEF 3696
	gi 7407144 gb A	QLTPBELVSDHWRNLQRFLSHKLDIKRANIHLASLQPAEAVAGVDVLLVFEGHSGTFFYEF 3696
	gi 12621132 ref	QLTPBELVSDHWRNLQRFLSNLDIKRANIHLASLQPAEAVAGVDVLLVFERHSGISYDL 3698
20	gi 4885229 ref	NLTPREEVGVYWRNEQRALRNIIQVVRNDIQVSLQSSPHPHLOVLLFVEKPGSAQIST 3710
	gi 14733833 ref	QLTPBELVSDHWRNLQRFLSHKLDIKRANIHLASLQPAEAVAGVDVLLVFEGHSGTFFYEF 2338
25	NOV2	<div> <div>373037403750376037703780</div> <div>..... </div> </div>
	gi 13787217 ref	QELASIIHSAKEMEHSSVGQMRSAFMPVPCQGPCTCQSQICHNTVHLDPKVGPITYSTARL 3756
	gi 7407144 gb A	QELASIIHSAKEMEHSSVGQMRSAFMPVPCQGPCTCQSQICHNTVHLDPKVGPITYSTARL 3756
	gi 12621132 ref	QELASIIHSAKEMEHSSVGQMRSAFMPVPCQGSQSQDQTCQETVSLERFVCGPSVSTARL 3758
30	gi 4885229 ref	KQILHKINSSTVDIETIGVRLNVFQKLCAGLDQPAKFCDEKVSVDSEVMSHSTARL 3769
	gi 14733833 ref	QELASIIHSAKEMEHSSVGQMRSAFMPVPCQGPCTCQSQICHNTVHLDPKVGPITYSTARL 2398
35	NOV2	<div> <div>379038003810382038303840</div> <div>..... </div> </div>
	gi 13787217 ref	SILTPRHHLQRSCSCN----- 3772
	gi 7407144 gb A	SILTPRHHLQRSCSCN----- 3772
	gi 12621132 ref	SILTPRHHLQRSCSCN----- 3772
	gi 4885229 ref	SILTPRHHLQRSCSCN----- 3774
40	gi 14733833 ref	SILTPRHHLQRSCSCN----- 2414
45	NOV2	<div> <div>385038603870388038903900</div> <div>..... </div> </div>
	gi 13787217 ref	GTATRFSGQSYVRYRAPAARN---WHIHFYLYKTLQPAQLLFTNETASVSLKLASGVPC 3828
	gi 7407144 gb A	GTATRFSGQSYVRYRAPAARN---WHIHFYLYKTLQPAQLLFTNETASVSLKLASGVPC 3828
	gi 12621132 ref	GTATRFSGQSYVRYRAPAARN---WHIHFYLYKTLQPAQLLFTNETASVSLKLASGVPC 3828
50	gi 4885229 ref	GSSSMTLICNSYKYRLTENEKLEMKLTWRLETYSTHAWMYARGDYSTLETHHGRLL 3889
	gi 14733833 ref	GTATRFSGQSYVRYRAPAARN---WHIHFYLYKTLQPAQLLFTNETASVSLKLASGVPC 2470
55	NOV2	<div> <div>391039203930394039503960</div> <div>..... </div> </div>
	gi 13787217 ref	LEYHCLGGFYGNLSSQRHVNDHEWHHSILVEENDASIRLAVDSMGNTSLVVPENCRGLRPE 3888
	gi 7407144 gb A	LEYHCLGGFYGNLSSQRHVNDHEWHHSILVEENDASIRLAVDSMGNTSLVVPENCRGLRPE 3888
60	gi 12621132 ref	LEYHCLGGFYGNLSSQRHVNDHEWHHSILVEENDASIRLAVDSMGNTSLVVPENCRGLRPE 3888
	gi 4885229 ref	YKEDCGSSPGIVSVQSIQVNDSCWHAVALSVNGNYARLVLDQVHTASGTAPGLKTLNLL 3949
65	gi 14733833 ref	LEYHCLGGFYGNLSSQRHVNDHEWHHSILVEENDASIRLAVDSMGNTSLVVPENCRGLRPE 2530
70	NOV2	<div> <div>397039803990400040104020</div> <div>..... </div> </div>
	gi 13787217 ref	RHLLLGGLILLH-----SSSNVSQ3FEGCLDAVVVNEEALDLPAGKTIVAGLLETQALTC 3943
	gi 7407144 gb A	RHLLLGGLILLH-----SSSNVSQ3FEGCLDAVVVNEEALDLPAGKTIVAGLLETQALTC 3943
75	gi 12621132 ref	RHLLLGGLILLH-----SSSNVSQ3FEGCLDAVVVNEEALDLPAGKTIVAGLLETQALTC 3943
	gi 4885229 ref	NYVFFGCHTRQOCTRHRGRSPQVGNPFGCCYDSIYLNCQELFNSKPRBYAHLESVDVSP 4009
	gi 14733833 ref	RHLLLGGLILLH-----SSSNVSQ3FEGCLDAVVVNEEALDLPAGKTIVAGLLETQALTC 2585
80	NOV2	<div> <div>403040404050406040704080</div> <div>..... </div> </div>
	gi 13787217 ref	CCLH--SDYCSQNTCLNGGKCSWTHGAGYVCKCPPQFSGKHCEQGRENCTFAPCLEGGTC 4001
	gi 7407144 gb A	CCLH--SDYCSQNTCLNGGKCSWTHGAGYVCKCPPQFSGKHCEQGRENCTFAPCLEGGTC 4001
	gi 12621132 ref	CCLH--SDYCSQNTCLNGGKCSWTHGAGYVCKCPPQFSGKHCEQGRENCTFAPCLEGGTC 4001
	gi 4885229 ref	GCPPLATFEDCASHPCNGGVONPSPAGCYCKCSALYICQHCEISVNDGSSNPCLYCGTC 4069
	gi 14733833 ref	CCLH--SDYCSQNTCLNGGKCSWTHGAGYVCKCPPQFSGKHCEQGRENCTFAPCLEGGTC 2643
85	NOV2	<div> <div>409041004110412041304140</div> <div>..... </div> </div>
	gi 14733833 ref	[1]-----SPKGASCNCPPHYTGDRCEME 4024

5	gi 13787217 ref	HL-----SPKGASCNCPHPYTGDRCEME	4024
	gi 7407144 gb A	HL-----SPKGASCNCPHPYTGDRCEME	4024
	gi 12621132 ref	MS-----SPEGTSNCPHPYTGDRCEME	4026
	gi 4885229 ref	VVDNGGFVQCRLGTYGRCQLSPYCKDBPCNNGGTCTFLSLDGLV-QQDSGFRGRCQSP	4129
	gi 14733833 ref	HL-----SPKGASCNCPHPYTGDRCEME	2666
10	NOV2	4150 4160 4170 4180 4190 4200	
	gi 13787217 ref	ARGCSEGHCLVTPEIQ-----RG-----DWGQOEELIITV	4054
	gi 7407144 gb A	ARGCSEGHCLVTPEIQ-----RG-----DWGQOEELIITV	4054
	gi 12621132 ref	ARGCSEGHCLVTPEIQ-----RG-----DWGQOEELIITV	4054
	gi 4885229 ref	IDECSEGNFCLHGALCENTHGSYHCNCSHEYRCGRHCEDAAPNQYVSTFWNTSLAEGLGHWV	4189
	gi 14733833 ref	ARGCSEGHCLVTPEIQ-----RG-----DWGQOEELIITV	2696
20	NOV2	4210 4220 4230 4240 4250 4260	
	gi 13787217 ref	AVAFIIISTVGLLFYCRCKSHKPVAMEDPD-----LLAR-----SVGVDTOAM	4098
	gi 7407144 gb A	AVAFIIISTVGLLFYCRCKSHKPVAMEDPD-----LLAR-----SVGVDTOAM	4098
	gi 12621132 ref	ADPLVIIATVGLLFYCRCKSHKPVAMEDPD-----LLAR-----SVGVDTOAM	4098
	gi 4885229 ref	FVAGIEFLLVV-MFVLCRKMRISRNKQHQAEPKDKHLGPATAFLQRPYFDSKLKNTYSDIP	4248
	gi 14733833 ref	AVAFIIISTVGLLFYCRCKSHKPVAMEDPD-----LLAR-----SVGVDTOAM	2740
30	NOV2	4270 4280 4290 4300 4310 4320	
	gi 13787217 ref	PAIELNPLSAS-----SCNNLNQPEPSKASVPR-----BLVTFGPNSKQ-----RPVVCSVPP	4146
	gi 7407144 gb A	PAIELNPLSAS-----SCNNLNQPEPSKASVPR-----BLVTFGPNSKQ-----RPVVCSVPP	4146
	gi 12621132 ref	PAIELNPLSAS-----SCNNLNQPEPSKASVPR-----BLVTFGPNSKQ-----RPVVCSVPP	4146
	gi 4885229 ref	PQVPRPRTSYKPSIPBDSRNNLDRNSFEGSATPEHPPEFTFNPESVHGHKKAVALCSVAP	4308
	gi 14733833 ref	PAIELNPLSAS-----SCNNLNQPEPSKASVPR-----BLVTFGPNSKQ-----RPVVCSVPP	2788
40	NOV2	4330 4340 4350 4360 4370 4380	
	gi 13787217 ref	RLPPAAVP-----SHSDNEPVIKRTN-----	4167
	gi 7407144 gb A	RLPPAAVP-----SHSDNEPVIKRTN-----	4167
	gi 12621132 ref	RLPPAAVP-----SHSDNEPVIKRTN-----	4167
	gi 4885229 ref	RLPPAAVS-SHPGHEPTIKRTN-----	4169
	gi 14733833 ref	RLPPPPPSNSPDSDSLOKPSWDFDYDTKVVDLPCLSKKPLEEKPSQPYSARESLSSEVQ	4368
50	NOV2	4390 4400 4410 4420 4430 4440	
	gi 13787217 ref	SSEEMVYPCGAMVWPPTYSRNERWEYPHSEVT-----QGPLPPSAHRHSTPVVME	4217
	gi 7407144 gb A	SSEEMVYPCGAMVWPPTYSRNERWEYPHSEVT-----QGPLPPSAHRHSTPVVME	4217
	gi 12621132 ref	SSEEMVYPCGAMVWPPTYSRNERWEYPHSEVT-----QGPIPPSAHRHSTPVVME	4217
	gi 4885229 ref	SGEELVYPCGAMVWPPTYSRNERWEYPHSEVT-----QGPIPPSPRRHVGPAVME	4219
	gi 14733833 ref	SLSSFQSESCDNGYHNDTSDMPSVPLPRICEFPNYEVIDECTPLYSADPNADIDYF	4428
60	NOV2	4450 4460 4470 4480 4490 4500	
	gi 13787217 ref	EPNGLYGGFPFP-----LEMENKRAPLPPRYSNQNLEDLMPDR-----PPSPRER-----L	4263
	gi 7407144 gb A	EPNGLYGGFPFP-----LEMENKRAPLPPRYSNQNLEDLMPDR-----PPSPRER-----L	4263
	gi 12621132 ref	EPNGLYGGFPFP-----LEMENKRAPLPPRYSNQNLEDLMPDR-----PPSPRER-----L	4263
	gi 4885229 ref	GGYDLSDFPFPPEDFPAADLEPLPPEFSNQ-FPSLEPPEDMPAAGSLGSSSRNQRFN	4487
	gi 14733833 ref	EPNGLYGGFPFP-----LEMENKRAPLPPRYSNQNLEDLMPDR-----PPSPRER-----L	2905
70	NOV2	4510 4520 4530 4540 4550 4560	
	gi 13787217 ref	VAPCLNEYTAISYYHSQFR-----QGGGGPCLADGGYKGVGMRLSRAGPSYAVCEVEGAPLACG	4322
	gi 7407144 gb A	VAPCLNEYTAISYYHSQFR-----QGGGGPCLADGGYKGVGMRLSRAGPSYAVCEVEGAPLACG	4322
	gi 12621132 ref	VAPCLNEYTAISYYHSQFR-----QGGGGPCLADGGYKGVGMRLSRAGPSYAVCEVEGAPLACG	4322
	gi 4885229 ref	INQYLPNFVPLDMSEPTKGTGENSTCRPHAPYPFGVQRHFEAPAVESMPMSVYASTAS	4547
	gi 14733833 ref	VAPCLNEYTAISYYHSQFR-----QGGGGPCLADGGYKGVGMRLSRAGPSYAVCEVEGAPLACG	2964
75	NOV2	4570 4580 4590 4600	
	gi 13787217 ref	GQPRVPPNYEGSDMVESDYGSCEVME-----	4349
	gi 7407144 gb A	GQPRVPPNYEGSDMVESDYGSCEVME-----	4349
	gi 12621132 ref	GQPRVPPNYEGSDMVESDYGSCEVME-----	4349
	gi 4885229 ref	CSDVSACCEVESVMMESDYGSCEVME-----	4351
	gi 14733833 ref	GQPRVPPNYEGSDMVESDYGSCEVME-----	2991

Tables 2E list the domain description from DOMAIN analysis results against NOV2. This indicates that the NOV2 sequence has properties similar to those of other proteins known to contain this domain.

Table 2E. Domain Results for NOV2		
PSSMs producing significant alignments:	Score (bits)	E value
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	97.8	1e-20
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	91.3	1e-18
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	89.7	3e-18
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	89.0	5e-18
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	89.0	5e-18
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	86.3	3e-17
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	84.3	1e-16
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	80.5	2e-15
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	75.9	5e-14
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	72.0	7e-13
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	72.0	7e-13
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	71.6	9e-13
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	71.6	9e-13
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	70.1	2e-12
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	69.7	3e-12
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	68.2	9e-12
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	66.6	3e-11
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	65.9	5e-11
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	65.1	8e-11
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	62.8	4e-10
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	61.2	1e-09
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	60.8	2e-09
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	60.1	3e-09
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	59.7	3e-09
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	55.5	6e-08
gnl Smart smart00112 CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	53.9	2e-07

gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	53.5	2e-07
gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	53.1	3e-07
gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	50.1	3e-06
gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	46.2	4e-05
gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	46.2	4e-05
gnl	Smart	smart00112	CA, Cadherin repeats.; Cadherins are glycoproteins involved in...	38.5	0.008
gnl	Pfam	pfam00028	cadherin, Cadherin domain	92.0	6e-19
gnl	Pfam	pfam00028	cadherin, Cadherin domain	85.9	4e-17
gnl	Pfam	pfam00028	cadherin, Cadherin domain	85.5	6e-17
gnl	Pfam	pfam00028	cadherin, Cadherin domain	80.5	2e-15
gnl	Pfam	pfam00028	cadherin, Cadherin domain	80.1	2e-15
gnl	Pfam	pfam00028	cadherin, Cadherin domain	79.7	3e-15
gnl	Pfam	pfam00028	cadherin, Cadherin domain	79.7	3e-15
gnl	Pfam	pfam00028	cadherin, Cadherin domain	79.7	3e-15
gnl	Pfam	pfam00028	cadherin, Cadherin domain	77.0	2e-14
gnl	Pfam	pfam00028	cadherin, Cadherin domain	76.3	3e-14
gnl	Pfam	pfam00028	cadherin, Cadherin domain	75.9	5e-14
gnl	Pfam	pfam00028	cadherin, Cadherin domain	74.7	1e-13
gnl	Pfam	pfam00028	cadherin, Cadherin domain	67.0	2e-11
gnl	Pfam	pfam00028	cadherin, Cadherin domain	66.6	3e-11
gnl	Pfam	pfam00028	cadherin, Cadherin domain	64.7	1e-10
gnl	Pfam	pfam00028	cadherin, Cadherin domain	64.3	1e-10
gnl	Pfam	pfam00028	cadherin, Cadherin domain	63.9	2e-10
gnl	Pfam	pfam00028	cadherin, Cadherin domain	59.3	4e-09

The above domains are located at amino acids 67-146, 170-254, 387-456, 463-541, 480-562, 587-661, 721-810, 737-818, 825-916, 842-923, 934-1021, 949-1026, 1038-1128, 1054-1135, 1145-1233, 1161-1240, 1247-1335, 1266-1335, 1374-1446, 1470-1553, 1577-1658, 1560-1650, 1688-1756, 1763-1862, 1787-1870, 1894-1963, 1998-2068, 2079-2163, 2092-2163, 2193-2270, 2277-2369, 2296-2377, 2401-2479, 2486-2576, 2505-2583, 2607-2681, 2716-2795, 2802-2897, 2819-2904, 2932-3009, 3016-3104, 3033-3111, 3120-3195, 3135-3195, 3224-3312, 3253-3319, 3326-3416, 3343-3424, 3451-3529, and 3431-3522 of NOV2. Cadherins are glycoproteins involved in Ca²⁺-mediated cell-cell adhesion.

- 5
10 Cadherin domains occur as repeats in the extracellular regions which are thought to mediate cell-cell contact when bound to calcium.

Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor has homology to the β -catenin binding regions of classical cadherin cytoplasmic tails and also ends with a PDZ domain-binding motif {mu}-protocadherin that regulates branching morphogenesis in the kidneys and lungs. Therefore, NOV2 has a role in cell growth and cell survival. Therapeutic targeting of NOV2 with a monoclonal antibody is anticipated to limit or block the extent of cell growth and cell survival in colon, breast, liver and gastric tumors.

The disclosed NOV2 nucleic acid of the invention encoding a Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor-like protein includes the nucleic acid whose sequence is provided in Table 2A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 2A while still encoding a protein that maintains its Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.

The disclosed NOV2 protein of the invention includes the Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor-like protein whose sequence is provided in Table 2B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2B while still encoding a protein that maintains its Protocadherin Fat 2 (FAT2) cadherin related tumor suppressor-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 56% percent of the residues may be so changed.

NOV2 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV2 protein has multiple hydrophilic regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which are useful in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies could also be used to treat certain pathologies as detailed above.

NOV3

A disclosed NOV3 nucleic acid of 3381 nucleotides (also referred to as CG-SC 17661211) encoding a novel orphan GPCR-like protein is shown in Table 3A. An open reading frame was identified beginning with a ATG initiation codon at nucleotides 62-64 and ending with a TGA codon at nucleotides 2882-2884. The start and stop codons are in bold letters, and the 5' and 3' untranslated regions are underlined.

Table 3A. NOV3 Nucleotide Sequence (SEQ ID NO:5)

CTAGAATT**CAGCGGCCGCTTAATT**CAGAACGGCCCCCTGCCACTGCCAGGAGGACGGCATCATGCTGTCTG
CCGACTGCTCTGAGCTCGGGCTGTCCGCCGTTCCGGGGGACCCGGACCCCTGACGGCTTACCTGGACCTC
AGCATGAACAACCTCACAGAGCTTCAGCCTGGCCTCTCCACCACCTGCGCTTCTTGGAGGAGCTGCGTCT
CTCTGGGAACCATCTCTCACACATCCAGGACAAGCATTCTCTGGTCTCTACAGCCTGAAAATCCTGATGC
TGCAGAACAAATCAGCTGGGAGGAATCCCGCAGAGGCGCTGTGGGAGCTGCCGAGCCTGCAGTCGCTGCGC
CTAGATGCCAACCTCATCTCCCTGGTCCCGGAGAGGAGCTTTGAGGGGCTGTCCCTCCCTCCGCCACCTCTG
GCTGGACGACAATGCACTACGGAGATCCCTGTGAGGGCCCTCAACAACCTCCCTGCCCTGCAGGCCATGA
CCCTGGCCCTCAACCGCATCAGCCACATCCCGACTACGCGTTCCAGAATCTACCAGCCTTGTGGTGCTG
CATTTGCATAACAACCGCATCCAGCATCTGGGGACCCACAGCTTCGAGGGGCTGCACAATCTGGAGACACT
AGACCTGAATTATAACAAGCTGCAGGAGTTCCTGTGGCCATCCGGACCTGGGCAGACTGCAGGAACTGG
GGTTCATAACAACAACATCAAGGCCATCCAGAAAAGGCCTTCATGGGGAACCTCTGCTACAGACGATA
CACTTTTATGATAACCCAATCCAGTTTGTGGGAAGATCGGCATTCAGTACCTGCCTAAACTCCACACACT
ATCTCTGAATGGTGCCATGGACATCCAGGAGTTTCCAGATCTCAAAGGCACCACCAGCCTGGAGATCCTGA
CCCTGACCCGCGCAGGCATCCGGCTGCTCCCATCGGGGATGTGCCAACAGCTGCCCAGGCTCCGAGTCCCTG
GAACTGTCTCAATCAAAATGAGGAGCTGCCCAGCCTGCACAGGTGTGAGAAATGGAGGAAATCGGCCT
CCAACACAACCGCATCTGGGAAATGGAGCTGACACCTTCAGCCAGCTGAGCTCCCTGCAAGCCCTGGATC
TTAGCTGGAAACGCCATCCGGTCCATCCACCCGAGGCCTTCTCCACCTGCACCTCCCTGGTCAAGCTGGAC
CTGACAGACAACAGCTGACCACACTGCCCTGGCTGGACTTGGGGGCTTGATGCATCTGAAGCTCAAAGG
GAACCTTGCTCTCTCCAGGCCTTCTCCAAGGACAGTTTCCAAAACCTGAGGATCCTGGAGGTGCCTTATG
CCTACCAGTGCTGTCCCTATGGGATGTGTGCCAGCTTCTTCAAGGCCTCTGGGCAGTGGGAGGCTGAAGAC
CTTCACCTTGATGATGAGGAGTCTTCAAAAAGGCCCTTGGGCCCTCCTTGCCAGACAAGCAGAGAACCATA
TGACCAGGACCTGGATGAGCTCCAGCTGGAGATGGAGGACTCAAAGCCACACCCAGTGTCCAGTGTAGCC
CTACTCCAGGCCCTTCAAGCCCTGTGAGTACCTCTTTGAAAGCTGGGGCATCCGCTGGCGGTGTGGGCC
ATCGTGTGCTCTCCGTGCTCTGCAATGGACTGGTGTGCTGACCGTGTTCGCTGGCGGGCTGCCCCCT
GCCCCCGGTCAAGTTTGTGGTAGGTGCGATTGCAGGCGCCAACACCTTGACTGGCATTCTCTGTGGCCTT
TAGCCTCAGTCGATGCCCTGACCTTGGTCAGTTCTCTGAGTACGGAGCCCGCTGGGAGACGGGGCTAGGC
TGCCGGGCCACTGGCTTCTGGCAGTACTTGGGTGGGAGGCATCGGTGCTGCTGCTCACTCTGGCCGCACT
GCAGTGCAGCGTCTCCGTCTCTGTGTCCGGCCTATGGGAAGTCCCCCTCCCTGGGCAGCGTTTCGAGCAG
GGGTCTTAGGCTGCCTGGCACTGGCAGGGCTGGCCGCCGCACTGCCCTGGCCTCAGTGGGAGAATACGGG
GCCTCCCCACTCTGCCTGCCCTACGCGCCACCTGAGGCTCAGCCAGCAGCCCTGGGCTTCAACGTGGCCCT
GGTGATGATGAATCCTTCTGTTTCTGGTCTGGCCGGTGCCTACATCAAACCTGTAAGTGTGACCTGCCGC
GGGGCGACTTTGAGCCGTGTGGACTGCGCATGGTGAGGCAGTGGCCTGGCTCATCTTCGAGACGGG
CTCCTCTACTGTCCCGTGGCCTTCTCAGCTTCGCCCTCCATGTGGGCCTCTTCCCTGTACGCCCGAGGC
CGTCAAGTCTGTCTGTGGTGGTGTGCCCTGCCTGCCTGCCTCAACCCACTGCTGTACCTGCTCTTCA
ACCCCACTTCCGGGATGACCTTCGGCGGCTTCGGCCCCGCGCAGGGGACTCAGGGCCCCCTAGCCTATGCT
GCGGCCCGGGAGCTGGAGAAGAGCTCCTGTGATTCTACCCAGGCCCTGGTAGCCTTCTCTGATGTGGATCT
CATTCTGGAAGCTTCTGAAGCTGGGCGGCCCTGGGCTGGAGACCTATGGCTTCCCCTCAGTGACCTCA
TCTCCTGTGACAGCCAGGGGCCCCAGGCTGGAGGCGAGCCATTGTGTAGAGCCAGAGGGGAACCACTTT
GGGAACCCCAACCTCCATGGATGGAGAAGTGTCTGTGAGGCGAGAGGATCTACGCCAGCAGGTGGAGG
CTTGTGAGGGGGTGGCGCTTTCAGCCCTCTGGCTTGGCCTTTGCTTACACGTGTAAATATCCCTCCCCAT
TCTTCTCTTCCCCTCTCTTCCCTTCTCTCTCCCCCTCGGTGAATGATGGCTGCTTCTAAAACAAATACA
ACCAAACTCAGCAGTGTGATCTATAGCAGGATGGCCAGTACCTGGCTCCACTGATCACCTCTCTCTGT
GACCATCAACAACGGGTGCCCTCTTGGCCTGGCTTTCCTTGGCCTTCTCAGCTTCACTTGTACTGAGG
CCTTCTCTTGTCTGTAAGCTGTGACCAAGACCTGGACTTTTGTCTGCTTAAGGGAAATGAGGGA
AGTAAAGACAGTGAAGGGGTGGAGGTTGATCAGGGCACAGTGGACAGGGAGACCTCACAGAGAAAGGCCT
GGAGGTTGATTTCCGTGTGACTCATGGATAGGATACAAATGTGTTCCATGTACCATTAATCTTGACATA
TGCCATGCATAAAGACTTCTATTAAATAAGCTTTGGAAGAGATTACACATGATGTCTTTTCTTAGAGA
TTACAGTGCATGTTAGTGAATAAAGAGATAAGTCTACAGTA

The disclosed NOV3 nucleic acid sequence has 1657 of 1659 bases (99%) identical to the 3119 nucleotide *Homo sapiens* VTS20631 mRNA, g-protein coupled receptor family partial cds (GENBANK-ID: gi|13447609|dbj|AB049405.1|AB049405) (E = 0.0).

A disclosed NOV3 protein (SEQ ID NO:6) encoded by SEQ ID NO:5 has 940 amino acid residues, and is presented using the one-letter code in Table 3B. Signal P, Psort and/or Hydropathy results predict that NOV3 does not have a signal peptide, and is likely to be localized to the plasma membrane as a Type IIIb membrane protein.

Table 3B. Encoded NOV3 protein sequence (SEQ ID NO:6).

```

MLSADCSSELGLSAVPGDPDPLTAYLDLSMNNLTQLPGLFHHLRFLLEELRLSGNHLSHIPGQAFSGLYSLK
ILMLQNNQLGGIPAEALWELPSLQSLRLDANLISLVPERSFEGLSLRHLWDDNALTEIPVRALNNLPAL
QAMTLALNRI SHIPDYAFQNLTSLVVLHLHNNRIQHLGTHSFEGLNHLETLDLNYNKLQEFPPVAIRTLGRL
QELGFHNNNIKAIPEKAFMGNEPLLQTIHFYDNPIQFVGRSAFQYLPKLTLSLNGAMDIQEFDDLKGTTS
EILTITRAGIRLLPSGMCQQLPRLRVLELSHNQIEELPSLHRCQKLEIEIGLQHNRIWEIGADTFSQLSSIQ
ALDLSWNAIRSIHPEAFSTLHSLVKLDLTDNQLTTLPLAGLGGLMHLKLGKGNLALSQAFSKDSFPKLRILE
VPYAYQCCPYGMCASFPAKSGQWEAEDLHLDDEESSKRPLGLLARQAENHYDQDLDELQLEMEDSKPHPSV
QCSPTPGPFKPCYLFESWGIRLAVWAIVLLSVLCNGLVLLTVFAGGPAPLPPVKFVVGAIAGANTLTGIS
CGLLASVDALTFGQFSEYGARWETGLGCRATGFLAVLGSEASVLLTLAAVQCSVSVSCVRAYGKSPSLGS
VRAGVLGCLALAGLAAALPLASVGEYGASPLCLPYAPPEGQPAALGFTVALVMMNSFCFLVAGAYIKLYC
DLPRGDFEAVWDCAMVRHVANLIFADGLLYCPVAFSLFASMLGLFPVTPEAVKSVLLVVLPLPACLNPLLY
LLFNPHFRDDLRLRLRPRAGDSGFLAYAAAGELEKSSCDSTQALVAFSDVDLILEASEAGRPPGLETYGFPS
VTLISCQQPGAPRLEGSHCPEPEGNHFGNPQPSMDGELLRLRAEGSTPAGGGLSGGAFSPPLAWPLLHTCKY
PSPFFSSPLPFPFLSPPR

```

TaqMan expression data for NOV3 is found below is Example 1, and SAGE data is found below in Example 2. The TaqMan data indicates overexpression of NOV3 in colon, breast, liver and gastric tumors.

NOV3 has homology to the amino acid sequences shown in the BLASTP data listed in Table 3C.

Table 3C. BLAST results for NOV3

Gène Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 13447610 dbj BAB 39854.1 (AB049405)	VTS20631 [Homo sapiens]	928	802/895 (89%)	802/895 (89%)	0.0
gi 15298008 ref XP_ 046692.2	similar to leucine-rich repeat- containing G protein- coupled receptor 6 (H. sapiens) [Homo sapiens]	893	774/867 (89%)	774/867 (89%)	0.0

gi 10441732 gb AAG17168.1 AF190501_1 (AF190501)	leucine-rich repeat-containing G protein-coupled receptor 6 [Homo sapiens]	828	638/798 (79%)	653/798 (80%)	0.0
gi 4504379 ref NP_03658.1	G protein-coupled receptor 49; orphan G protein-coupled receptor HG38; G protein-coupled receptor 67 [Homo sapiens]	907	436/869 (50%)	556/869 (63%)	0.0
gi 3885472 gb AAC77911.1 (AF061444)	G protein-coupled receptor LOR5 [Homo sapiens]	907	434/869 (49%)	554/869 (62%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3D.

Table 3D. ClustalW Analysis of NOV3

- ```

1) NOV3 (SEQ ID NO:6)
2) gi|13447610|dbj|BAB39854.1| (AB049405) VTS20631 [Homo sapiens] (SEQ ID NO:23)
3) gi|15298008|ref|XP_046692.2| similar to leucine-rich repeat-containing G
protein-coupled receptor 6 [H. sapiens] [Homo sapiens] (SEQ ID NO:24)
4) gi|10441732|gb|AAG17168.1|AF190501.1 (AF190501) leucine-rich repeat-containing G
protein-coupled receptor 6 [Homo sapiens] (SEQ ID NO:25)
5) gi|4504379|ref|NP_03658.1| G protein-coupled receptor 49; orphan G protein-
coupled receptor HG38; G protein-coupled receptor 67 [Homo sapiens] (SEQ ID NO:26)
6) gi|3885472|gb|AAC77911.1| (AF061444) G protein-coupled receptor LGR5 [Homo
sapiens] (SEQ ID NO:27)

```

20 NOV3  
gi|13447610|dbj  
gi|15298008|ref  
gi|10441732|gb  
gi|4504379|ref  
gi|3885472|gb|A

25

30

35

10 20 30 40 50 60

70 80 90 100 110 120

130 140 150 160 170 180

14 21 1 17 60 60

74 81 46 77 120 120

134 141

|    |      |          |     |                                                               |     |
|----|------|----------|-----|---------------------------------------------------------------|-----|
|    | gi   | 15298008 | ref | LQNNQLGGIPAEALWELPSLQSLRLDANLISLVVERSEEGISLSRHLWLDNLTPIVVR    | 106 |
|    | gi   | 10441732 | gb  | LQNNQLGGIPAEALWELPSLOSI-----                                  | 100 |
|    | gi   | 4504379  | ref | LQNNQLRHVFTEALQNLRSLSLQSLRLDANLISVVPSCFSGLHSLRHLWLDNLTPIVQ    | 180 |
| 5  | gi   | 3885472  | gb  | LQNNQLRHVFTEALQNLRSLSLQSLRLDANLISVVPSCFSGLHSLRHLWLDNLTPIVQ    | 180 |
|    |      |          |     | 190 200 210 220 230 240                                       |     |
|    | NOV3 |          |     | ALNNLPALQAMTLALNRISHIPDYAFONLISLVVLHLHNNRIQHGLGTHSFEGLHNLETLD | 194 |
| 10 | gi   | 13447610 | dbj | ALNNLPALQAMTLALNRISHIPDYAFONLISLVVLHLHNNRIQHGLGTHSFEGLHNLETLD | 201 |
|    | gi   | 15298008 | ref | ALNNLPALQAMTLALNRISHIPDYAFONLISLVVLHLHNNRIQHGLGTHSFEGLHNLETLD | 166 |
|    | gi   | 10441732 | gb  | -----D                                                        | 101 |
|    | gi   | 4504379  | ref | AFRSLSALQAMTLALNKTHIPDYAFONLISLVVLHLHNNRIHSLGKKCFDGLHSLETLD   | 240 |
|    | gi   | 3885472  | gb  | AFRSLSALQAMTLALNKTHIPDYAFONLISLVVLHLHNNRIHSLGKKCFDGLHSLETLD   | 240 |
|    |      |          |     | 250 260 270 280 290 300                                       |     |
| 15 | NOV3 |          |     | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 254 |
|    | gi   | 13447610 | dbj | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 261 |
|    | gi   | 15298008 | ref | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 226 |
| 20 | gi   | 10441732 | gb  | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 161 |
|    | gi   | 4504379  | ref | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 300 |
|    | gi   | 3885472  | gb  | LNYNKLQEFFVAIRTLGRLOELGFHNNNIKAPEKAFMGNPLLQTIHFYDNPIQFVGRSA   | 300 |
|    |      |          |     | 310 320 330 340 350 360                                       |     |
| 25 | NOV3 |          |     | FQYLPKLHTLSLNGAMDIQEPDLKGTTSLEILTLAGIRLLPSGMCOQLPRLRVLELS     | 314 |
|    | gi   | 13447610 | dbj | FQYLPKLHTLSLNGAMDIQEPDLKGTTSLEILTLAGIRLLPSGMCOQLPRLRVLELS     | 321 |
|    | gi   | 15298008 | ref | FQYLPKLHTLSLNGAMDIQEPDLKGTTSLEILTLAGIRLLPSGMCOQLPRLRVLELS     | 286 |
| 30 | gi   | 10441732 | gb  | FQYLPKLHTLSLNGAMDIQEPDLKGTTSLEILTLAGIRLLPSGMCOQLPRLRVLELS     | 221 |
|    | gi   | 4504379  | ref | FOHLPRLHTLSLNGASQITEFPDLGTANLESLTITGAQISSLPOTVCNOLPNLOVDLS    | 360 |
|    | gi   | 3885472  | gb  | FOHLPRLHTLSLNGASQITEFPDLGTANLESLTITGAQISSLPOTVCNOLPNLOVDLS    | 360 |
|    |      |          |     | 370 380 390 400 410 420                                       |     |
| 35 | NOV3 |          |     | HNQIEELPSLHRCQKLEELGLQHNRIWEIGADTFSQLSSLOALDLSWNAIRSIHPEAFST  | 374 |
|    | gi   | 13447610 | dbj | HNQIEELPSLHRCQKLEELGLQHNRIWEIGADTFSQLSSLOALDLSWNAIRSIHPEAFST  | 381 |
|    | gi   | 15298008 | ref | HNQIEELPSLHRCQKLEELGLQHNRIWEIGADTFSQLSSLOALDLSWNAIRSIHPEAFST  | 346 |
|    | gi   | 10441732 | gb  | HNQIEELPSLHRCQKLEELGLQHNRIWEIGADTFSQLSSLOALDLSWNAIRSIHPEAFST  | 281 |
| 40 | gi   | 4504379  | ref | YNLLEDLPSFSVCQKLOKIDLRHNEIYEIKVDTFQQLSLRSNLAWNKIAIHNPAFST     | 420 |
|    | gi   | 3885472  | gb  | YNLLEDLPSFSVCQKLOKIDLRHNEIYEIKVDTFQQLSLRSNLAWNKIAIHNPAFST     | 420 |
|    |      |          |     | 430 440 450 460 470 480                                       |     |
| 45 | NOV3 |          |     | LHSLVKLDLTDNQLTTPLPLAGLGLMHLKLGKLNLSQAFSKDSFPKLRILEVPYAYQCC   | 434 |
|    | gi   | 13447610 | dbj | LHSLVKLDLTDNQLTTPLPLAGLGLMHLKLGKLNLSQAFSKDSFPKLRILEVPYAYQCC   | 441 |
|    | gi   | 15298008 | ref | LHSLVKLDLTDNQLTTPLPLAGLGLMHLKLGKLNLSQAFSKDSFPKLRILEVPYAYQCC   | 406 |
|    | gi   | 10441732 | gb  | LHSLVKLDLTDNQLTTPLPLAGLGLMHLKLGKLNLSQAFSKDSFPKLRILEVPYAYQCC   | 341 |
|    | gi   | 4504379  | ref | LPSLKLKDLSSNLSSEFPITGHLGHTLKLTHALQSLISSNFPPELKVIEVPYAYQCC     | 480 |
| 50 | gi   | 3885472  | gb  | LPSLKLKDLSSNLSSEFPITGHLGHTLKLTHALQSLISSNFPPELKVIEVPYAYQCC     | 480 |
|    |      |          |     | 490 500 510 520 530 540                                       |     |
| 55 | NOV3 |          |     | PYGMCAEFFKASGQWEAEDLHLDDEESSKRPLGLLARQAENHYDQDLDELQLEMEDS-KP  | 493 |
|    | gi   | 13447610 | dbj | PYGMCAEFFKASGQWEAEDLHLDDEESSKRPLGLLARQAENHYDQDLDELQLEMEDS-KP  | 500 |
|    | gi   | 15298008 | ref | PYGMCAEFFKASGQWEAEDLHLDDEESSKRPLGLLARQAENHYDQDLDELQLEMEDS-KP  | 465 |
|    | gi   | 10441732 | gb  | PYGMCAEFFKASGQWEAEDLHLDDEESSKRPLGLLARQAENHYDQDLDELQLEMEDS-KP  | 400 |
|    | gi   | 4504379  | ref | AFQVCENAYKTSNQNNKGDNSSMOI-LHKQDAGMFOAQDE---RDLEDFLDFEEDLKA    | 535 |
|    | gi   | 3885472  | gb  | AFQVCENAYKTSNQNNKGDNSSMOI-LHKQDAGMFOAQDE---RDLEDFLDFEEDLKA    | 535 |
|    |      |          |     | 550 560 570 580 590 600                                       |     |
| 60 | NOV3 |          |     | HPSVQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 553 |
|    | gi   | 13447610 | dbj | HPSVQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 560 |
|    | gi   | 15298008 | ref | HPSVQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 525 |
| 65 | gi   | 10441732 | gb  | HPSVQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 460 |
|    | gi   | 4504379  | ref | LHVSQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 594 |
|    | gi   | 3885472  | gb  | LHVSQCSPTPGPFKPCBYLFESWGIRLAVNAIVLLSVLCNGLVLLTVFAGGPAFLPPVKF  | 594 |
|    |      |          |     | 610 620 630 640 650 660                                       |     |
| 70 |      |          |     | .....                                                         |     |
|    |      |          |     | .....                                                         |     |
|    |      |          |     | .....                                                         |     |
|    |      |          |     | .....                                                         |     |
|    |      |          |     | .....                                                         |     |
|    |      |          |     | .....                                                         |     |

|    |                       |                                                                |     |
|----|-----------------------|----------------------------------------------------------------|-----|
|    | NOV3                  | VVGAIAGANTLTGISCGLLASVDALTFGQFSEYGARWETGLGCRATGFLAVLGSEASVLL   | 613 |
|    | gi   13447610   dbj   | VVGAIAGANTLTGISCGLLASVDALTFGQFSEYGARWETGLGCRATGFLAVLGSEASVLL   | 620 |
|    | gi   15298008   ref   | VVGAIAGANTLTGISCGLLASVDALTFGQFSEYGARWETGLGCRATGFLAVLGSEASVLL   | 585 |
| 5  | gi   10441732   gb    | VVGAIAGANTLTGISCGLLASVDALTFGQFSEYGARWETGLGCRATGFLAVLGSEASVLL   | 520 |
|    | gi   4504379   ref    | LIGVIAAVNMLTGVSSAVLAGVDAFTFGSFARHGAWWENGVCCHVIGFLSTFASSSVFL    | 654 |
|    | gi   3885472   gb   A | LIGVIAAVNMLTGVSSAVLAGVDAFTFGSFARHGAWWENGVCCHVIGFLSTFASSSVFL    | 654 |
|    |                       | 670 680 690 700 710 720                                        |     |
| 10 | NOV3                  | LTAAVQCSVSVSCVRAYGKSPSLGSRVAGVLGCLALAGLAAALPLASVGEYGASPLCLP    | 673 |
|    | gi   13447610   dbj   | LTAAVQCSVSVSCVRAYGKSPSLGSRVAGVLGCLALAGLAAALPLASVGEYGASPLCLP    | 680 |
|    | gi   15298008   ref   | LTAAVQCSVSVSCVRAYGKSPSLGSRVAGVLGCLALAGLAAALPLASVGEYGASPLCLP    | 645 |
|    | gi   10441732   gb    | LTAAVQCSVSVSCVRAYGKSPSLGSRVAGVLGCLALAGLAAALPLASVGEYGASPLCLP    | 580 |
|    | gi   4504379   ref    | LTAAALERGF SVKYSAKFETKAPFSSLLKVIILLICALLALTMAAVPLGGSKYASPLCLP  | 714 |
| 15 | gi   3885472   gb   A | LTAAALERGF SVKYSAKFETKAPFSSLLKVIILLICALLALTMAAVPLGGSKYASPLCLP  | 714 |
|    |                       | 730 740 750 760 770 780                                        |     |
| 20 | NOV3                  | YAPPEGQPAALGFTVALVMMNSFCFLVVAGAYIKLYCDLPRGDFEAVWDCAMVRHVAVLI   | 733 |
|    | gi   13447610   dbj   | YAPPEGQPAALGFTVALVMMNSFCFLVVAGAYIKLYCDLPRGDFEAVWDCAMVRHVAVLI   | 740 |
|    | gi   15298008   ref   | YAPPEGQPAALGFTVALVMMNSFCFLVVAGAYIKLYCDLPRGDFEAVWDCAMVRHVAVLI   | 705 |
|    | gi   10441732   gb    | YAPPEGQPAALGFTVALVMMNSFCFLVVAGAYIKLYCDLPRGDFEAVWDCAMVRHVAVLI   | 640 |
|    | gi   4504379   ref    | --LPFGEPSTMGYVVALILLNSLCFLMTTAYTKLYCNLDKGDLENTWDCSNVKKHIALLI   | 772 |
| 25 | gi   3885472   gb   A | --LPFGEPSTMGYVVALILLNSLCFLMTTAYTKLYCNLDKGDLENTWDCSNVKKHIALLI   | 772 |
|    |                       | 790 800 810 820 830 840                                        |     |
| 30 | NOV3                  | FADGLLYCPVAFLSFASMLGLFPVTPEAVKSVLLVVLPLPACLNPLLYLLFNPFRDDLRL   | 793 |
|    | gi   13447610   dbj   | FADGLLYCPVAFLSFASMLGLFPVTPEAVKSVLLVVLPLPACLNPLLYLLFNPFRDDLRL   | 800 |
|    | gi   15298008   ref   | FADGLLYCPVAFLSFASMLGLFPVTPEAVKSVLLVVLPLPACLNPLLYLLFNPFRDDLRL   | 765 |
|    | gi   10441732   gb    | FADGLLYCPVAFLSFASMLGLFPVTPEAVKSVLLVVLPLPACLNPLLYLLFNPFRDDLRL   | 700 |
|    | gi   4504379   ref    | FTNCILNCPVAFLSFSSLLINLTFTISPEVTKFILLVVVPLPACLNPLLYLLFNPFRKEDLV | 832 |
|    | gi   3885472   gb   A | FTNCILNCPVAFLSFSSLLINLTFTISPEVTKFILLVVVPLPACLNPLLYLLFNPFRKEDLV | 832 |
| 35 |                       | 850 860 870 880 890 900                                        |     |
| 40 | NOV3                  | RLRPR-----AGDSGPLAYAAAGELEKSSCDSTQALVAFSDVDLILEASEAGRPPGLETY   | 848 |
|    | gi   13447610   dbj   | RLRPR-----AGDSGPLAYAAAGELEKSSCDSTQALVAFSDVDLILEASEAGRPPGLETY   | 855 |
|    | gi   15298008   ref   | RLRPR-----AGDSGPLAYAAAGELEKSSCDSTQALVAFSDVDLILEASEAGRPPGLETY   | 820 |
|    | gi   10441732   gb    | RLRPR-----AGDSGPLAYAAAGELEKSSCDSTQALVAFSDVDLILEASEAGRPPGLETY   | 755 |
|    | gi   4504379   ref    | SLRKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFSSSTTYDLPPS-----        | 883 |
|    | gi   3885472   gb   A | SLRKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFSSSTTYDLPPS-----        | 883 |
| 45 |                       | 910 920 930 940 950 960                                        |     |
| 50 | NOV3                  | GFPSVTLISCQOPGAPRLEGSHCVEPEGNHFGNPQPSMDGELLRLAEGSTPAGGGLSGGG   | 908 |
|    | gi   13447610   dbj   | GFPSVTLISCQOPGAPRLEGSHCVEPEGNHFGNPQPSMDGELLRLAEGSTPAGGGLSGGG   | 915 |
|    | gi   15298008   ref   | GFPSVTLISCQOPGAPRLEGSHCVEPEGNHFGNPQPSMDGELLRLAEGSTPAGGGLSGGG   | 880 |
|    | gi   10441732   gb    | GFPSVTLISCQOPGAPRLEGSHCVEPEGNHFGNPQPSMDGELLRLAEGSTPAGGGLSGGG   | 815 |
|    | gi   4504379   ref    | ---SVP-----SPAYPVTECHLS-----                                   | 899 |
|    | gi   3885472   gb   A | ---SVP-----SPAYPVTECHLS-----                                   | 899 |
| 55 |                       | 970 980 990                                                    |     |
| 55 | NOV3                  | AFSPFLAWPLHTCKYPSFFSSPLFPFLSPPR                                | 940 |
|    | gi   13447610   dbj   | GFQPSGLAFASHY-----                                             | 928 |
|    | gi   15298008   ref   | GFQPSGLAFASHY-----                                             | 893 |
|    | gi   10441732   gb    | GFQPSGLALHTY-----                                              | 828 |
|    | gi   4504379   ref    | -----SVAFVPCI-----                                             | 907 |
| 60 | gi   3885472   gb   A | -----SVAFVPCI-----                                             | 907 |

According to InterPro Domains searches, NOV3 contains 16 Leucine Rich Repeats domains and 2 seven transmembrane receptor (rhodopsin) domains.

Because of its high homology to GPCRs and its containing GPCR 7 transmembrane domains, NOV3 is thought to be involved with cell growth and cell survival. Therapeutic

targeting of NOV3 with a monoclonal antibody is anticipated to limit or block the extent of cell growth and cell survival in colon, breast, liver and gastric tumors.

The disclosed NOV3 nucleic acid of the invention encoding a Orphan GPCR-like protein includes the nucleic acid whose sequence is provided in Table 3A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 3A while still encoding a protein that maintains its Orphan GPCR-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.

The disclosed NOV3 protein of the invention includes the Orphan GPCR -like protein whose sequence is provided in Table 3B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 3B while still encoding a protein that maintains its Orphan GPCR -like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 51% percent of the residues may be so changed.

The protein similarity information, expression pattern, and map location for the Orphan GPCR-like protein and nucleic acid (NOV3) disclosed herein suggest that NOV3 may have important structural and/or physiological functions characteristic of the citron kinase-like family. Therefore, the NOV3 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.

NOV3 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. This novel protein also has value in development of powerful assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies could also be used to treat certain pathologies as detailed above.

#### 10 NOV4

A disclosed NOV4 nucleic acid of 2397 nucleotides (designated CuraGen Acc. No. CG-SC28471525) encoding a novel Slit-like protein is shown in Table 4A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 2395-2397. In Table 4A the start and stop codons are in bold letters.

**Table 4A. NOV4 Nucleotide Sequence (SEQ ID NO:7)**

```

ATGCTAATAAAATGTGAAGCAAAGGTATCAAGATGGTATCTGAAATAAGTGTGCCACCATCAGACCTT
TCCAAC TAAGCTTATTAATAACGGCTTGACGATGCTTCACACAAATGACTTTTCTGGGCTTACCAATGC
TATTTC AATACACCTTGGATTTAACAATATTGCAGATATTGAGATAGGTGCATTTAATGGCCTTGGCCTC
CTGAAACAACCTTCATATCAATCAAAATCTTTAGAAATCTTAAAGAGGATACCTTCCATGGACTGGAAA
ACCTGGAATTCCTGCAAGCAGATAACAATTTTATCACAGTGATTGAACCAAGTGCCTTTAGCAAGCTCAA
CAGACTCAAAGTGTAAATTTTAAATGACAATGCTATTGAGAGTCTTCTCCAAACATCTTCCGATTTGTT
CCTTTA ACCCATCTAGATCTTCTGGAATCAATTACAAACATTGCCTTATGTTGGTTTCTCGAACACA
TTGGCCGAATATTGGATCTTCAGTTGGAGGACAACAAATGGGCCTGCAATTGTGACTTATTGCAGTTAAA
AATCTGGATTGGAGAACATGCCTCCACAGTCTATAATTGGTGATGTTGTCTGCAACAGCCCTCCATTTT
AAAGGAAGTATACTCAGTAGACTAAAGAAGGAATCTATTTGCCCTACTCCACCAGTGTATGAAGAATG
AGGATCCTTCAGGATCATTACATCTGGCAGCAACATCTTCAATAAATGATAGTCGCATGTCAACTAAGAC
CACGTCCATTCTAAACTACCCACCAAGCACCAGTTTGATACCTTATATTACAAAGCCATCCACTCAA
CTTCAGGACTTACTGCCCTATTCCTTGTAACTGCAAAGTCTATCCCATCAGGACTTCTAATACATT
GTCAGGAGCGCAACATTGAAAGCTTATCAGATCTGAGACCTCCTCGCAAAATCTAGAAAGCTCATTCT
AGCGGGAATATTATTACAGTTTAATGAAGTCTGATCTAGTGGAATATTTCATTGGAAATGCTTCAC
TTGGGAACAATCGTATTGAAGTCTTGAAGAAGGATCGTTTATGAACCTAACGAGATTACAAAACTCT
ATCTAAATGGTAACCACTGACCAAAATTAAGTAAAGGCATGTTCTTGGTCTCCATAATCTGAATACTT
ATATCTTGAATACAATGCCATTAAAGGAATACTGCCAGGAACCTTTAATCCAATGCCATAACTTAAAGTC
CTGTATTTAAATAACAACCTCCTCCAAGTTTACCACCACATATTTTTCAGGGGTTCTCTAATCAAGG
TAAATCTTAAACAACAGTTTACCCATCTACCTGTAAGTAATATTTGGATGATCTTGATTGCTAAC
CCAGATTGACCTTGAGGATAACCCCTGGGACTGCTCCTGTGACCTGGTGGACTGCAGCAATGGATACAA
AAGTTAAGCAAGACACAGTGACAGATGACATCCTCTGCACTTCCCCGGGCATCTCGACAAAAAGGAAT
TGAAAGCCCTAAATAGTGAAATCTCTCTGCCAGGTTAGTAAATAACCCATCCATGCCAACACAGACTAG
TTACCTTATGGTCACCACTCCTGCAACAACAACAAATACGGCTGATACTATTTACGATCTCTTACGGAC
GCTGTGCCACTGCTGTTCTAATATTGGGACTTCTGATTATGTTTCATCACTATTGTTTCTGTGCTGCAG
GGATAGTGGTTCTTGTCTTCACCGCAGGAGAAGATACAAAAGAAACAAGTAGATGAGCAAATGAGAGA
CAACAGTCTCTGTGCATCTTCAGTACAGCATGTATGGCCATAAAACCACTCATCACTACTGAAAGACCC
TCTGCCCTCACTCTATGAACAGCAGATGGTGAGCCCATGGTTCATGTCTATAGAAGTCCATCCTTGTGTC
CAAGCATCTGGAGAGGAGAAAGAGAGAGGAATGAGAAAGGAAGTATGCAAAACATCTCCAAAGAAG
TCTTTTGGAAACAGGAAAAATCATTACCACTCAGGGGTCAAATATGAAATACAAACACGAACCAATCA
ACAGAATTTTATCCTTCCAAGATGCCAGCTCATTGTACAGAAACATTTAGAAAAGAAAGGGAACCTC
AGCAACTGGGAATCACAGAATACCTAAGGAAAAACATTGCTCAGCTCCAGCCTGATATGGAGGCACATTA
TCCTGGAGCCACGAAGAGCTGAAGTTAATGGAAACATTATGTACTCACGTCCAGGAAGGTATTAGTG
GAACAGACAAAAATGAGTATTTTGAACCTAAAGCTAATTTACATGCTGAACCTGACTATTTAGAAGTCC
TGGAGCAGCAACATAG

```

The nucleic acid sequence of NOV4, located on chromosome 13, has 2397 of 2397 bases (100%) identical to a 2593 nucleotide *Homo sapiens* hypothetical protein FLJ22774 (FLJ22774), mRNA (GENBANK-ID: gi|14758125|ref|XM\_033182.1) (E = 0.0).

- 5 A NOV4 polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 is 798 amino acid residues and is presented using the one letter code in Table 4B. Signal P, Psort and/or Hydropathy results predict that NOV4 is likely to be localized at the plasma membrane and is a Type Ib transmembrane protein.

**Table 4B. NOV4 protein sequence (SEQ ID NO:8)**

```

MLINCEAKGIKVVSEISVPPSRPQLSLLNGLTMLHTNDFSGLTNAISIHGFNNIADIEIGAFNGLGLLKQL
HINHNSLEILKEDTFHGLENLFLQADNNFITVIEPSAFSKLNRLKVLILNDNAIESLPNIFRFVPLTHLDLR
GNQLQTLFPVVGFLBHGRIIDLQLEDNKWACNDLLQLKTWLENMPPQSIIGDVVCNSPPFFKGSILSRKKES
ICPTFPVYEEHEDPSGSLHLAATSSINDSRMSTKTTISILKLPKAPGLIPYITKPTQLPGPYCPIPCNCKVLS
PSGLLIHCQERNIBSLSDLRPPPNRKLILAGNIHSLMKSDDLVEYFTLEMLHLGNRIEVLSEGSFNMNTRL
QKLYLNGNHLTKLSKGMFLGLHNLLEYLYLEYNAIKEILPGTFNPMPLKVLVYLNLLQVLPPIHPSGVPLTKV
NLKTNQFTHLPVSNILDDLDLLTQIDLEDNPDWDCSDLVGLQQWIKLSKNTVTDDILCTSPGHLDKKEKALN
SEILCPGLVNNPSMPTQTSYLMVTPATTNTADTILRSLTDAVPLSVLILQLLIMFITIVFCAAGIVVLVLR
RRRYKKQVDEQMRDNPVHLQYSMYGHKTTHTTERPSASLYEQHMVSPMVHVYRSPSFGPKHLEEEERNEK
EGSDAKHLQRSLLRQENHSPLTGSNMKYKTTNQSTBFLSFQDASSLYRNILEKERELQQLGITETLRKNIAQLQ

```

PDMEAHYPGAHEELKLMETLMSRPRKVLVEQTKNEYFELKANLHAEFDPYLEVLEQQT\*

The full amino acid sequence of the protein of the invention was found to have 1263 of 1857 amino acid residues (68%) identical to, and 1501 of 1857 amino acid residues (80%) similar to, the 1884 amino acid residue Slit-2 protein from mouse (SPTREMBL-P70207) ( $E = 0.0$ ), and 364 of 801 amino acid residues (45%) identical to, and 520 of 801 amino acid residues (64%) similar to, the 2135 amino acid residue Human Slit protein (patp:AAU00019) ( $E = 2.6^{-283}$ ).

The disclosed NOV4 protein is expressed in at least the following tissues: fibroblast like synoviocytes (normal), fetal brain, adipose, microvascular endothelial cells-lung, thalamus, fetal cerebral cortex, temporal lobe, parietal lobe, fetal cerebellum, and testis. TaqMan expression data for NOV4 is shown below in Example 1 and SAGE data is shown below in Example 2. The TaqMan data shows overexpression in several cell lines, especially those derived from brain tumors, metastatic breast and bladder tumors. EST analysis showed expression of NOV2 in neuroendocrine lung carcinoid and Endometrial tumor, plus 2 annotated as breast and bladder tumors.

NOV4 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 4C.

| Table 4C. BLAST results for NOV4               |                                                                                |                |                 |                  |        |
|------------------------------------------------|--------------------------------------------------------------------------------|----------------|-----------------|------------------|--------|
| Gene Index/<br>Identifier                      | Protein/ Organism                                                              | Length<br>(aa) | Identity<br>(%) | Positives<br>(%) | Expect |
| gi 5532493 gb AAD44758.1 AF144627_1 (AF144627) | SLIT1 [Mus musculus]                                                           | 1531           | 123/520 (23%)   | 194/520 (36%)    | 5e-25  |
| gi 11321571 ref NP_003053.1                    | slit (Drosophila) homolog 3; slit2; slit (Drosophila) homolog 2 [Homo sapiens] | 1523           | 128/525 (24%)   | 202/525 (38%)    | 7e-25  |
| gi 4507061 ref NP_03052.1                      | slit (Drosophila) homolog 1; slit1 [Homo sapiens]                              | 1534           | 120/519 (23%)   | 190/519 (36%)    | 7e-24  |
| gi 12621130 ref NP_075242.1                    | Slit1 [Rattus norvegicus]                                                      | 1531           | 120/519 (23%)   | 191/519 (36%)    | 8e-24  |
| gi 11526771 gb AAG36773.1  (AF210321)          | Slit2 [Danio rerio]                                                            | 1512           | 132/531 (24%)   | 199/531 (36%)    | 1e-23  |

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 4D.

Table 4D ClustalW Analysis of NOV4

- 1) NOV4 (SEQ ID NO:8)
- 2) gi|5532493|gb|AAD44758.1|AF144627\_1 (AF144627) SLIT1 [Mus musculus] (SEQ ID NO:28)



- 3) gi|11321571|ref|NP\_003053.1| slit (Drosophila) homolog 3; slit2; slit (Drosophila) homolog 2 [Homo sapiens] (SEQ ID NO:29)  
 4) gi|4507061|ref|NP\_003052.1| slit (Drosophila) homolog 1; slit1 [Homo sapiens] (SEQ ID NO:30)  
 5) gi|12621130|ref|NP\_075242.1| Slit1 [Rattus norvegicus] (SEQ ID NO:31)  
 6) gi|11526771|gb|AAG36773.1| (AF210321) Slit2 [Danio rerio] (SEQ ID NO:32)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----|
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | </ |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----|

|                |                 |                                                               |                                                       |
|----------------|-----------------|---------------------------------------------------------------|-------------------------------------------------------|
| gi 11526771 gb |                 | RIQTIAGTFSLSLRATQTLHLAONPFCDCCLKWLADYLAQNPDIETSGARCTSPRLANK   | 457                                                   |
|                |                 | .....490.....500.....510.....520.....530.....540.....         |                                                       |
| 5              | NOV4            | .....                                                         | 378                                                   |
|                | gi 5532493 gb A | RIGQIKSKKFRCSAKSCYPIPGTSDYHINSECTSDVACPHKRCCEASVVECSGLKLSKIP  | 535                                                   |
|                | gi 11321571 ref | RIQIKSKKFRCSGSDYRS-----RFSSECTMDLVCPKRCCECTIVPCSNQKIVRIIP     | 527                                                   |
|                | gi 4507061 ref  | RIGQIKSKKFRCSAKSCYPIPGTSDYHINSECTSDVACPHKRCCEANVVECSGLKLSKIP  | 535                                                   |
| 10             | gi 12621130 ref | RIGQIKSKKFRCSAKSCYPIPGTSDYHINSECTSDVACPHKRCCEASVVECSGLKLSKIP  | 535                                                   |
|                | gi 11526771 gb  | RIGQIKSKKFRCSGVSDYRS-----KLGDCFAADLACEKRCCECTIVPCSGOKLTKIP    | 511                                                   |
|                |                 | .....550.....560.....570.....580.....590.....600.....         |                                                       |
| 15             | NOV4            | .....-HIT-----KLAK-----GMLGDMNHYVLYEVNATMELLPCTENPMPLKVVY     | 422                                                   |
|                | gi 5532493 gb A | ERIPQSTITELRLNNNEISTLEATGLFKKLSHLKINLSNNKVSIEDCTFEGAASVSELE   | 595                                                   |
|                | gi 11321571 ref | SHLEVVTDRLADNEVSGLVLEATGIFKKLPMLRKINLSNNKVEVRECAIDGAASVSEIM   | 587                                                   |
|                | gi 4507061 ref  | ERIPQSTITELRLNNNEISTLEATGMFKKLTHLKKINLSNNKVSIEDCTFEGAASVSELE  | 595                                                   |
|                | gi 12621130 ref | ERIPQSTITELRLNNNEISTLEATGLFKKLSHLKINLSNNKVSIEDCTFEGATSVSELE   | 595                                                   |
| 20             | gi 11526771 gb  | DHIPQSTITELRLNNNEISTLEATGIFKKLPQLRKINLSNNKINLTHEGTFEGASGUMELT | 571                                                   |
|                |                 | .....610.....620.....630.....640.....650.....660.....         |                                                       |
| 25             | NOV4            | .....LNNMLDQVPPHIFSCVP-LTKVMILKING-----FTHEP-----VSN-----     | 458                                                   |
|                | gi 5532493 gb A | LTANQLESIRSGMFRGLDGLRTLMRLNRISCHNDSFTGLRNVRLLSLYDNHITTTISPG   | 655                                                   |
|                | gi 11321571 ref | LTANQLETVHGRMFRGLSGLKTLMLRSNTTCOVSNDFAGLSSVRLLSLYDNHITTTITPG  | 647                                                   |
|                | gi 4507061 ref  | LTANQLESIRSGMFRGLDGLRTLMRLNRISCHNDSFTGLRNVRLLSLYDNHITTTISPG   | 655                                                   |
|                | gi 12621130 ref | LTANQLESIRSGMFRGIDGLRTLMRLNRISCHNDSFTGLRNVRLLSLYDNHITTTISPG   | 655                                                   |
|                | gi 11526771 gb  | L1SNRLLEGVHYSMLKGLGGLRTLMRLNRISCHNDSFTGICSSVRILSLYDNHITTEMSPG | 631                                                   |
| 30             |                 |                                                               | .....670.....680.....690.....700.....710.....720..... |
|                | NOV4            | .....IILDDLLTQIDLEDNFDSCDVGILQCHICRLSNITVDILICTSPGHIDKKSFKAIN | 518                                                   |
|                | gi 5532493 gb A | AFDTLQALSTLNLLANPFCNCQHLAWLGLWLRK--RKIVTGNPRCONDFLRQIPLQDVA   | 713                                                   |
|                | gi 11321571 ref | AFDTLQALSTLNLLANPFCNCQHLAWLGLWLRK--RKIVTGNPRCONDFLRQIPLQDVA   | 705                                                   |
|                | gi 4507061 ref  | AFDTLQALSTLNLLANPFCNCQHLAWLGLWLRK--RKIVTGNPRCONDFLRQIPLQDVA   | 713                                                   |
| 35             | gi 12621130 ref | AFDTLQALSTLNLLANPFCNCQHLAWLGLWLRK--RKIVTGNPRCONDFLRQIPLQDVA   | 713                                                   |
|                | gi 11526771 gb  | AFDTLQALSTLNLLANPFCNCQHLAWLGLWLRK--RKIVTGNPRCONDFLRQIPLQDVA   | 689                                                   |
|                |                 | .....730.....740.....750.....760.....770.....780.....         |                                                       |
| 40             | NOV4            | .....S-FILCP-SLVNPNPSMPTQTSYLMVITPATITNTADTIERSLDAVP-----     | 563                                                   |
|                | gi 5532493 gb A | FPDFRCBEGQEEVGQERPRCPCECEACLDIVVRCSNKHIALPKGIPKPVTELYLEGNOH   | 773                                                   |
|                | gi 11321571 ref | IQDFTCQ-ENBESSQOLSRCPCQCTOMETTVVRCSNKHIALPKGIPKPVTELYLEGNHL   | 764                                                   |
|                | gi 4507061 ref  | FPDFRCBEGQEEGGQERPRCPCEACLDIVVRCSNKHIALPKGIPKPVTELYLEGNOH     | 773                                                   |
| 45             | gi 12621130 ref | FPDFRCBEGQEEVGQERPRCPCEACLDIVVRCSNKHIALPKGIPKPVTELYLEGNOH     | 773                                                   |
|                | gi 11526771 gb  | VDFACEBGNENSCSPLACCPACSCLDIVVRCSNKHIALPKGIPKPVTELYLEGNEE      | 749                                                   |
|                |                 | .....790.....800.....810.....820.....830.....840.....         |                                                       |
| 50             | NOV4            | .....                                                         | 563                                                   |
|                | gi 5532493 gb A | TLVPGQLSNRYKQVQLVDSNNKISSLNSGFFNMSQLTLILSYNALQCIPIPLAFGLRS    | 833                                                   |
|                | gi 11321571 ref | TAVPRELQALRHETLIDLSNNSTSLNMYFNSMGLSLTLILSYNRLRCIPIVHAENGLRS   | 824                                                   |
|                | gi 4507061 ref  | TLVPGQLSNRYKQVQLVDSNNKISSLNSGFFNMSQLTLILSYNALQCIPIPLAFGLRS    | 833                                                   |
|                | gi 12621130 ref | TLVPGQLSNRYKQVQLVDSNNKISSLNSGFFNMSQLTLILSYNALQCIPIPLAFGLRS    | 833                                                   |
| 55             | gi 11526771 gb  | TOVLELSNRYKQVQLVDSNNQISTLSNMSFNSMSQLTLILSYNRLRCIPIPAEDGLRS    | 809                                                   |
|                |                 | .....850.....860.....870.....880.....890.....900.....         |                                                       |
| 60             | NOV4            | .....LSVLELGLLIMFTTIVFCASIVVLVLRHRRRYK-----KKQVD-----         | 602                                                   |
|                | gi 5532493 gb A | LRLLSLHGNDVSTQEGIFADVLSLHLAIGANPLYCDCHLRWLSWVKIGYKEPGIARC     | 893                                                   |
|                | gi 11321571 ref | LRLVLSLHGNDIGSVPEGSPNDLTSLSHLAGANPLYCDCHLRWLSWVKAGYKEPGIARC   | 884                                                   |
|                | gi 4507061 ref  | LRLLSLHGNDISTQEGIFADVLSLHLAIGANPLYCDCHLRWLSWVKIGYKEPGIARC     | 893                                                   |
|                | gi 12621130 ref | LRLLSLHGNDVSTQEGIFADVLSLHLAIGANPLYCDCHLRWLSWVKIGYKEPGIARC     | 893                                                   |
| 65             | gi 11526771 gb  | LRLLSLHGNDIAVTPGAKDLSSLHLAIGANPLYCDCHLRWLSWVKIGYKEPGIARC      | 869                                                   |
|                |                 | .....910.....920.....930.....940.....950.....960.....         |                                                       |
| 70             | NOV4            | .....EQMRD-----N-----SPVHLQVEMYGHKTHHITTERE                   | 630                                                   |
|                | gi 5532493 gb A | AGPPEMEGKLLLTTPAKKRECCGPPSLAVQAKCOPCLSSPCNQGTCHNDPLVYRCTCH    | 953                                                   |
|                | gi 11321571 ref | ASPEPMADRLLLTTPCHROCKGFVDINTVAKONACLSSPCNQGTCTODPVLVYRCACH    | 944                                                   |
|                | gi 4507061 ref  | AGPPEMEGKLLLTTPAKKRECCGPPSLAVQAKCOPCLSSPCNQGTCHNDPLVYRCACH    | 953                                                   |
|                | gi 12621130 ref | AGPPEMEGKLLLTTPAKKRECCGPPSLAVQAKCOPCLSSPCNQGTCHNDPLVYRCTCH    | 953                                                   |
|                | gi 11526771 gb  | TSPCDMTDKLLLTTPSKKFTCCGFVDVSTLAKONPCLSNPCNQGTCSNHVLFVYRCTCH   | 929                                                   |
|                |                 | .....970.....980.....990.....1000.....1010.....1020.....      |                                                       |
| 75             | NOV4            | .....S-----                                                   | 631                                                   |
|                | gi 5532493 gb A | SGYKGRHCEVSLGCSNPNPCNGGTCHAQEGSDAGETSCSPSSFEGPTSGVDIDDOVKHA   | 1013                                                  |

|    |      |          |     |                                                              |      |
|----|------|----------|-----|--------------------------------------------------------------|------|
| 5  | gi   | 11321571 | ref | YGYKGRDCVPLNLCIQNPQGGGTCHLSDSHKDGFS CSCPLGFEGRQCEINPDCCBND   | 1004 |
|    | gi   | 4507061  | ref | SGYKGRDCVSLNSCSGSPGSGGTCHAQEGDAFFLCSCPTGFEGRQCEINPDCCBND     | 1013 |
|    | gi   | 12621130 | ref | SGYKGRDCVSLNSCSGSPGSGGTCHAQEGDAFFLCSCPTGFEGRQCEINPDCCBND     | 1013 |
|    | gi   | 11526771 | gb  | YGYKGRDCVPLNLCIQNPQGGGTCHLSDSHKDGFS CSCPLGFEGRQCEINPDCCBND   | 989  |
| 10 | NOV4 |          |     | .....1030.....1040.....1050.....1060.....1070.....1080.....  |      |
|    | gi   | 5532493  | gb  | ASLTEQHVMVSPMHHVYR-----SF                                    | 650  |
|    | gi   | 11321571 | ref | CYNGGVCDGVGNYTCQCELOLTGRACEQLVDFCSFDLNPQHEAQQVGPDPSPRCBML    | 1073 |
|    | gi   | 4507061  | ref | CYNGGVCDGVGNYTCQCELOLTGRACEQLVDFCSFDLNPQHEAQQVGPDPSPRCBML    | 1073 |
| 15 | gi   | 12621130 | ref | CYNGGVCDGVGNYTCQCELOLTGRACEQLVDFCSFDLNPQHEAQQVGPDPSPRCBML    | 1073 |
|    | gi   | 11526771 | gb  | CYNGGVCDGVGNYTCQCELOLTGRACEQLVDFCSFDLNPQHEAQQVGPDPSPRCBML    | 1049 |
| 20 | NOV4 |          |     | .....1090.....1100.....1110.....1120.....1130.....1140.....  |      |
|    | gi   | 5532493  | gb  | SYGPKHLREBS-----ENKKGSDAKHLQSRILEQ                           | 682  |
|    | gi   | 11321571 | ref | GYTGDCNSENQDDCKDHKQNGAQCVDEVNSYACLCEGYSGQLCEIP-----PAPRSCE   | 1129 |
|    | gi   | 4507061  | ref | GYTGDCNSENQDDCKDHKQNGAQCVDEVNSYACLCEGYSGQLCEIP-----PAPRSCE   | 1129 |
| 25 | gi   | 12621130 | ref | GYTGDCNSENQDDCKDHKQNGAQCVDEVNSYACLCEGYSGQLCEIP-----PAPRSCE   | 1129 |
|    | gi   | 11526771 | gb  | GYTGDCNSENQDDCKDHKQNGAQCVDEVNSYACLCEGYSGQLCEIP-----PAPRSCE   | 1109 |
| 30 | NOV4 |          |     | .....1150.....1160.....1170.....1180.....1190.....1200.....  |      |
|    | gi   | 5532493  | gb  | NHSPLTCSNMKYXTTNQSTETIS-----FQDASSLYRNILKRRRLQOLGTFEYLRKNTAQ | 738  |
|    | gi   | 11321571 | ref | GTECONGANCVDGGRPRVCCQLPGFGGPECEKLLSVNFVDRDITLQFTDLQWPRANITL  | 1189 |
|    | gi   | 4507061  | ref | GTECONGANCVDGGRPRVCCQLPGFGGPECEKLLSVNFVDRDITLQFTDLQWPRANITL  | 1184 |
| 35 | gi   | 12621130 | ref | GTECONGANCVDGGRPRVCCQLPGFGGPECEKLLSVNFVDRDITLQFTDLQWPRANITL  | 1189 |
|    | gi   | 11526771 | gb  | GTECONGANCVDGGRPRVCCQLPGFGGPECEKLLSVNFVDRDITLQFTDLQWPRANITL  | 1169 |
| 40 | NOV4 |          |     | .....1210.....1220.....1230.....1240.....1250.....1260.....  |      |
|    | gi   | 5532493  | gb  | LQPDMEAH-----VPCAHSEALMETLMYSRPRKVLVRQTKMEYFELRANLHAEFDYLV   | 794  |
|    | gi   | 11321571 | ref | QVSTAEDNGILLYNGDNDHIAVELYQGHVRSYDPSGYESSAIYSATINDGQFHVVELV   | 1249 |
|    | gi   | 4507061  | ref | QVSTAEDNGILLYNGDNDHIAVELYQGHVRSYDPSGYESSAIYSATINDGQFHVVELV   | 1244 |
| 45 | gi   | 12621130 | ref | QVSTAEDNGILLYNGDNDHIAVELYQGHVRSYDPSGYESSAIYSATINDGQFHVVELV   | 1252 |
|    | gi   | 11526771 | gb  | QVSTAEDNGILLYNGDNDHIAVELYQGHVRSYDPSGYESSAIYSATINDGQFHVVELV   | 1249 |
| 50 | NOV4 |          |     | .....1270.....1280.....1290.....1300.....1310.....1320.....  |      |
|    | gi   | 5532493  | gb  | EQQT-----                                                    | 798  |
|    | gi   | 11321571 | ref | TFDQVNLSDGGSPMTMDFNFCGHTYTMSEAPLYVGGMFDVNSAARLWQILNCTSFHG    | 1309 |
|    | gi   | 4507061  | ref | TFDQVNLSDGGSPMTMDFNFCGHTYTMSEAPLYVGGMFDVNSAARLWQILNCTSFHG    | 1304 |
| 55 | gi   | 12621130 | ref | TFDQVNLSDGGSPMTMDFNFCGHTYTMSEAPLYVGGMFDVNSAARLWQILNCTSFHG    | 1312 |
|    | gi   | 11526771 | gb  | TFDQVNLSDGGSPMTMDFNFCGHTYTMSEAPLYVGGMFDVNSAARLWQILNCTSFHG    | 1309 |
| 60 | NOV4 |          |     | .....1330.....1340.....1350.....1360.....1370.....1380.....  |      |
|    | gi   | 5532493  | gb  | -----                                                        | 798  |
|    | gi   | 11321571 | ref | CIRNLYINNELQDFTTQMK-EGVVPGCCPCRLYCLHGICQPNATPGFVCHCEAGWGL    | 1368 |
|    | gi   | 4507061  | ref | CIRNLYINNELQDFTTQMK-EGVVPGCCPCRLYCLHGICQPNATPGFVCHCEAGWGL    | 1362 |
| 65 | gi   | 12621130 | ref | CIRNLYINNELQDFTTQMK-EGVVPGCCPCRLYCLHGICQPNATPGFVCHCEAGWGL    | 1371 |
|    | gi   | 11526771 | gb  | CIRNLYINNELQDFTTQMK-EGVVPGCCPCRLYCLHGICQPNATPGFVCHCEAGWGL    | 1368 |
| 70 | NOV4 |          |     | .....1390.....1400.....1410.....1420.....1430.....1440.....  |      |
|    | gi   | 5532493  | gb  | -----                                                        | 798  |
|    | gi   | 11321571 | ref | HCDQPVDPCHGHKCVHGKCVPLDALAYSCQODGYSCALCNQVGAVALPCCGLQCHH     | 1428 |
|    | gi   | 4507061  | ref | HCDQPVDPCHGHKCVHGKCVPLDALAYSCQODGYSCALCNQVGAVALPCCGLQCHH     | 1421 |
| 75 | gi   | 12621130 | ref | HCDQPVDPCHGHKCVHGKCVPLDALAYSCQODGYSCALCNQVGAVALPCCGLQCHH     | 1431 |
|    | gi   | 11526771 | gb  | HCDQPVDPCHGHKCVHGKCVPLDALAYSCQODGYSCALCNQVGAVALPCCGLQCHH     | 1428 |
| 80 | NOV4 |          |     | .....1450.....1460.....1470.....1480.....1490.....1500.....  |      |
|    | gi   | 5532493  | gb  | -----                                                        | 798  |
|    | gi   | 11321571 | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1488 |
|    | gi   | 4507061  | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1481 |
| 85 | gi   | 12621130 | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1491 |
|    | gi   | 11526771 | gb  | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1488 |
| 90 | NOV4 |          |     | .....1510.....1520.....1530.....1540.....                    |      |
|    | gi   | 5532493  | gb  | -----                                                        | 798  |
|    | gi   | 11321571 | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1488 |
|    | gi   | 4507061  | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1481 |
| 95 | gi   | 12621130 | ref | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1491 |
|    | gi   | 11526771 | gb  | CGASATKCAHCVSGPGSGELCEQBSSECRGDVVRDFHVRQGYALCQTRPLSMVECRGS   | 1488 |

NOV4

|                 |                                                 |      |
|-----------------|-------------------------------------------------|------|
|                 | ..... ..... ..... ..... ..... ..... ..... ..... | 798  |
| gi 5532493 gb A | CPG-QGCCGSLRLKRRKLTFFCSDGTSFAEEVEKPTKCGCAQCV-   | 1531 |
| gi 11321571 ref | CGP--CCCCPIRSKRRKYVFCIDGSSSFVEEVERHLECGCLACS-   | 1523 |
| gi 4507061 ref  | CPG-QGCCGSLRLKRRKLTFFCSDGTSFAEEVEKPTKCGCALCA-   | 1534 |
| gi 12621130 ref | CPG-QGCCGSLRLKRRKLTFFCSDGTSFAEEVEKPTKCGCAPCA-   | 1531 |
| gi 11526771 gb  | CGDGTSCCAFLRSKRRKMTFFCSDGSSFVQEEVKVVKCGCTKPS    | 1512 |

- 10 Tables 4E-H list the domain description from DOMAIN analysis results against NOV4. This indicates that the NOV4 sequence has properties similar to those of other proteins known to contain this domain.

**Table 4E. Domain Analysis of NOV4**

gnl|Smart|smart00082, LRRCT, Leucine rich repeat C-terminal domain  
(SEQ ID NO:43)  
CD-Length = 51 residues, 100.0% aligned  
Score = 49.7 bits (117), Expect = 6e-07

- 15 Query: 474 NPWDCSCDLVGLQQWIQKLSKNTVTDDILCTSPGHLDKKELKALNSEILCP 524  
||+ | |+| | +| | | + | | | | |  
Sbjct: 1 NPFICDCELRWLLRWLQANRHLQDPVDLRCASPESLRGPLLLLLPSSFKCP 51

**Table 4F. Domain Analysis of NOV4**

gnl|Smart|smart00082, LRRCT, Leucine rich repeat C-terminal domain  
(SEQ ID NO:43)  
CD-Length = 51 residues, 100.0% aligned  
Score = 45.1 bits (105), Expect = 2e-05

- 20 Query: 175 NKWACNCDLLQLKTWLENMPPQSIIGDVVCNSPFFKGSILSRLLKESICP 225  
| + | +| +| | | + | | | | + | +| | |  
Sbjct: 1 NPFICDCELRWLLRWLQANRHLQDPVDLRCASPESLRGPLLLLLPSSFKCP 51

**Table 4G. Domain Analysis of NOV4**

gnl|Pfam|pfam01463, LRRCT, Leucine rich repeat C-terminal domain.  
Leucine Rich Repeats pfam00560 are short sequence motifs present in a number of proteins with diverse functions and cellular locations. Leucine Rich Repeats are often flanked by cysteine rich domains. This domain is often found at the C-terminus of tandem leucine rich repeats. (SEQ ID NO:49)  
CD-Length = 51 residues, 100.0% aligned  
Score = 48.1 bits (113), Expect = 2e-06

- 25 Query: 474 NPWDCSCDLVGLQQWIQKLSKNTVTDDILCTSPGHLDKKELKALNSEILCP 524  
||+ | |+| | +|+++ + | + | | | | | + | | + | |  
Sbjct: 1 NPFICDCELRWLLRWLREPRRLDPEDLRCASPESLRGPILLELLPSDFSCP 51

**Table 4H. Domain Analysis of NOV4**

gnl|Pfam|pfam01463, LRRCT, Leucine rich repeat C-terminal domain.  
 Leucine Rich Repeats pfam00560 are short sequence motifs present in a  
 number of proteins with diverse functions and cellular locations.  
 Leucine Rich Repeats are often flanked by cysteine rich domains. This  
 domain is often found at the C-terminus of tandem leucine rich repeats  
 (SEQ ID NO:49)  
 CD-Length = 51 residues, 100.0% aligned  
 Score = 46.6 bits (109), Expect = 5e-06

Query: 175 NKWACNCDLLQLKTWLENMPPQSIIGDVVCNSPPFFKGSILSRLKKESICP 225  
 | + | + | + | | | | + | | | + | | | + |  
 Sbjct: 1 NPFICDCELRWLLRWLREPRRLLEDPEDLRCA SPESLRGPLELLELPDFSCP 51

5

NOV4 blocks Natriuretic peptide receptor proteins, possibly a receptor with ATP binding and Kinase activity. NOV4 is thought to be involved with metastatic potential. Therapeutic targeting of NOV4 with a monoclonal antibody is anticipated to limit or block the extent of metastasis in breast and brain tumors.

10 The disclosed NOV4 nucleic acid of the invention encoding a Slit-like protein includes the nucleic acid whose sequence is provided in Table 4A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 4A while still encoding a protein that maintains its Slit-like activities and physiological functions, or a fragment of such a nucleic acid. The invention  
 15 further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar  
 20 phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.

25 The disclosed NOV4 protein of the invention includes the Slit-like protein whose sequence is provided in Table 4B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 4B while still encoding a protein that maintains its Slit-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 76% percent of the  
 30 residues may be so changed.

The protein similarity information, expression pattern, and map location for the Slit-like protein and nucleic acid (NOV4) disclosed herein suggest that this NOV4 protein may have important structural and/or physiological functions characteristic of the Slit family.

Therefore, the NOV4 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.

NOV4 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies could also be used to treat certain pathologies as described above.

## NOV5

A disclosed NOV5 nucleic acid of 3825 nucleotides (also referred to as AC133) encoding a novel AC133 antigen-like protein is shown in Table 5A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 69-71 and ending with a TGA codon at nucleotides 2664-2666. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 5A, and the start and stop codons are in bold letters.

**Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:9)**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p> GNNNNNNANNNNATTCNTNCANTGNACNNNACCAAGTTCTACCTCATGTTTGGAGG<br/> <u>ATCTTGCTAGCTATGGCCCTCGTACTCGGCTCCCTGTTGCTGCTGGGGCTGTGCGG</u><br/> GAACTCCTTTTCAGGAGGGCAGCCTTCATCCACAGATGCTCCTAAGGCTTGGAATT<br/> ATGAATGCCTGCAACAAATTATGAGACCCAAGACTCCCATAAAGCTGGACCCATT<br/> GGCATTCTCTTTGAACTAGTGCATATCTTTCTCTATGTGGTACAGCCGCGTGATTT<br/> CCCAGAAGATACTTTGAGAAAATTCTTACAGAAGGCATATGAATCCAAAATTGATT<br/> ATGACAAGCCAGAACTGTAATCTTAGGCTCAAAGATTGTCTACTATGAAGCAGGG<br/> ATTATTCTATGCTGTGTCTGGGGCTGCTGTTTATTATTCTGATGCCTCTGGTG<br/> GTTATTTCTTTGTATGTGTCGTTGCTGTAACAAATGTGGTGGAGAAATGCACCAGC </p> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

GACAGAAGGAAAATGGGCCCTTCCCTGAGGAAATGCTTTGCAATCTCCCTGTTGGTG  
ATTTGTATAATAAAGCATTGGCATCTTCTATGGTTTTGTGGCAAATCACCAGGT  
AAGAACCCGGATCAAAGGAGTCGGAACTGGCAGATAGCAATTTCAAGGACTTGC  
GAACTCTCTTGAATGAACTCCAGAGCAAATCAAATATATATTGGCCCAGTACAAC  
ACTACCAAGGACAAGGCGTTCACAGATCTGAACAGTATCAATTCAGTGCTAGGAGG  
CGGAATTCCTTGACCGACTGAGACCAACATCATCCCTGTTCTTGATGAGATTAAGT  
CCATGGCAACAGCGATCAAGGAGACCAAAGAGGCGTTGGAGAACATGAACAGCACC  
TTGAAGAGCTTGACCAACAAAGTACACAGCTTAGCAGCAGTCTGACCAGCGTGAA  
AACTAGCCTGCGGTCTCTCTCAATGACCTCTGTGCTTGGTGCATCCATCAAGTG  
AAACCTGCAACAGCATCAGATTGTCTCTAAGCCAGCTGAATAGCAACCCTGAACTG  
AGGCAGCTTCCACCCGTGGATGCAGAACTTGACAACGTTAATAACGTTCTTAGGAC  
AGATTTGGATGGCCTGGTCCAACAGGGCTATCAATCCCTTAATGATATACCTGACA  
GAGTACAACGCCAAACCAGACTGTCGTAGCAGGTATCAAAGGGTCTTGAATTCC  
ATTGGTTCAGATATCGACAATGTAACCTCAGCGTCTTCCCTATTCAGGATATACCTC  
AGCATTTCTCTGTTTTATGTTAATAACACTGAAAGTTACATCCACAGAAATTTACCTA  
CATTGGAAGAGTATGATTCTACTGTTGGTGGTGGTGGCCTGGTCTGCTCTCTG  
CTGACCCTCATCGTGATTTTTTACTACCTGGGCTTACTGTGTGGCGTGTGCGGCTA  
TGACAGGCATGCCACCCGACCACCCGAGGCTGTGTCTCCAACACCGAGGCGTCT  
TCCTCATGGTTGGAGTTGGATTAAAGTTTCTCTTTTGCTGGATATTGATGATCATT  
GTGGTTCTTACCTTTGTCTTTGGTGCAAATGTGGAAAACTGATCTGTGAACCTTA  
CACGAGCAAGGAATTTATCCGGGTTTTGGATACACCTACTTACTAAATGAAGACT  
GGGAATCTATCTCTCTGGGAAGCTATTTAATAAATCAAATAAGAGTCACTTTT  
GAACAAGTTTACAGTGACTGCAAAAAAATAGAGGCACTTACGGCACTCTTACCT  
GCAGAACAGCTTCAATATCAGTGAACATCTCAACATTAATGAGCATACTGGAAGCA  
TAAGCAGTGAATTGGAAGTCTGAAGTAAATCTTAATATCTTTCTGTTGGGTGCA  
GCAGGAAGAAAAACCTTCAGGATTTTGCTGCTTGTGGAAATAGACAGAATGAATTA  
TGACAGCTACTTGGCTCAGACTGGTAAATCCCCCGCAGGAGTGAATCTTTTATCAT  
TTGCATATGATCTAGAAGCAAAAGCAACAGTTTGCCCCCAGGAAATTTGAGGAAC  
TCCCTGAAAAGAGATGCACAACTATTAAAACAATTCACCAGCAACGAGTCTTCC  
TATAGAACAATCACTGAGCAGCTTATACCAAAGCGTCAAGATACTTCAACGCACAG  
GGAATGGATTGTTGGAGAGAGTAACTAGGATTCTAGCTTCTCTGGATTTTGCTCAG  
AACTTCATCACAACAATACTTCTCTGTTATTATTGAGGAACTAAGAAGTATGG  
GAGAACAATAATAGGATATTTTGAACATTATCTGCAGTGGATCGAGTTCTCTATCA  
GTGAGAAAGTGGCATCGTGCAACCTGTGGCCACCGCTCTAGATACTGCTGTTGAT  
GTCTTTCTGTGTAGCTACATTATCGACCCCTTGAATTTGTTTGGTTTGGCATAGG  
AAAAGCTACTGTATTTTACTTCCGGCTCTAATTTTGGCGTAAAACTGGCTAAGT  
ACTATCGTCAATGGATTGCGAGGACGTGTACGATGATGTTGAAACTATACCCATG  
AAAAATATGGAATGTAATAATGGTTATCATAAAGATCATGTATATGGTATTCA  
CAATCCTGTTATGACAAGCCCATCACAACATTGATAGCTGATGTTGAAACTGCTTG  
AGCATCAGGATACTCAAAGTGGAAAGGATCACAGATTTTGGTAGTTTCTGGGTCT  
ACAAGGACTTTCCAAATCCAGGAGCAACGCCAGTGGCAACGTAGTGACTCAGGCGG  
GCACCAAGGCAACGGCACCATTGGTCTCTGGGTAGTGCTTTAAGAATGAACCAAT  
CACGTTATAGTCCATGGTCCATCACTATTCAAGGATGACTCCCTCCCTTCCCTGTCT  
ATTTTGTGTTTTTACTTTTTTACACTGAGTTTCTATTTAGACACTACAACATATGG  
GGTGTGTTGTTCCCATTTGGATGCAATTTCTATCAAACTCTATCAAATGTGATGGCTA  
GATTCTAACATATTGCCATGTGTGGAGTGTGCTGAACACACACCAGTTTACAGGAA  
AGATGCATTTTGTGTACAGTAAACGGTGTATATACCTTTTGTACCACAGAGTTT  
TTAAACAAATGAGTATTATAGGACTTTCTTCTAAATGAGCTAAATAAGTCACCAT  
GACTTCTTGGTGTGTTGAAAATAATCCATTTTCACTAAAAGTGTGTGAAACCTAC  
AGCATATTCTTCACGCAGAGATTTTCATCTATTATACCTTTATCAAAGATTGGCCAT  
GTTCCCAATTGGAAATGGCATGCAAAAGCCATCATAGAGAACTGCGTAACCTCAT  
CTGACAATTTCAAAGAGAGAGAGAGATCTTGAGAGAGAAATGCTGTTCTGTTCAAA  
AGTGAGTTGTTTTTAAACAGATGCCAATTACGGTGTACAGTTTAAACAGAGTTTCTG  
TTGCATTAGGATAAACATTAATTGGAGTGCAGCTAACATGAGTATCATCAGACTAG  
TATCAAGTGTCTTAAATGAAATATGAGAAGATCCTGTCACAATTCTTAGATCTGG  
TGTCAGCATGGATGAAACCTTTGAGTTTGGTCCCTAAATTTGCATGAAAGCACAA  
GGTAAATATTCAATTGCTTCAGGAGTTTCATGTTGGATCTGTCAATTATCAAAGTG  
ATCAGCAATGAAGAACTGGTGGACAAAATTTAACGTTGATGTAATGGAATTCAG  
ATGTAGGCATTTCCCCAGGTCTTTTCTGTGCAGATTGCAGTTCTGATTCAATTG  
AATAAAAAGGAACTTGG

The NOV5 nucleic acid was identified on chromosome 4 and has 2874 of 2882 bases (99%) identical to a *Homo sapiens* prominin (mouse)-like 1 (PROML1), mRNA of 3794 nucleotides (GENBANK-ID: gi|5174386|ref|NM\_006017.1|) (E = 0.0)

A disclosed NOV5 polypeptide (SEQ ID NO:10) encoded by SEQ ID NO:9 is 865 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and/or Hydropathy results predict that NOV5 has is likely to be localized in the plasma membrane.

| Table 5B. Encoded NOV5 protein sequence (SEQ ID NO:10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| MALVLGSLLLGLCGNSFSGGQPSSTDAPKAWNYELPATNYETQDSHKAGPIGILFELVHIFLYV<br>VQPRDFPEDTLRKFLQKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIILMPLVGYFF<br>CMCRCCNKCGGEMHORQKENGPFRLKCFALISLLVICIIISIGIFYGFVANHQVRTRIKRSRKLAD<br>SNFKDLRTLLNETPEQIKYILAQYNTTKDKAFTDLNSINSLVGGGILDRLRPNIIPVLDEIKSMA<br>TAIKETKEALENMNSTLKSLLHQSTQLSSSLTSVKTSLSRSSLNDPLCLVHPSSSETCNSIRLSLQ<br>LNSNPELRQLPPVDAELDNVNNVLRDLDGLVQQGYQSLNDIPDRVQRQTTTVVAGIKRVLNSIG<br>SDIDNVTQRLPIQDILSAFSVYVNTESYIHRNLTLEEDSYWVLGGLVICSLTLLIVIFYYLG<br>LLCGVCGYDRHATPTTRGCVSNTGGVFLMVGVGLSFLFCWILMIIVVLTFFVGANVEKLICEPYT<br>SKELFRVLDTPYLLNEDWEYYSGLFNKSKMKLTFEQVYSDCKKNRGTYGTLHLQNSFNISEHL<br>NINEHTGISSELESCLKVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLISF<br>AYDLEAKANSLPPGNLRLNSLKRDAQTIKTIHQQRVLPVIEQSLSTLYQSVKILQRTGNGLLERVTR<br>ILASLDFAQNFITNNTSSVIEETKKYGRITIGYFEHYLQWIEFSISEKVASCKPVATALDITAVD<br>VFLCSYIIDPLNLFWFGIGKATVFLPALIFAVKLAKYYRRMDESDVYDDVETIPMKNMENGNNG<br>YHKDHVYGIHNPVMTSPSQH |  |

The disclosed NOV5 amino acid sequence has 865 of 865 amino acid residues (100%) identical to, and 865 of 864 amino acid residues (100%) similar to, the 865 amino acid residue AC133 antigen from *Homo sapiens* (Human) (GenBank Acc. No.: AF027208) (E = 0.0).

NOV5 is expressed in at least the following tissues: fetal heart, pooled human melanocyte, fetal heart, and pregnant uterus. TaqMan data for NOV5 is shown below in Example 1, and SAGE data is shown below in Example 2. The TaqMan data shows overexpression in cell lines derived from colon, ovarian, lung and liver tumors. The EST analysis showed that NOV5 was found in well-differentiated endometrial adenocarcinoma, 7 pooled tumors, and retina.

NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.

| Table 5C. BLAST results for NOV5 |                                                     |                |                  |                  |        |
|----------------------------------|-----------------------------------------------------|----------------|------------------|------------------|--------|
| Gene Index/<br>Identifier        | Protein/ Organism                                   | Length<br>(aa) | Identity<br>(%)  | Positives<br>(%) | Expect |
| gi 11437151 ref XP_003591.1      | prominin (mouse)-<br>like 1 [ <i>Homo sapiens</i> ] | 727            | 437/480<br>(91%) | 670/718<br>(93%) | 0.0    |



|                                                 |                                                                         |     |               |                 |     |
|-------------------------------------------------|-------------------------------------------------------------------------|-----|---------------|-----------------|-----|
| gi 15082356 gb AAH12089.1 AAH12089 (BC012089)   | Similar to prominin (mouse)-like 1 [Homo sapiens]                       | 856 | 788/844 (93%) | 788/844 (93%)   | 0.0 |
| gi 5174387 ref NP_06008.1                       | prominin (mouse)-like 1; hematopoietic stem cell antigen [Homo sapiens] | 865 | 797/844 (94%) | 797/844 (94%)   | 0.0 |
| gi 15042603 gb AAK82364.1 AF386758_1 (AF386758) | prominin [Rattus norvegicus]                                            | 857 | 484/845 (57%) | 625/845 (73%) , | 0.0 |
| gi 13124464 sp O54990 PROM_MOUSE                | PROMININ PRECURSOR (ANTIGEN AC133 HOMOLOG)                              | 867 | 485/846 (57%) | 627/846 (73%)   | 0.0 |

### Table 5D Clustal W Sequence Alignment

```

5 1) NOV5 (SEQ ID NO:10)
 2) gi|11437151|ref|XP_003591.1| prominin (mouse)-like 1 [Homo sapiens] (SEQ ID
 NO:33)
10 3) gi|15082356|gb|AAH12089.1|AAH12089 (BC012089) Similar to prominin (mouse)-like 1
 [Homo sapiens] (SEQ ID NO:34)
 4) gi|5174387|ref|NP_006008.1| prominin (mouse)-like 1; hematopoietic stem cell
 antigen [Homo sapiens] (SEQ ID NO:35)
 5) gi|15042603|gb|AAK82364.1|AF386758_1 (AF386758) prominin [Rattus norvegicus]
 (SEQ ID NO:36)
15 6) gi|13124464|sp|O54990|PROM_MOUSE PROMININ PRECURSOR (ANTIGEN AC133 HOMOLOG) (SEQ
 ID NO:37)

```

|    |                     |  |             |                                                      |                                      |                    |                        |     |     |
|----|---------------------|--|-------------|------------------------------------------------------|--------------------------------------|--------------------|------------------------|-----|-----|
|    |                     |  | 10          | 20                                                   | 30                                   | 40                 | 50                     | 60  |     |
| 20 | NOV5                |  | MALVLGSL    | LLLLGLCGNSFSGGQPSSTDA                                | PKAWNYELPATNYETQDSHKAGP              | IIGILFFELVH        |                        |     | 60  |
|    | gi   11437151   ref |  |             |                                                      |                                      |                    |                        |     | 1   |
|    | gi   15082356   gb  |  | MALVLGSL    | LLLLGLCGNSFSGGQPSSTDA                                | PKAWNYELPATNYETQDSHKAGP              | IIGILFFELVH        |                        |     | 60  |
|    | gi   5174387   ref  |  | MALVLGSL    | LLLLGLCGNSFSGGQPSSTDA                                | PKAWNYELPATNYETQDSHKAGP              | IIGILFFELVH        |                        |     | 60  |
|    | gi   15042603   gb  |  | MALVFVS     | LLLLGLCGKMASGGQPADFDP                                | GALANYELPTTEYETQDTFNAGI              | IDPLVKMVH          |                        |     | 60  |
| 25 | gi   13124464   sp  |  | MALVFSA     | LLLLGLCGKISSEGOAFHNTEGA                              | MNVELETPKYETQDTFNAGIVGP              | LKMH               |                        |     | 60  |
|    |                     |  |             |                                                      |                                      |                    |                        |     |     |
|    |                     |  | 70          | 80                                                   | 90                                   | 100                | 110                    | 120 |     |
| 30 | NOV5                |  | IFLYVVQPRD  | FPECTLRKFLIQ                                         | KAYESKIDYDKPETVILGLK                 | IIVYEAGIIICCVLGLLF |                        |     | 119 |
|    | gi   11437151   ref |  | MWWRNAP     |                                                      |                                      | AT                 |                        |     | 9   |
|    | gi   15082356   gb  |  | IFLYVVQPRD  | FPECTLRKFLIQ                                         | KAYESKIDYDKPETVILGLK                 | IIVYEAGIIICCVLGLLF |                        |     | 110 |
|    | gi   5174387   ref  |  | IFLYVVQPRD  | FPECTLRKFLIQ                                         | KAYESKIDYDKPETVILGLK                 | IIVYEAGIIICCVLGLLF |                        |     | 119 |
|    | gi   15042603   gb  |  | IFLNVPND    | FPDLVKKLIQ                                           | KREDISVDTKELVAIVEIGVLC               | VILGLLF            |                        |     | 110 |
| 35 | gi   13124464   sp  |  | IFLSVVQPNDF | LDLIRKLIONKKEFDISVDSKSPETIIVLALK                     | IALVEIGVLCANLGLLF                    |                    |                        |     | 120 |
|    |                     |  |             |                                                      |                                      |                    |                        |     |     |
|    |                     |  | 130         | 140                                                  | 150                                  | 160                | 170                    | 180 |     |
| 40 | NOV5                |  | IILMPLVG    | YFFCMCRCCNKCGGEMHQROKENG                             | PFLRKCFAISLLVICIIISIGIFYGFVA         |                    |                        |     | 179 |
|    | gi   11437151   ref |  |             |                                                      | EENGPF                               | LKRKF              | FAISLLVICIIISIGIFYGFVA |     | 41  |
|    | gi   15082356   gb  |  | IILMPLVG    | YFFCMCRCCNKCGGEMHQROKENG                             | PFLRKCFAISLLVICIIISIGIFYGFVA         |                    |                        |     | 170 |
|    | gi   5174387   ref  |  | IILMPLVG    | YFFCMCRCCNKCGGEMHQROKENG                             | PFLRKCFAISLLVICIIISIGIFYGFVA         |                    |                        |     | 179 |
|    | gi   15042603   gb  |  | IILMPLVG    | EFFCMCRCCNKCGGEMHQROKONESCRRKCTAISLLVICILMSLGIAFGFVA |                                      |                    |                        |     | 170 |
| 45 | gi   13124464   sp  |  | IILMPLVG    | CFFCMCRCCNKCGGEMHQROKNABERRKCLGISLLVICILMSLGIIFYGFVA |                                      |                    |                        |     | 180 |
|    |                     |  |             |                                                      |                                      |                    |                        |     |     |
|    |                     |  | 190         | 200                                                  | 210                                  | 220                | 230                    | 240 |     |
|    | NOV5                |  | NHQVRTRI    | KSRKLADSNFKDLRTL                                     | LLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGG |                    |                        |     | 239 |
|    | gi   11437151   ref |  | NHQVRTRI    | KSRKLADSNFKDLRTL                                     | LLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGG |                    |                        |     | 101 |
|    | gi   15082356   gb  |  | NHQVRTRI    | KSRKLADSNFKDLRTL                                     | LLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGG |                    |                        |     | 230 |

|    |      |          |     |                                                                |     |
|----|------|----------|-----|----------------------------------------------------------------|-----|
|    | gi   | 5174387  | ref | NHQRTRIKRSRLADSNFQDLRLTLLNETPEQIKYILAQYNTTKQKAFDTLNSINSVLGG    | 239 |
|    | gi   | 15042603 | gb  | NOQRTRTRIQRTOKLAESNFRDLRLALLTEAPKQIDYILGOYNTTKKAFSDILSDISVLGG  | 230 |
|    | gi   | 13124464 | sp  | NOQRTRTRIKGTOKLAKSNFRDFTLLTETPKQIDYVVEQYNTTKKAFSDIDIGISVLGG    | 240 |
| 5  |      |          |     | .....250.....260.....270.....280.....290.....300.....          |     |
|    | NOV5 |          |     | GILDRLRPNII PVLDEIKSMATAIKETKEALENMNSTLKSLSHQOSTQLSSSLTSVKTSRL | 299 |
|    | gi   | 11437151 | ref | GILDRLRPNII PVLDEIKSMATAIKETKEALENMNSTLKSLSHQOSTQLSSSLTSVKTSRL | 161 |
|    | gi   | 15082356 | gb  | GILDRLRPNII PVLDEIKSMATAIKETKEALENMNSTLKSLSHQOSTQLSSSLTSVKTSRL | 290 |
| 10 | gi   | 5174387  | ref | GILDRLRPNII PVLDEIKSMATAIKETKEALENMNSTLKSLSHQOSTQLSSSLTSVKTSRL | 299 |
|    | gi   | 15042603 | gb  | RIKGOLKPKVTPVLEEIKAMATAITQTKDALONMSSSLKSLRDASTQLSTNLTISVNSIE   | 290 |
|    | gi   | 13124464 | sp  | RIKGOLKPKVTPVLEEIKAMATAIKOTKDALONMSSSLKSLQDAATQLNTNLSVNSIE     | 300 |
| 15 |      |          |     | .....310.....320.....330.....340.....350.....360.....          |     |
|    | NOV5 |          |     | SSLNDPLCLVHPSSSETCNSIRLSLSQLNSNPRLQPPVDAELDNVNNVLRDTDLGLVQQ    | 359 |
|    | gi   | 11437151 | ref | SSLNDPLCLVHPSSSETCNSIRLSLSQLNSNPRLQPPVDAELDNVNNVLRDTDLGLVQQ    | 221 |
|    | gi   | 15082356 | gb  | SSLNDPLCLVHPSSSETCNSIRLSLSQLNSNPRLQPPVDAELDNVNNVLRDTDLGLVQQ    | 350 |
|    | gi   | 5174387  | ref | SSLNDPLCLVHPSSSETCNSIRLSLSQLNSNPRLQPPVDAELDNVNNVLRDTDLGLVQQ    | 359 |
| 20 | gi   | 15042603 | gb  | NSLNSNDQASDPASKIODSTRPOLNSNHNHGSQLPVDRELNTVNDVDRDLESILVKR      | 350 |
|    | gi   | 13124464 | sp  | NSLSSSDCTSDPASKIODSTRPOLNSLCCGILNSSQLPSVDRELNTVTEVDRTDLESILVKR | 360 |
| 25 |      |          |     | .....370.....380.....390.....400.....410.....420.....          |     |
|    | NOV5 |          |     | GYQSLNDIPDRVQRTTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESY   | 419 |
|    | gi   | 11437151 | ref | GYQSLNDIPDRVQRTTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESY   | 281 |
|    | gi   | 15082356 | gb  | GYQSLNDIPDRVQRTTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESY   | 410 |
|    | gi   | 5174387  | ref | GYQSLNDIPDRVQRTTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESY   | 419 |
|    | gi   | 15042603 | gb  | GYMSIDEIPNTIONQTDVILKDYKTLDSVSSKVKNNMSQSTPVEEVLLQFSHYLNDSNRY   | 410 |
| 30 | gi   | 13124464 | sp  | GYTIDEIPNTIONQTDVILKDYKTLDSISSNKKMSQSTPIEDMLLOVSHYLNDSNRY      | 420 |
| 35 |      |          |     | .....430.....440.....450.....460.....470.....480.....          |     |
|    | NOV5 |          |     | IHRNLPTELEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 479 |
|    | gi   | 11437151 | ref | IHRNLPTELEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 341 |
|    | gi   | 15082356 | gb  | IHRNLPTELEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 470 |
|    | gi   | 5174387  | ref | IHRNLPTELEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 479 |
|    | gi   | 15042603 | gb  | IHESLPRVEEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 470 |
| 40 | gi   | 13124464 | sp  | LNQELPKLEEYDSYWNLGLGIVICSLLTLLIVIFYYLGLLCCGVCYDRHATPTTRGCVSNTG | 480 |
| 45 |      |          |     | .....490.....500.....510.....520.....530.....540.....          |     |
|    | NOV5 |          |     | GVFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYSKELFRVLDTPYLLNEDWE   | 539 |
|    | gi   | 11437151 | ref | GVFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYSKELFRVLDTPYLLNEDWE   | 401 |
|    | gi   | 15082356 | gb  | GVFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYSKELFRVLDTPYLLNEDWE   | 530 |
|    | gi   | 5174387  | ref | GVFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYSKELFRVLDTPYLLNEDWE   | 539 |
|    | gi   | 15042603 | gb  | GIFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYENKLLQVLDTPYLLNEDWE   | 530 |
|    | gi   | 13124464 | sp  | GIFLNVGVGLSFLFCWILMIIVLTFVFGANVEKLI CEPTYENKLLQVLDTPYLLNEDWE   | 540 |
| 50 |      |          |     | .....550.....560.....570.....580.....590.....600.....          |     |
|    | NOV5 |          |     | YYLSGKLFNKSMMKLTFFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELE  | 599 |
|    | gi   | 11437151 | ref | YYLSGKLFNKSMMKLTFFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELE  | 461 |
|    | gi   | 15082356 | gb  | YYLSGKLFNKSMMKLTFFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELE  | 590 |
| 55 | gi   | 5174387  | ref | YYLSGKLFNKSMMKLTFFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELE  | 599 |
|    | gi   | 15042603 | gb  | YYLSGILLKNPDINMTFFEQVYRDCKKRGVYAFQLENVFNITENFNIERLSEDIKVELE    | 590 |
|    | gi   | 13124464 | sp  | YYLSGMLFNPDINMTFFEQVYRDCKKRGVYAFQLENVFNISDFNIDQISENINTELE      | 600 |
| 60 |      |          |     | .....610.....620.....630.....640.....650.....660.....          |     |
|    | NOV5 |          |     | SLKVNLLN-IFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKA  | 658 |
|    | gi   | 11437151 | ref | SLKVNLLN-IFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKA  | 520 |
|    | gi   | 15082356 | gb  | SLKVNLLN-IFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKA  | 649 |
|    | gi   | 5174387  | ref | SLKVNLLN-IFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKA  | 658 |
| 65 | gi   | 15042603 | gb  | KLNVNIDSIEILLDKTKGRKLEDFQSGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKA   | 650 |
|    | gi   | 13124464 | sp  | KLNVNIDSIEILLDNKGRKLEDFQSGIDITIDYSTYLKETEKSPTENLLTFASTLEAKA    | 660 |
| 70 |      |          |     | .....670.....680.....690.....700.....710.....720.....          |     |
|    | NOV5 |          |     | NSLPPGNLRNSLKRDAQTIKTIHQQRVLPTEQSLSTLYQSVKILQRTGNGLLSEVTRILA   | 718 |

MoAb AC133 is an antibody with specificity for a novel cell surface antigen that is expressed on CD34bright subpopulations of HSCs found in adult bone marrow, fetal bone marrow and liver, cord blood, and adult peripheral blood. MoAb AC133 can be used for magnetic bead immunoselection of HSC populations for transplantation, as well as for phenotypic analysis of stem and progenitor cell populations using flow cytometric techniques.

The AC133 antigen is a glycosylated protein with a molecular weight of 120 kD. The AC133 polypeptide has a predicted size of 97 kD and contains five transmembrane (5-TM) domains with an extracellular N-terminus and a cytoplasmic C-terminus (containing 5 tyrosine residues, potential for signalling), 2 small cysteine-rich cytoplasmic loops, and 2 very large extracellular loops each containing 4 consensus sequences for N-linked glycosylation.

The AC133 antigen transcript was also noted in nonlymphoid tissues, particularly the pancreas, kidney, and placenta. Weaker signals were observed for the liver, lung, brain, and heart. This is in contrast to immunohistochemical staining of paraffin tissue sections, where AC133 antigen expression was detectable only in bone marrow. Its presence on early, undifferentiated cells is suggestive of a growth factor receptor, and the presence of five tyrosine residues on the 50-aa cytoplasmic tail may indicate that the protein is phosphorylated in response to ligand binding and initiates a signal transduction cascade. (Miraglia S, Godfrey

W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood*. 1997 Dec 15;90(12):5013-21.) Human CD34+ progenitor cells expressed AC133, expression was rapidly downregulated during differentiation. In apparent contrast to normal primitive haematopoietic cells, the AC133 protein was undetectable on cells from 24 different human haematopoietic cells lines, even though the majority of these cells expressed AC133 mRNA. (Majka M, Ratajczak J, Machalinski B, Carter A, Pizzini D, Wasik MA, Gewirtz AM, Ratajczak MZ). Expression, regulation and function of AC133, a putative cell surface marker of primitive human haematopoietic cells. (*Folia Histochem Cytobiol*. 2000;38(2):53-63.)

The human AC133 antigen and mouse prominin are structurally related plasma membrane proteins. The human AC133 antigen shows the features characteristic of mouse prominin in epithelial and transfected non-epithelial cells, i.e. a selective association with apical microvilli and plasma membrane protrusions, respectively. Conversely, flow cytometry of murine CD34(+) bone marrow progenitors revealed the cell surface expression of prominin. Taken together, the data strongly suggest that the AC133 antigen is the human orthologue of prominin. (Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB). The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. (*J Biol Chem*. 2000 Feb 25;275(8):5512-20.)

NOV5 is thought to be involved in metastatic potential and chemotherapy resistance. Therapeutic targeting of AC133 with a monoclonal antibody is anticipated to limit or block the extent of metastasis and chemotherapy resistance in colon, gastric, ovarian and lung tumors.

The disclosed NOV5 nucleic acid of the invention encoding a AC133 Antigen -like protein includes the nucleic acid whose sequence is provided in Table 5A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 5A while still encoding a protein that maintains its AC133 Antigen -like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or

derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.

5 The disclosed NOV5 protein of the invention includes the AC133 Antigen -like protein whose sequence is provided in Table 5B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 5B while still encoding a protein that maintains its AC133 Antigen -like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 43% percent of the residues may be so changed.

NOV5 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies could also be used to treat certain pathologies as described above.

## 20 NOV6

A disclosed NOV6 nucleic acid of 1807 nucleotides (also referred to as NM\_012445) encoding a novel Spondin 2-like protein is shown in Table 6A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 276-278 and ending with a TAA codon at nucleotides 1269-1271. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 6A, and the start and stop codons are in bold letters.

**Table 6A. NOV6 Nucleotide Sequence (SEQ ID NO:11)**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>GCACGAGGGAAGAGGGTGATCCGACCCGGGGAAGGTCGCTGGGCAGGGCGAGTTGGGAAAGCGGCAGCCC<br/> CCGCCGCCCCCGCAGCCCTTCTCCTCCTTCTCCACGTCCTATCTGCCTCTCGCTGGAGGCCAGGCCG<br/> TGCAGCATCGAAGACAGGAGGAAGTGGAGCCTCATTTGGCCGGCCCGGGCGCCGGCCTCGGGCTTAAATA<br/> GGAGCTCCGGGCTCTGGCTGGGACCCGACCGCTGCCGGCCGCGCTCCCGCTGCTCCTGCCGGGTGATGGA<br/> AAACCCAGCCCGGCCCGCCCTGGGCAAGGCCCTCTGCGCTCTCCTCCTGGCCACTCTCGGCGCCGCC<br/> GGCCAGCCTCTTGGGGGAGAGTCCATCTGTTCCGCCAGAGCCCCGGCCAAATACAGCATCACCTTCACGG<br/> GCAAGTGGAGCCAGACGGCCTTCCCCAAGCAGTACCCCTGTTCCGCCCCCTGCGCAGTGGTCTTCGCT<br/> GCTGGGGCCGCGCATAGCTCCGACTACAGCATGTGGAGGAAGAACCAGTACGTCACTAACGGGCTGCGC<br/> GACTTTGCGGAGCGCGGCGAGGCTGGGCGCTGATGAAGGAGATCGAGGCGGCGGGGAGGCGCTGCAGA<br/> GCGTGACAGCGGTGTTTTCGGCGCCCGCGTCCCCAGCGGCACCGGGCAGACGTCCGGCGGAGCTGGAGGT<br/> GCAGCGAGGCACTCGCTGGTCTCGTTTGTGGTGCATCGTGCCAGCCCCGACTGGTTCTGTGGGCGTG<br/> GACAGCCTGGACCTGTGCGACGGGGACCGTTGGCGGGAACAGGCGCGCTGGACCTGTACCCCTACGACG</p> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

CCGGGACGGACAGCGGCTTACCTTCTCCTCCCCCACTTCGCCACCATCCCGCAGGACACGGTGACCGA  
 GATAACGTCCTCCTCTCCAGCCACCCGCGCACTCCTTCTACTACCCGCGGCTGAAGGCCCTGCCTCCC  
 ATCGCCAGGGTGACACTGGTGCGGCTGCGACAGAGCCCCAGGGCCTTCATCCCTCCCGCCCCAGTCTCTGC  
 CCAGCAGGGACAATGAGATTGTAGACAGCGCCTCAGTTCCAGAAACGCCGCTGGACTGCGAGGTCTCCCT  
 GTGGTCGTCCTGGGACTGTGCGGAGGCCACTGTGGGAGGCTCGGGACCAAGAGCAGGACTCGCTACGTC  
 CGGGTCCAGCCCGCAACAACGGGAGCCCTGCCCGAGCTCGAAGAAGAGGCTGAGTGCCTCCCTGATA  
 ACTGCGTCTAAGACCAGAGCCCCGAGCCCTGGGGCCCCCGAGCCATGGGGTGTGGGGGCTCTCTGTG  
 CAGGCTCATGCTGCAGGCGGCCGAGGCACAGGGGGTTTCGCGCTGCTCCTGACCGCGGTGAGGCCGCGCC  
 GACCATCTCTGCACTGAAGGGCCCTCTGGTGGCCGGCACGGGCATTGGGAACAGCCTCCTCCTTTCCCA  
 ACCTTGCTTCTTAGGGGCCCCCGTGTCCCGTCTGCTCTCAGCCTCCTCCTGTCAGGATAAAGTCATCC  
 CCAAGGCTCCAGCTACTCTAAATTATGGTCTCCTTATAAGTTATTGCTGCTCCAGGAGATTGCTCTCAT  
 CGTCCAGGGGCTGGCTCCACGTGGTTGCAGATACCTCAGACCTGGTGTCTAGGCTGTGTGAGCCCA  
 CTCTCCGAGGGCGCATCAAGCGGGGGCCACTTGAGAAGTGAATAAATGGGCGGTTTCGGAAGCGTCA  
 GTGTTTCCATGTTATGGATCTCTGCGTTGAATAAAGACTATCTCTGTTGCTCAC

The disclosed NOV6 nucleic acid sequence localized to chromosome 4, has 1587 of 1591 bases (99%) identical to a Homo sapiens spondin 2, extracellular matrix protein (SPON2), mRNA (GENBANK-ID: gi|14728622|ref|XM\_042674.1|) (E = 0.0).

- 5 A disclosed NOV6 polypeptide (SEQ ID NO:12) encoded by SEQ ID NO:11 is 331 amino acid residues and is presented using the one-letter amino acid code in Table 6B. Signal P, Psort and/or Hydropathy results predict that NOV6 is likely to be localized extracellularly.

**Table 6B. Encoded NOV6 protein sequence (SEQ ID NO:12).**

MENFSPAALGKALCALLLATLGAAGQPLGGESIC SARAPAKYSITFTGKWSQTAFPKQYPLFRPPAQWSSLLGA  
 AHSSDYSMWRKNQYVSNGLRDFAEERGEAWALMKEIEAAGEALQSVHAVFSAPAVPSGTGQTSAELEVQRRHSLVS  
 FVVRIVPSPDWVFGVDSLDCGDRWREQAALDLYPYDAGTDSGFTFSSPNFATIPQDTVTEITSSSPSHPANF  
 YYPRLKALPPIARVTLVRLRQSPRAFIPPAVLPSPDNEIVDSASVPETPLDCEVSLWSSWGLCGHCGRLGTS  
 RTRYVRVQPANNGSPCELEEEAECPDNCV

- 10 The disclosed NOV6 amino acid sequence has 877 of 879 amino acid residues (99%) identical to, and 878 of 879 amino acid residues (99%) similar to, the 879 amino acid residue SPONDIN 2 3 PROTEIN protein from *Mus musculus* (Mouse (Q9QYS2) (E = 0.0).

TaqMan data for NOV6 is shown below in Example 1. It shows overexpression in selected tumor derived cell lines and liver cancers.

- 15 NOV6 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 6C.

**Table 6C. BLAST results for NOV6**

| Gene Index/<br>Identifier  | Protein/ Organism                                               | Length<br>(aa) | Identity<br>(%)  | Positives<br>(%) | Expect |
|----------------------------|-----------------------------------------------------------------|----------------|------------------|------------------|--------|
| gi 6912682 ref NP_036577.1 | spondin 2,<br>extracellular<br>matrix protein<br>[Homo sapiens] | 331            | 306/331<br>(92%) | 306/331<br>(92%) | e-163  |

|                                                |                                                        |     |               |               |       |
|------------------------------------------------|--------------------------------------------------------|-----|---------------|---------------|-------|
| gi 13630725 ref XP_003447.2                    | spondin 2, extracellular matrix protein [Homo sapiens] | 331 | 305/331 (92%) | 305/331 (92%) | e-163 |
| gi 12803741 gb AAH02707.1 AAH02707 (BC002707)  | spondin 2, extracellular matrix protein [Homo sapiens] | 331 | 304/331 (91%) | 305/331 (91%) | e-163 |
| gi 5031506 gb AAD38195.1 AF155196_1 (AF155196) | mindin precursor [Rattus norvegicus]                   | 330 | 268/300 (89%) | 282/300 (93%) | e-149 |
| gi 2529223 dbj BAA22809.1  (AB006085)          | MINDIN2 [Danio rerio]                                  | 331 | 192/304 (63%) | 241/304 (79%) | e-113 |

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 6D.

**Table 6D Information for the ClustalW proteins**

- 1) NOV6 (SEQ ID NO:12)
- 2) gi|6912682|ref|NP\_036577.1| spondin 2, extracellular matrix protein [Homo sapiens] (SEQ ID NO:38)
- 3) gi|13630725|ref|XP\_003447.2| spondin 2, extracellular matrix protein [Homo sapiens] (SEQ ID NO:39)
- 4) gi|12803741|gb|AAH02707.1|AAH02707 (BC002707) spondin 2, extracellular matrix protein [Homo sapiens] (SEQ ID NO:40)
- 5) gi|5031506|gb|AAD38195.1|AF155196\_1 (AF155196) mindin precursor [Rattus norvegicus] (SEQ ID NO:41)
- 6) gi|2529223|dbj|BAA22809.1| (AB006085) MINDIN2 [Danio rerio] (SEQ ID NO:42)

|                 |  |                         |                    |                   |                  |                  |       |  |
|-----------------|--|-------------------------|--------------------|-------------------|------------------|------------------|-------|--|
|                 |  | 10                      | 20                 | 30                | 40               | 50               | 60    |  |
| NOV6            |  | .....                   | .....              | .....             | .....            | .....            | ..... |  |
| gi 6912682 ref  |  | MENPSPAAALGKALCALLLATLG | AAGQPLGGESICSARA   | PAKYSITFTGKWSQTAF | PKQ              | 59               |       |  |
| gi 13630725 ref |  | MENPSPAAALGKALCALLLATLG | AAGQPLGGESICSARA   | PAKYSITFTGKWSQTAF | PKQ              | 59               |       |  |
| gi 12803741 gb  |  | MENPSPAAALGKALCALLLATLG | AAGQPLGGESICSARA   | PAKYSITFTGKWSQTAF | PKQ              | 59               |       |  |
| gi 5031506 gb A |  | MENVS--FSLDRTLVVFLMLMLG | STAGQPLGGESVCTARPI | AKYSITFTGKWSQTAF  | PKQ              | 58               |       |  |
| gi 2529223 dbj  |  | MEVTL--SLRVNCWLTMTLAL   | SGVPAMGVDDRMCA     | PSAKYRLTFTGQWQTAF | PKQ              | 58               |       |  |
|                 |  | 70                      | 80                 | 90                | 100              | 110              | 120   |  |
| NOV6            |  | .....                   | .....              | .....             | .....            | .....            | ..... |  |
| gi 6912682 ref  |  | YPLFRPPAQWSSLLGAHSSDY   | SMWRKNQYVSNGLRDF   | FAERGEAWALMKEIEA  | AAGEALQS         | 119              |       |  |
| gi 13630725 ref |  | YPLFRPPAQWSSLLGAHSSDY   | SMWRKNQYVSNGLRDF   | FAERGEAWALMKEIEA  | AAGEALQS         | 119              |       |  |
| gi 12803741 gb  |  | YPLFRPPAQWSSLLGAHSSDY   | SMWRKNQYVSNGLRDF   | FAERGEAWALMKEIEA  | AAGEALQS         | 119              |       |  |
| gi 5031506 gb A |  | YPLFRPPAQWSSLLGAHSSDY   | SMWRKNQYVSNGLRDF   | FAERGEAWALMKEIEA  | AAGEALQS         | 118              |       |  |
| gi 2529223 dbj  |  | YPLFRPPAQWSSLLGVTHSSDY  | HMWRNEVASNGVR      | EFSEAEAWTLKEVEA   | AAGEALQS         | 118              |       |  |
|                 |  | 130                     | 140                | 150               | 160              | 170              | 180   |  |
| NOV6            |  | .....                   | .....              | .....             | .....            | .....            | ..... |  |
| gi 6912682 ref  |  | VHAVFSAPAVPSGTGQTS      | AELEVQRRHSLVSFV    | VRIVPSPDWFVGV     | DSLDCDGRWREQ     | 179              |       |  |
| gi 13630725 ref |  | VHAVFSAPAVPSGTGQTS      | AELEVQRRHSLVSFV    | VRIVPSPDWFVGV     | DSLDCDGRWREQ     | 179              |       |  |
| gi 12803741 gb  |  | VHAVFSAPAVPSGTGQTS      | AELEVQRRHSLVSFV    | VRIVPSPDWFVGV     | DSLDCDGRWREQ     | 179              |       |  |
| gi 5031506 gb A |  | VHAVFSAPAVPSGTGQTS      | AELEVHPRHSLVSFV    | VRIVPSPDWFVGV     | DSLDCDGRWREQ     | 178              |       |  |
| gi 2529223 dbj  |  | VVGTFSAAPAVVAGTGH       | ATTEFEVFAHSLSE     | IVRIVPSPDWFVGV    | DSLNLCEGDHCKEN   | 178              |       |  |
|                 |  | 190                     | 200                | 210               | 220              | 230              | 240   |  |
| NOV6            |  | .....                   | .....              | .....             | .....            | .....            | ..... |  |
| gi 6912682 ref  |  | AALDLYPYDACTDSGFT       | FSSPNFATIPQDTV     | TEITSSSPSHPAN     | SFYYPRLKALPPIARV | 239              |       |  |
| gi 13630725 ref |  | AALDLYPYDACTDSGFT       | FSSPNFATIPQDTV     | TEITSSSPSHPAN     | SFYYPRLKALPPIARV | 239              |       |  |
| gi 12803741 gb  |  | AALDLYPYDACTDSGFT       | FSSPNFATIPQDTV     | TEITSSSPSHPAN     | SFYYPRLKALPPIARV | 239              |       |  |
| gi 5031506 gb A |  | VVLDLYPYDACTDSGFT       | FSSPNFATIPQDTV     | TEITASSPSHPAN     | SFYYPRLKSLPPIAKV | 238              |       |  |
| gi 2529223 dbj  |  | ISLGLYPYDACTDSGFT       | FSSPNFETIPQDTV     | ITSSFP            | SHPAN            | SFYYPRLKSLPPIAKV | 238   |  |
|                 |  | 250                     | 260                | 270               | 280              | 290              | 300   |  |
| NOV6            |  | .....                   | .....              | .....             | .....            | .....            | ..... |  |
| gi 6912682 ref  |  | TLVRLRQSPRAFI           | PPAPVLPSRDNEIV     | DSASVETPLDCEVSLW  | SSWGLCGGHCGR     | 295              |       |  |
| gi 13630725 ref |  | TLVRLRQSPRAFI           | PPAPVLPSRDNEIV     | DSASVETPLDCEVSLW  | SSWGLCGGHCGR     | 295              |       |  |

|    |                 |                                                             |     |
|----|-----------------|-------------------------------------------------------------|-----|
| 5  | gi 13630725 ref | TLVRLRQSPRAFIPAPVLPSPRDNEIVDSASVF---ETPLDCEVSLWSSWGLCGGHCGR | 295 |
|    | gi 12803741 gb  | TLVRLRQSPRAFIPAPVLPSPRDNEIVDSASVF---ETPLDCEVSLWSSWGLCGGHCGR | 295 |
|    | gi 5031506 gb A | TLVRLRQSPRAFIPAPVLPSPRDNEIVDSASVF---ETPLDCEVSLWSSWGLCGGHCGR | 294 |
|    | gi 2529223 dbj  | SLTKIKNNQ---IFSLPQPTGSGNIPSGNETDGLINETPLDCEVSLWSSWGLCGGHCGR | 295 |
|    |                 | 310 320 330                                                 |     |
|    | NOV6            | LGTKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 331 |
| 10 | gi 6912682 ref  | LGTKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 331 |
|    | gi 13630725 ref | LGTKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 331 |
|    | gi 12803741 gb  | LGTKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 331 |
|    | gi 5031506 gb A | LGAKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 330 |
|    | gi 2529223 dbj  | KGVKSRTRYVRVQPANNGSPCPELEEEAECPDNCV                         | 331 |
| 15 |                 |                                                             |     |

Table 6E-F lists the domain description from DOMAIN analysis results against NOV6. This indicates that the NOV6 sequence has properties similar to those of other proteins known to contain this domain.

**Table 6E. Domain Analysis of NOV6**

gnl|Smart|smart00209, TSP1, Thrombospondin type 1 repeats; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta (SEQ ID NO:46)  
CD-Length = 51 residues, 98.0% aligned  
Score = 42.4 bits (98), Expect = 4e-05

20

Query: 280 VSLWSSWGLCGGHCGR LGTKSRTRYVRVQPANNGSPCPELEEEAE-CVPDNC 330  
Sbjct: 1 WGEWSEWSPCSVTCGG-GVQTRTRCCN-PPPNGGGPCTGPDTEACNEQPC 50

25 It is thought that NOV6 is involved with liver cancer. Therapeutic targeting of NOV6 with a monoclonal antibody is anticipated to limit or block the extent of angiogenesis and tumor growth in liver cancer.

The disclosed NOV6 nucleic acid of the invention encoding a Spondin 2-like protein includes the nucleic acid whose sequence is provided in Table 6A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 6A while still encoding a protein that maintains its Spondin 2-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be



used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.

The disclosed NOV6 protein of the invention includes the Spondin 2 -like protein whose sequence is provided in Table 6B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 6B while still encoding a protein that maintains its Spondin 2 -like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 37% percent of the residues may be so changed.

NOV6 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. For example the disclosed NOV6 protein have multiple hydrophilic regions, each of which can be used as an immunogen. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. These antibodies could also be used to treat certain pathologies as detailed above.

## **NOVX Nucleic Acids and Polypeptides**

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (*e.g.*, NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring

polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver,

spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

5           A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, and 11, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11 as a hybridization probe, NOVX molecules  
10 can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

          A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively,  
15 genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

20           As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.  
25           Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:1, 3, 5, 7, 9, and 11, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used  
30 as probes.

          In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, and 11, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX

polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, or 11 is one that is sufficiently complementary to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, or 11 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, and 11, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of

hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. *See e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

5 A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous  
10 nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence  
15 does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, and 11, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

20 An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or  
25 TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, *e.g.*, a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes  
30 allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, *e.g.* from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350

or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, or 11; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, or 11; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, and 11.

Probes based on the human NOVX nucleotide sequences can be used to detect  
5 transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in  
10 a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

"A polypeptide having a biologically-active portion of an NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological  
15 assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, or 11, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of  
20 NOVX.

### **NOVX Nucleic Acid and Polypeptide Variants**

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, and 11 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide  
25 sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, and 11. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, or 12.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, and 11, it will be appreciated by those skilled in the art that DNA sequence  
30 polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules

comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:1, 3, 5, 7, 9, and 11 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target

sequence at equilibrium. Since the target sequences are generally present at excess, at  $T_m$ , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at

- 5 pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

- Stringent conditions are known to those skilled in the art and can be found in Ausubel, 10 *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM 15 EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:1, 3, 5, 7, 9, and 11, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or 20 DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

- In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. 25 A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and 30 Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, and 11, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting



example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C.

Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). *See, e.g.,* Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

### Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, and 11, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ ID NOS:2, 4, 6, 8, 10, or 12. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:1, 3, 5, 7, 9, and 11 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, and 12. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, and 12; more preferably at least about 70% homologous to SEQ ID NOS:2, 4, 6, 8, 10, or 12; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, or 12; even more preferably at least about 90%

homologous to SEQ ID NOS:2, 4, 6, 8, 10, or 12; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, or 12.

An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, or 12 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOS:1, 3, 5, 7, 9, and 11 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS:1, 3, 5, 7, 9, and 11, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

### Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, or 12, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, and 11, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example,

the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (*v*), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (*v*), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)*w*, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered

systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other. See, e.g., Gaultier, *et al.*, 1987. *Nucl. Acids Res.* 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, *et al.* 1987. *Nucl. Acids Res.* 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, *et al.*, 1987. *FEBS Lett.* 215: 327-330).

### Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, and 11). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic

RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g., Bartel et al., (1993) Science 261:1411-1418.*

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g., the NOVX promoter and/or enhancers*) to form triple helical structures that prevent transcription of the NOVX gene in target cells. *See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.*

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g., the stability, hybridization, or solubility* of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. *See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23.* As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g., DNA mimics*) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al., 1996. supra;* Perry-O'Keefe, *et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.*

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g., inducing transcription or translation arrest or inhibiting replication.* PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S<sub>1</sub> nucleases (See, Hyrup, et al., 1996. supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).*

In another embodiment, PNAs of NOVX can be modified, *e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.* For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g., RNase H and DNA polymerases*) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking,

number of bonds between the nucleobases, and orientation (*see*, Hyrup, et al., 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. *supra* and Finn, et al., 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and  
5 modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g.*, Mag, et al., 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g.*, Finn, et al., 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA  
10 segment and a 3' PNA segment. *See, e.g.*, Petersen, et al., 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger, et al., 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86:  
15 6553-6556; Lemaitre, et al., 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g.*, Krol, et al., 1988. *BioTechniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another  
20 molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

### NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6,  
25 8, 10, or 12. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, or 12 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, an NOVX variant that preserves NOVX-like function includes any variant  
30 in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed

by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.



Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, or 12) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2, 4, 6, 8, 10, or 12. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, or 12, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, or 12, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, or 12, and retains the functional activity of the NOVX proteins of SEQ ID NOS:2, 4, 6, 8, 10, or 12.

#### **Determining Homology Between Two or More Sequences**

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings

for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, and 11.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

#### **Chimeric and Fusion Proteins**

The invention also provides NOVX chimeric or fusion proteins. As used herein, an NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NOS:2, 4, 6, 8, 10, or 12, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX

polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR*

BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

5

### NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein).

10 An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific  
15 biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics)  
20 or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example,  
25 enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical  
30 synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3;

Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

### **Polypeptide Libraries**

5 In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per  
10 molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S<sub>1</sub> nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX  
15 proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most  
20 widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble  
25 mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, *e.g.*, Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, *et al.*, 1993. *Protein Engineering* 6:327-331.

### **Anti-NOVX Antibodies**

30 Also included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such

antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain,  $F_{ab}$ ,  $F_{ab}'$  and  $F_{(ab)2}$  fragments, and an  $F_{ab}$  expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG<sub>1</sub>, IgG<sub>2</sub>, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOVX-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX-related protein that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX-related protein sequence will indicate which regions of a NOVX-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

## 10 Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson

### Monoclonal Antibodies

5       The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus  
10       contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

      Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to  
15       elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

      The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human  
20       mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE*, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines  
25       are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which  
30       substances prevent the growth of HGPRT-deficient cells.

      Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San



Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the

immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5

### Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

### Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma

technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al. (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse<sup>TM</sup> as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human

variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

5 An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable  
10 marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture,  
15 introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that  
20 binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

#### **F<sub>ab</sub> Fragments and Single Chain Antibodies**

According to the invention, techniques can be adapted for the production of  
25 single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F<sub>ab</sub> expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F<sub>ab</sub> fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the  
30 idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F<sub>(ab)<sub>2</sub></sub> fragment produced by pepsin digestion of an antibody molecule; (ii) an F<sub>ab</sub> fragment generated by reducing the disulfide bridges of an F<sub>(ab)<sub>2</sub></sub> fragment; (iii) an F<sub>ab</sub> fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F<sub>v</sub> fragments.

### Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')<sub>2</sub> bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., *Science* 229:81 (1985) describe a  
5 procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol compound sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is  
10 mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992)  
15 describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

20 Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced  
25 at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>)  
30 by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary V<sub>L</sub> and V<sub>H</sub> domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm  
5 of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific  
10 antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

#### 15           **Heteroconjugate Antibodies**

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO  
20 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No.  
25 4,676,980.

#### **Effector Function Engineering**

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For  
30 example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., *J. Exp Med.*, 176: 1191-1195 (1992) and Shopes, *J. Immunol.*, 148: 2918-2922 (1992). Homodimeric antibodies with

enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. *Cancer Research*, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design*, 3: 219-230 (1989).

5

### Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

10

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcun, croton, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

15

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., *Science*, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

20

25

30

In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation



using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-NOVX antibodies may be used in methods known within the art relating to the localization and/or quantitation of an NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for NOVX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-NOVX antibody (e.g., monoclonal antibody) can be used to isolate an NOVX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NOVX antibody can facilitate the purification of natural NOVX polypeptide from cells and of recombinantly-produced NOVX polypeptide expressed in host cells. Moreover, an anti-NOVX antibody can be used to detect NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NOVX protein. Anti-NOVX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include

luciferase, luciferin, and aequorin, and examples of suitable radioactive material include <sup>125</sup>I, <sup>131</sup>I, <sup>35</sup>S or <sup>3</sup>H.

### NOVX Recombinant Expression Vectors and Host Cells

5 Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA  
10 segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon  
15 introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the  
20 plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that  
25 the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the  
30 host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN

ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrec (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION

TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43:

235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477),  
5 pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

10 The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the  
15 antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the  
20 control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.*, Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant  
25 expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent  
30 cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

### Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful

for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, and 11 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, and 11), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:1, 3, 5, 7, 9, and 11 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g.*, Thomas, *et al.*, 1987. *Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g.*, Li, *et al.*, 1992. *Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. *See, e.g.*, Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.



In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g., by* mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al., 1997. Nature* 385: 810-813. In brief, a cell (*e.g., a somatic cell*) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, *e.g., through the use of* electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g., the somatic cell*) is isolated.

### Pharmaceutical Compositions

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be

used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

5           A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile  
10   diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be  
15   adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

          Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous  
20   preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating  
25   action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of  
30   surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by

including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

5 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of 10 the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form 15 of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar 20 nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

25 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be 30 permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

5 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be  
10 obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

15 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The  
20 specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as  
25 gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery  
30 vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

### Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

### Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries,

while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the

assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein  
5 determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof,  
10 on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target  
15 molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an  
20 NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the  
25 association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the  
30 target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*,

luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and  
5 determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test  
10 compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX  
15 protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described  
20 above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein  
25 or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the  
30 ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent



such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton<sup>®</sup> X-100, Triton<sup>®</sup> X-114, Thesit<sup>®</sup>,

- 5 Isotridecypoly(ethylene glycol ether)<sub>n</sub>, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in

the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to

interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

### Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

### Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:1, 3, 5, 7, 9, and 11, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

### Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding

regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

5        Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a  
10       noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, and 11 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

### **Predictive Medicine**

15        The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*,  
20       blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders,  
25       and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a  
30       biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or

prophylactic agents for that individual (referred to herein as "pharmacogenomics").

Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

### Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, and 11, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in*

*vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

### Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test



sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (*e.g.*, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional

means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (*see*, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwoh, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q $\beta$  Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human*

Mutation 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (*see, e.g.*, Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (*see, e.g.*, PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. *See, e.g.*, Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S<sub>1</sub> nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.*, Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85:

4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, *e.g.*, Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to an exemplary embodiment, a probe based on an NOVX sequence, *e.g.*, a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, *e.g.*, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, *e.g.*, Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, *e.g.*, Keen, *et al.*, 1991. *Trends Genet.* 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, *e.g.*, Myers, *et al.*, 1985. *Nature* 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, *e.g.*, Rosenbaum and Reissner, 1987. *Biophys. Chem.* 265: 12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448*) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g., Prossner, 1993. Tibtech. 11: 238*). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1.* It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. *See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189.* In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.,* in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

### Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic

polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

### **Monitoring of Effects During Clinical Trials**

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting

increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

5 By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of  
10 NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological  
15 response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the  
20 screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the  
25 post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels  
30 than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.



## Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

## Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be

utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an  
5 aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).  
10

### Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the  
15 subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is  
20 prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

25

### Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein  
30 activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX

that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

#### **Determination of the Biological Effect of the Therapeutic**

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

#### **Prophylactic and Therapeutic Uses of the Compositions of the Invention**

The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder,

immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

## Examples

### Example 1. Quantitative expression analysis of clones in various cells and tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM® 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing cells and cell lines from normal and cancer sources), Panel 2 (containing samples derived from tissues, in particular from surgical samples, from normal and cancer sources), Panel 3 (containing samples derived from a wide variety of cancer sources), Panel 4 (containing cells and cell lines from normal cells and cells related to inflammatory conditions) and Panel CNSD.01 (containing samples from normal and diseased brains).

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example,  $\beta$ -actin and GAPDH). Normalized RNA (5  $\mu$ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's *Primer Express* Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature ( $T_m$ ) range = 58°-60° C, primer optimal  $T_m$  = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe  $T_m$  must be 10° C greater than primer  $T_m$ , amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

PCR conditions: Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1X TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl<sub>2</sub>, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/ $\mu$ l RNase inhibitor, and 0.25 U/ $\mu$ l reverse transcriptase. Reverse transcription was performed at 48° C for 30 minutes followed by amplification/PCR cycles as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

In the results for Panel 1, the following abbreviations are used:

ca. = carcinoma,

\* = established from metastasis,

met = metastasis,

s cell var = small cell variant,  
non-s = non-sm = non-small,  
squam = squamous,  
pl. eff = pl effusion = pleural effusion,  
5 glio = glioma,  
astro = astrocytoma, and  
neuro = neuroblastoma.

## 10 Panel 2

The plates for Panel 2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN)  
15 or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists  
20 and again by a pathologists at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR).  
25 In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

RNA integrity from all samples is controlled for quality by visual assessment of  
30 agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

#### Panel 4

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4r) or cDNA (Panel 4d) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) were employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and

grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at  
5 approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS  
10 (Hyclone), 100  $\mu$ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2  $\mu$ g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in  
15 DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5  $\mu$ g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using  
20 Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately  $2 \times 10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol ( $5.5 \times 10^{-5}$  M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

25 Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml  
30 GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100



ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 µg/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and plated at  $10^6$  cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 µg/ml anti-CD28 (Pharmingen) and 3 µg/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at  $10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 µg/ml or anti-CD40 (Pharmingen) at approximately 10 µg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 µg/ml anti-CD28 (Pharmingen) and 2 µg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems,

German Town, MD) were cultured at  $10^5$  -  $10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1  $\mu$ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1  $\mu$ g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1  $\mu$ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at  $5 \times 10^5$  cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to  $5 \times 10^5$  cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1  $\mu$ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately  $10^7$  cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase

was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 µl of RNase-free water and 35 µl buffer (Promega) 5 µl DTT, 7 µl RNAsin and 8 µl DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

#### 10           **Panel CNSD.01**

The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus pallidus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus pallidus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA

contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

PSP = Progressive supranuclear palsy

Sub Nigra = Substantia nigra

Glob Palladus= Globus palladus

Temp Pole = Temporal pole

Cing Gyr = Cingulate gyrus

BA 4 = Brodman Area 4

### NOV1

Expression of gene NOV1 was assessed using the primer-probe sets Ag1395, described in Table 7. Results from RTQ-PCR runs are shown in Tables 8 and 9.

**Table 7. Probe and Primer Ag 1395**

| Primers | Sequences                                 | TM   | Length | Start Position | SEQ ID NO: |
|---------|-------------------------------------------|------|--------|----------------|------------|
| Forward | 5'-CTGCACTTCAAGGACAGTTACC-3'              | 59.8 | 22     | 2184           | 50         |
| Probe   | FAM-5'-CTATCCATCCACGATGTGCCCAGCT-3'-TAMRA | 71.1 | 25     | 2217           | 51         |
| Reverse | 5'-TGACAAGGAGCTTACTCTTCCA-3'              | 59.1 | 22     | 2247           | 52         |

**Table 8. Panel 1.2**

| Tissue Name              | Rel. Expr., %<br>1.2tm1636f ag1395 | Rel. Expr., %<br>1.2tm1675f ag1395* |
|--------------------------|------------------------------------|-------------------------------------|
| Endothelial cells        | 0                                  | 0                                   |
| Heart (fetal)            | 0.2                                | 0.1                                 |
| Pancreas                 | 0                                  | 0                                   |
| Pancreatic ca. CAPAN 2   | 0.4                                | 0.6                                 |
| Adrenal Gland (new lot*) | 1.1                                | 3.6                                 |
| Thyroid                  | 0                                  | 0                                   |
| Salivary gland           | 0.2                                | 0.3                                 |
| Pituitary gland          | 0                                  | 0                                   |
| Brain (fetal)            | 1.8                                | 1.9                                 |
| Brain (whole)            | 11.3                               | 3.3                                 |
| Brain (amygdala)         | 9.8                                | 18.2                                |
| Brain (cerebellum)       | 3.1                                | 3.6                                 |
| Brain (hippocampus)      | 31.4                               | 42.6                                |
| Brain (thalamus)         | 2.1                                | 2.9                                 |

|                                     |      |     |
|-------------------------------------|------|-----|
| Cerebral Cortex                     | 100  | 100 |
| Spinal cord                         | 0.1  | 0   |
| CNS ca. (glio/astro) U87-MG         | 0    | 0   |
| CNS ca. (glio/astro) U-118-MG       | 0    | 0   |
| CNS ca. (astro) SW1783              | 0    | 0   |
| CNS ca.* (neuro; met) SK-N-AS       | 0.1  | 0.3 |
| CNS ca. (astro) SF-539              | 0    | 0   |
| CNS ca. (astro) SNB-75              | 0    | 0   |
| CNS ca. (glio) SNB-19               | 0    | 0   |
| CNS ca. (glio) U251                 | 0    | 0   |
| CNS ca. (glio) SF-295               | 0.1  | 0.1 |
| Heart                               | 0    | 0.3 |
| Skeletal Muscle (new lot*)          | 0    | 0   |
| Bone marrow                         | 0.9  | 0.8 |
| Thymus                              | 0    | 0   |
| Spleen                              | 0    | 0.1 |
| Lymph node                          | 0    | 0   |
| Colorectal                          | 0    | 0   |
| Stomach                             | 0.3  | 0.1 |
| Small intestine                     | 0.2  | 0.2 |
| Colon ca. SW480                     | 0.5  | 0.1 |
| Colon ca.* (SW480 met)SW620         | 0.2  | 0.1 |
| Colon ca. HT29                      | 0    | 0   |
| Colon ca. HCT-116                   | 1.3  | 1.8 |
| Colon ca. CaCo-2                    | 0    | 0   |
| 83219 CC Well to Mod Diff (ODO3866) | 0    | 0   |
| Colon ca. HCC-2998                  | 3.2  | 3.4 |
| Gastric ca.* (liver met) NCI-N87    | 0    | 0   |
| Bladder                             | 0.8  | 0.8 |
| Trachea                             | 0    | 0   |
| Kidney                              | 0    | 0   |
| Kidney (fetal)                      | 0    | 0   |
| Renal ca. 786-0                     | 0.1  | 0.1 |
| Renal ca. A498                      | 6    | 4.7 |
| Renal ca. RXF 393                   | 0    | 0   |
| Renal ca. ACHN                      | 0.8  | 1   |
| Renal ca. UO-31                     | 0.3  | 0.2 |
| Renal ca. TK-10                     | 6    | 3   |
| Liver                               | 0.3  | 0.3 |
| Liver (fetal)                       | 0    | 0.1 |
| Liver ca. (hepatoblast) HepG2       | 0    | 0   |
| Lung                                | 0    | 0   |
| Lung (fetal)                        | 0    | 0   |
| Lung ca. (small cell)LX-1           | 0    | 0   |
| Lung ca. (small cell) NCI-H69       | 16.3 | 9.3 |
| Lung ca. (s.cell var.) SHP-77       | 0.4  | 0.4 |
| Lung ca. (large cell)NCI-H460       | 0    | 0   |
| Lung ca. (non-sm. cell) A549        | 0    | 0   |
| Lung ca. (non-s.cell) NCI-H23       | 0.4  | 0.4 |
| Lung ca (non-s.cell) HOP-62         | 0    | 0   |

|                                  |      |      |
|----------------------------------|------|------|
| Lung ca. (non-s.cl) NCI-H522     | 9    | 11.5 |
| Lung ca. (squam.) SW 900         | 1.5  | 0.9  |
| Lung ca. (squam.) NCI-H596       | 18.8 | 16.6 |
| Mammary gland                    | 0.1  | 0.1  |
| Breast ca.* (pl. effusion) MCF-7 | 0    | 0.2  |
| Breast ca.* (pl.ef) MDA-MB-231   | 0    | 0    |
| Breast ca.* (pl. effusion) T47D  | 0.5  | 1.3  |
| Breast ca. BT-549                | 0    | 0    |
| Breast ca. MDA-N                 | 0    | 0    |
| Ovary                            | 0.4  | 0.3  |
| Ovarian ca. OVCAR-3              | 0    | 0    |
| Ovarian ca. OVCAR-4              | 0.2  | 0.3  |
| Ovarian ca. OVCAR-5              | 18.4 | 11.7 |
| Ovarian ca. OVCAR-8              | 1    | 1.4  |
| Ovarian ca. IGROV-1              | 20.2 | 11.7 |
| Ovarian ca.* (ascites) SK-OV-3   | 0.4  | 0.6  |
| Uterus                           | 0    | 0    |
| Placenta                         | 0    | 0    |
| Prostate                         | 0.2  | 0.2  |
| Prostate ca.* (bone met)PC-3     | 0    | 0    |
| Testis                           | 0.2  | 0    |
| Melanoma Hs688(A).T              | 0    | 0    |
| Melanoma* (met) Hs688(B).T       | 0    | 0    |
| Melanoma UACC-62                 | 0    | 0    |
| Melanoma M14                     | 0    | 0    |
| Melanoma LOX IMVI                | 0    | 0    |
| Melanoma* (met) SK-MEL-5         | 0    | 0    |
| Adipose                          | 6.5  | 7    |

Table 9. Panel 2D

| Tissue Name                                 | Rel. Expr., %<br>2dtm2448f ag1395 | Rel. Expr., %<br>2dx4tm4720f ag1395 a2 |
|---------------------------------------------|-----------------------------------|----------------------------------------|
| Normal Colon GENPAK 061003                  | 4.2                               | 1.9                                    |
| 83219 CC Well to Mod Diff (ODO3866)         | 0.7                               | 1.8                                    |
| 83220 CC NAT (ODO3866)                      | 0                                 | 1                                      |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 0                                 | 1.1                                    |
| 83222 CC NAT (ODO3868)                      | 0                                 | 0                                      |
| 83235 CC Mod Diff (ODO3920)                 | 0                                 | 1.2                                    |
| 83236 CC NAT (ODO3920)                      | 0                                 | 0.8                                    |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 0.9                               | 2.3                                    |
| 83238 CC NAT (ODO3921)                      | 0                                 | 0.4                                    |
| 83241 CC from Partial Hepatectomy (ODO4309) | 0.7                               | 0.2                                    |
| 83242 Liver NAT (ODO4309)                   | 0                                 | 0.9                                    |
| 87472 Colon mets to lung (OD04451-01)       | 0                                 | 2.3                                    |
| 87473 Lung NAT (OD04451-02)                 | 0.8                               | 0                                      |
| Normal Prostate Clontech A+ 6546-1          | 9                                 | 8.2                                    |

|                                             |      |      |
|---------------------------------------------|------|------|
| 84140 Prostate Cancer (OD04410)             | 0    | 3.5  |
| 84141 Prostate NAT (OD04410)                | 2    | 1.7  |
| 87073 Prostate Cancer (OD04720-01)          | 0.8  | 1.7  |
| 87074 Prostate NAT (OD04720-02)             | 0    | 1.5  |
| Normal Lung GENPAK 061010                   | 3.1  | 10.9 |
| 83239 Lung Met to Muscle (ODO4286)          | 4.4  | 4.1  |
| 83240 Muscle NAT (ODO4286)                  | 0    | 0.5  |
| 84136 Lung Malignant Cancer (OD03126)       | 2.2  | 2.6  |
| 84137 Lung NAT (OD03126)                    | 3.2  | 4.6  |
| 84871 Lung Cancer (OD04404)                 | 2.4  | 1.1  |
| 84872 Lung NAT (OD04404)                    | 3.3  | 4.2  |
| 84875 Lung Cancer (OD04565)                 | 0    | 1.6  |
| 84876 Lung NAT (OD04565)                    | 1.7  | 1.7  |
| 85950 Lung Cancer (OD04237-01)              | 0.8  | 4.5  |
| 85970 Lung NAT (OD04237-02)                 | 3.8  | 7.1  |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 0    | 0    |
| 83256 Liver NAT (ODO4310)                   | 6.2  | 2.1  |
| 84139 Melanoma Mets to Lung (OD04321)       | 0.8  | 0    |
| 84138 Lung NAT (OD04321)                    | 3.8  | 5.3  |
| Normal Kidney GENPAK 061008                 | 0.8  | 1.6  |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)  | 1.2  | 2.8  |
| 83787 Kidney NAT (OD04338)                  | 0    | 1.8  |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339) | 5.9  | 5.4  |
| 83789 Kidney NAT (OD04339)                  | 0    | 0    |
| 83790 Kidney Ca, Clear cell type (OD04340)  | 1.3  | 7.5  |
| 83791 Kidney NAT (OD04340)                  | 0    | 0.3  |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)  | 0    | 2.1  |
| 83793 Kidney NAT (OD04348)                  | 0.8  | 0.8  |
| 87474 Kidney Cancer (OD04622-01)            | 2.2  | 4.1  |
| 87475 Kidney NAT (OD04622-03)               | 0.7  | 0.4  |
| 85973 Kidney Cancer (OD04450-01)            | 0    | 0.4  |
| 85974 Kidney NAT (OD04450-03)               | 0    | 0    |
| Kidney Cancer Clontech 8120607              | 27.9 | 60.6 |
| Kidney NAT Clontech 8120608                 | 0.8  | 2.1  |
| Kidney Cancer Clontech 8120613              | 0.8  | 1.7  |
| Kidney NAT Clontech 8120614                 | 0.7  | 0.7  |
| Kidney Cancer Clontech 9010320              | 4.7  | 6.4  |
| Kidney NAT Clontech 9010321                 | 0    | 2.7  |
| Normal Uterus GENPAK 061018                 | 0    | 2.2  |
| Uterus Cancer GENPAK 064011                 | 0    | 8.9  |
| Normal Thyroid Clontech A+ 6570-1           | 8.7  | 1.2  |
| Thyroid Cancer GENPAK 064010                | 0    | 0    |
| Thyroid Cancer INVITROGEN A302152           | 0    | 2.5  |
| Thyroid NAT INVITROGEN A302153              | 1.1  | 0.8  |
| Normal Breast GENPAK 061019                 | 2.8  | 4.1  |
| 84877 Breast Cancer (OD04566)               | 0    | 1.8  |
| 85975 Breast Cancer (OD04590-01)            | 28.3 | 27.5 |
| 85976 Breast Cancer Mets (OD04590-03)       | 13.3 | 14.2 |
| 87070 Breast Cancer Metastasis (OD04655-05) | 37.9 | 100  |
| GENPAK Breast Cancer 064006                 | 12   | 19.3 |

|                                                         |      |      |
|---------------------------------------------------------|------|------|
| Breast Cancer Res. Gen. 1024                            | 33.9 | 25.2 |
| Breast Cancer Clontech 9100266                          | 6.7  | 7.7  |
| Breast NAT Clontech 9100265                             | 0.5  | 9.1  |
| Breast Cancer INVITROGEN A209073                        | 3.7  | 6.9  |
| Breast NAT INVITROGEN A2090734                          | 0.7  | 0    |
| Normal Liver GENPAK 061009                              | 0    | 2.6  |
| Liver Cancer GENPAK 064003                              | 0    | 1.3  |
| Liver Cancer Research Genetics RNA 1025                 | 0.4  | 2    |
| Liver Cancer Research Genetics RNA 1026                 | 0    | 1.6  |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 1.6  | 3.4  |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 1.4  | 0.7  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 0.8  | 0.8  |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0    | 0    |
| Normal Bladder GENPAK 061001                            | 3.5  | 3.8  |
| Bladder Cancer Research Genetics RNA 1023               | 0.8  | 0.5  |
| Bladder Cancer INVITROGEN A302173                       | 3.2  | 1.1  |
| 87071 Bladder Cancer (OD04718-01)                       | 3.8  | 2.3  |
| 87072 Bladder Normal Adjacent (OD04718-03)              | 5.2  | 7.4  |
| Normal Ovary Res. Gen.                                  | 3    | 2.9  |
| Ovarian Cancer GENPAK 064008                            | 3.2  | 2.9  |
| 87492 Ovary Cancer (OD04768-07)                         | 3.5  | 4.6  |
| 87493 Ovary NAT (OD04768-08)                            | 0.9  | 2.2  |
| Normal Stomach GENPAK 061017                            | 2.7  | 3.7  |
| Gastric Cancer Clontech 9060358                         | 0.4  | 0.2  |
| NAT Stomach Clontech 9060359                            | 4.3  | 1.3  |
| Gastric Cancer Clontech 9060395                         | 3    | 1.2  |
| NAT Stomach Clontech 9060394                            | 2.5  | 1    |
| Gastric Cancer Clontech 9060397                         | 100  | 48   |
| NAT Stomach Clontech 9060396                            | 1    | 2.2  |
| Gastric Cancer GENPAK 064005                            | 4.9  | 6.7  |

## NOV2

Expression of gene NOV2 was assessed using the primer-probe sets Ag395 and Ag888, described in Tables 10 and 11. Results from RTQ-PCR runs are shown in Tables 12, 13, 14, 15 and 16.

**Table 10. Probe and Primer Ag395**

| Primers | Sequences                           | TM | Length | Start Position | SEQ ID NO: |
|---------|-------------------------------------|----|--------|----------------|------------|
| Forward | 5'-CAGGAAGAAATAAGCCAAGTCCA-3'       |    | 23     | 1409           | 53         |
| Probe   | TET-5'-TCCTTGGCCTCCCGCCTGC-3'-TAMRA |    | 19     | 1433           | 54         |
| Reverse | 5'-GAGGTCATGTTCTAGCTTCCATT-3'       |    | 24     | 1463           | 55         |



Table 11. Probe and Primer Ag888

| Primers | Sequences                                          | TM   | Length | Start Position | SEQ ID NO: |
|---------|----------------------------------------------------|------|--------|----------------|------------|
| Forward | 5'-CATAGCTGACCGCATCTGAA-3'                         | 60   | 20     | 3101           | 56         |
| Probe   | FAM-5'-<br>AATGCTCCATCTCCTTGGCTGAGTG<br>A-3'-TAMRA | 70.1 | 26     | 3130           | 57         |
| Reverse | 5'-GGAGCTAGCATCCATCATCAC-3'                        | 59.7 | 21     | 3156           | 58         |

5 Probe and Primer Ag784 mentioned in the provisional application for panel 1 is an error.

Table 12: Panel 1.1 (Ag395)

| Tissue Name                      | Rel. Expr., %<br>tm671t ag395 |
|----------------------------------|-------------------------------|
| Adipose                          | 0.2                           |
| Adrenal gland                    | 0.1                           |
| Bladder                          | 1.4                           |
| Brain (amygdala)                 | 0                             |
| Brain (cerebellum)               | 100                           |
| Brain (hippocampus)              | 0.2                           |
| Brain (substantia nigra)         | 1.2                           |
| Brain (thalamus)                 | 0.2                           |
| Cerebral Cortex                  | 1.5                           |
| Brain (fetal)                    | 0.9                           |
| Brain (whole)                    | 4.5                           |
| CNS ca. (glio/astro) U-118-MG    | 0.1                           |
| CNS ca. (astro) SF-539           | 0.2                           |
| CNS ca. (astro) SNB-75           | 0.3                           |
| CNS ca. (astro)SW1783            | 0                             |
| CNS ca. (glio) U251              | 0.1                           |
| CNS ca. (glio) SF-295            | 0.4                           |
| CNS ca. (glio) SNB-19            | 0.1                           |
| CNS ca. (glio/astro) U87-MG      | 0.8                           |
| CNS ca.* (neuro; met ) SK-N-AS   | 1.2                           |
| Mammary gland                    | 1.4                           |
| Breast ca. BT-549                | 0.2                           |
| Breast ca. MDA-N                 | 0.7                           |
| Breast ca.* (pl. effusion) T47D  | 0.5                           |
| Breast ca.* (pl. effusion) MCF-7 | 0.3                           |
| Breast ca.* (pl.ef) MDA-MB-231   | 0                             |
| Small intestine                  | 0.6                           |
| Colorectal                       | 0.2                           |
| Colon ca. HT29                   | 0.1                           |

|                                  |     |
|----------------------------------|-----|
| Colon ca. CaCo-2                 | 1   |
| Colon ca. HCT-15                 | 0.3 |
| Colon ca. HCT-116                | 0.3 |
| Colon ca. HCC-2998               | 1.1 |
| Colon ca. SW480                  | 0.3 |
| Colon ca.* (SW480 met)SW620      | 1   |
| Stomach                          | 0.3 |
| Gastric ca.* (liver met) NCI-N87 | 0.5 |
| Heart                            | 0.4 |
| Fetal Skeletal                   | 0.5 |
| Skeletal muscle                  | 0.8 |
| Endothelial cells                | 0.2 |
| Heart (fetal)                    | 0   |
| Kidney                           | 0.7 |
| Kidney (fetal)                   | 0.7 |
| Renal ca. 786-0                  | 0   |
| Renal ca. A498                   | 0.3 |
| Renal ca. ACHN                   | 0.3 |
| Renal ca. TK-10                  | 0.5 |
| Renal ca. UO-31                  | 0   |
| Renal ca. RXF 393                | 0   |
| Liver                            | 0.5 |
| Liver (fetal)                    | 0.5 |
| Liver ca. (hepatoblast) HepG2    | 0   |
| Lung                             | 0.1 |
| Lung (fetal)                     | 0.2 |
| Lung ca (non-s.cell) HOP-62      | 1   |
| Lung ca. (large cell)NCI-H460    | 0.8 |
| Lung ca. (non-s.cell) NCI-H23    | 0.2 |
| Lung ca. (non-s.cl) NCI-H522     | 0.7 |
| Lung ca. (non-sm. cell) A549     | 0.3 |
| Lung ca. (s.cell var.) SHP-77    | 0.2 |
| Lung ca. (small cell) LX-1       | 1.2 |
| Lung ca. (small cell) NCI-H69    | 0.4 |
| Lung ca. (squam.) SW 900         | 0   |
| Lung ca. (squam.) NCI-H596       | 0.5 |
| Lymph node                       | 0.3 |
| Spleen                           | 0.1 |
| Thymus                           | 1.1 |
| Ovary                            | 0   |
| Ovarian ca. IGROV-1              | 0.1 |
| Ovarian ca. OVCAR-3              | 7.7 |
| Ovarian ca. OVCAR-4              | 6.4 |
| Ovarian ca. OVCAR-5              | 1.5 |
| Ovarian ca. OVCAR-8              | 0.5 |
| Ovarian ca.* (ascites) SK-OV-3   | 0.7 |
| Pancreas                         | 0.9 |
| Pancreatic ca. CAPAN 2           | 0   |
| Pituitary gland                  | 0.5 |
| Placenta                         | 0.6 |

|                              |     |
|------------------------------|-----|
| Prostate                     | 2.4 |
| Prostate ca.* (bone met)PC-3 | 0.2 |
| Salavary gland               | 2.4 |
| Trachea                      | 1.9 |
| Spinal cord                  | 0.4 |
| Testis                       | 2   |
| Thyroid                      | 0.1 |
| Uterus                       | 0.1 |
| Melanoma M14                 | 0.4 |
| Melanoma LOX IMVI            | 0.1 |
| Melanoma UACC-62             | 0   |
| Melanoma SK-MEL-28           | 1.6 |
| Melanoma* (met) SK-MEL-5     | 0.1 |
| Melanoma Hs688(A).T          | 0   |
| Melanoma* (met) Hs688(B).T   | 0.1 |

Table 13: Panel 1.2 (Ag888)

| Tissue Name                    | Rel. Expr., %<br>1.2tm1002f ag888 | Rel. Expr., %<br>1.2tm1042f ag888 |
|--------------------------------|-----------------------------------|-----------------------------------|
| Endothelial cells              | 0                                 | 0                                 |
| Heart (fetal)                  | 0                                 | 0                                 |
| Pancreas                       | 0.2                               | 0                                 |
| Pancreatic ca. CAPAN 2         | 0                                 | 0                                 |
| Adrenal Gland (new lot*)       | 0                                 | 0                                 |
| Thyroid                        | 0                                 | 0                                 |
| Salavary gland                 | 8.8                               | 2.7                               |
| Pituitary gland                | 0.5                               | 0                                 |
| Brain (fetal)                  | 0.7                               | 0                                 |
| Brain (whole)                  | 22.7                              | 20.2                              |
| Brain (amygdala)               | 0.5                               | 0                                 |
| Brain (cerebellum)             | 100                               | 100                               |
| Brain (hippocampus)            | 0.4                               | 0                                 |
| Brain (thalamus)               | 0.2                               | 0                                 |
| Cerebral Cortex                | 2.7                               | 0                                 |
| Spinal cord                    | 0.2                               | 0                                 |
| CNS ca. (glio/astro) U87-MG    | 0                                 | 0                                 |
| CNS ca. (glio/astro) U-118-MG  | 0                                 | 0                                 |
| CNS ca. (astro) SW1783         | 0                                 | 0                                 |
| CNS ca.* (neuro; met ) SK-N-AS | 0                                 | 0                                 |
| CNS ca. (astro) SF-539         | 0                                 | 0                                 |
| CNS ca. (astro) SNB-75         | 0.2                               | 0                                 |
| CNS ca. (glio) SNB-19          | 0                                 | 0                                 |
| CNS ca. (glio) U251            | 0                                 | 0                                 |
| CNS ca. (glio) SF-295          | 0                                 | 0                                 |
| Heart                          | 0                                 | 0                                 |
| Skeletal Muscle (new lot*)     | 0                                 | 0                                 |
| Bone marrow                    | 0.3                               | 0                                 |

|                                     |      |      |
|-------------------------------------|------|------|
| Thymus                              | 0.8  | 0    |
| Spleen                              | 0    | 0    |
| Lymph node                          | 0.2  | 0    |
| Colorectal                          | 0.1  | 0    |
| Stomach                             | 0.3  | 0    |
| Small Intestine                     | 0    | 0    |
| Colon ca. SW480                     | 0    | 0    |
| Colon ca.* (SW480 met)SW620         | 0.1  | 0    |
| Colon ca. HT29                      | 0    | 0    |
| Colon ca. HCT-116                   | 0    | 0    |
| Colon ca. CaCo-2                    | 0    | 0    |
| 83219 CC Well to Mod Diff (ODO3866) | 0    | 0    |
| Colon ca. HCC-2998                  | 0    | 0    |
| Gastric ca.* (liver met) NCI-N87    | 0    | 0    |
| Bladder                             | 1.3  | 0    |
| Trachea                             | 3.7  | 1.2  |
| Kidney                              | 0.4  | 0    |
| Kidney (fetal)                      | 1.7  | 0.2  |
| Renal ca. 786-0                     | 0    | 0    |
| Renal ca. A498                      | 0.1  | 0    |
| Renal ca.RXF 393                    | 0    | 0    |
| Renal ca. ACHN                      | 0    | 0    |
| Renal ca. UO-31                     | 0    | 0    |
| Renal ca. TK-10                     | 0    | 0    |
| Liver                               | 0    | 0    |
| Liver (fetal)                       | 0    | 0    |
| Liver ca. (hepatoblast) HepG2       | 0    | 0    |
| Lung                                | 0    | 0    |
| Lung (fetal)                        | 0    | 0    |
| Lung ca. (small cell) LX-1          | 0.3  | 0    |
| Lung ca. (small cell) NCI-H69       | 1.4  | 0    |
| Lung ca. (s.cell var.) SHP-77       | 0    | 0    |
| Lung ca. (large cell)NCI-H460       | 0.1  | 0    |
| Lung ca. (non-sm. cell) A549        | 0    | 0    |
| Lung ca. (non-s.cell) NCI-H23       | 0    | 0    |
| Lung ca (non-s.cell) HOP-62         | 0    | 0    |
| Lung ca. (non-s.cl) NCI-H522        | 0    | 0    |
| Lung ca. (squam.) SW 900            | 0    | 0    |
| Lung ca. (squam.) NCI-H596          | 0.7  | 0    |
| Mammary gland                       | 5.8  | 2.9  |
| Breast ca.* (pl. effusion) MCF-7    | 0    | 0    |
| Breast ca.* (pl.ef) MDA-MB-231      | 0    | 0    |
| Breast ca.* (pl. effusion) T47D     | 0.2  | 0    |
| Breast ca. BT-549                   | 0    | 0    |
| Breast ca. MDA-N                    | 0    | 0    |
| Ovary                               | 0    | 0    |
| Ovarian ca. OVCAR-3                 | 29.3 | 16.3 |
| Ovarian ca. OVCAR-4                 | 35.6 | 22.2 |
| Ovarian ca. OVCAR-5                 | 0.5  | 0    |
| Ovarian ca.OVCAR-8                  | 0    | 0    |

|                                |      |      |
|--------------------------------|------|------|
| Ovarian ca.IGROV-1             | 0    | 0    |
| Ovarian ca.* (ascites) SK-OV-3 | 0.3  | 0    |
| Uterus                         | 0    | 0    |
| Placenta                       | 1.1  | 0.2  |
| Prostate                       | 3.8  | 0.6  |
| Prostate ca.* (bone met)PC-3   | 0    | 0    |
| Testis                         | 20.6 | 10.5 |
| Melanoma Hs688(A).T            | 0    | 0    |
| Melanoma* (met) Hs688(B).T     | 0    | 0    |
| Melanoma UACC-62               | 0    | 0    |
| Melanoma M14                   | 0    | 0    |
| Melanoma LOX IMVI              | 0    | 0    |
| Melanoma* (met) SK-MEL-5       | 0.2  | 0    |
| Adipose                        | 1.6  | 0    |

Table 14. Panel 1.3D (Ag888)

| Tissue Name              | Rel. Expr., %<br>1.3dx4tm5629f ag888 b2 |
|--------------------------|-----------------------------------------|
| Adipose                  | 0                                       |
| Adrenal gland            | 0                                       |
| Bladder                  | 0                                       |
| Bone marrow              | 0                                       |
| Brain (amygdala)         | 0.1                                     |
| Brain (cerebellum)       | 100                                     |
| Brain (fetal)            | 0.1                                     |
| Brain (hippocampus)      | 0.2                                     |
| Cerebral Cortex          | 0.2                                     |
| Brain (substantia nigra) | 0.4                                     |
| Brain (thalamus)         | 0.1                                     |
| Brain (whole)            | 19.5                                    |
| Colorectal               | 0.1                                     |
| Heart (fetal)            | 0                                       |
| Liver adenocarcinoma     | 0                                       |
| Heart                    | 0                                       |
| Kidney                   | 0.2                                     |
| Kidney (fetal)           | 0                                       |
| Liver                    | 0                                       |
| Liver (fetal)            | 0                                       |
| Lung                     | 0                                       |
| Lung (fetal)             | 0                                       |
| Lymph node               | 0                                       |
| Mammary gland            | 1.2                                     |
| Fetal Skeletal           | 0                                       |
| Ovary                    | 0                                       |
| Pancreas                 | 0                                       |
| Pituitary gland          | 0.3                                     |
| Placenta                 | 1.4                                     |

|                     |      |
|---------------------|------|
| Prostate            | 0.6  |
| Salivary gland      | 1.4  |
| Skeletal muscle     | 0    |
| Small Intestine     | 0    |
| Spinal cord         | 0.1  |
| Spleen              | 0    |
| Stomach             | 0.2  |
| Testis              | 3.5  |
| Thymus              | 1    |
| Thyroid             | 0    |
| Trachea             | 1    |
| Uterus              | 0    |
| genomic DNA control | 93.7 |
| Chemistry Control   | 67.6 |

Table 15. Panel 3D (Ag395)

| Tissue Name                                 | Rel. Expr., %<br>2Dtm2317t ag395 |
|---------------------------------------------|----------------------------------|
| Normal Colon GENPAK 061003                  | 20.2                             |
| 83219 CC Well to Mod Diff (ODO3866)         | 6                                |
| 83220 CC NAT (ODO3866)                      | 5.8                              |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 1.8                              |
| 83222 CC NAT (ODO3868)                      | 1.9                              |
| 83235 CC Mod Diff (ODO3920)                 | 2.2                              |
| 83236 CC NAT (ODO3920)                      | 5.6                              |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 1.2                              |
| 83238 CC NAT (ODO3921)                      | 0.9                              |
| 83241 CC from Partial Hepatectomy (ODO4309) | 0.9                              |
| 83242 Liver NAT (ODO4309)                   | 1.3                              |
| 87472 Colon mets to lung (OD04451-01)       | 2.2                              |
| 87473 Lung NAT (OD04451-02)                 | 5.4                              |
| Normal Prostate Clontech A+ 6546-1          | 43.8                             |
| 84140 Prostate Cancer (OD04410)             | 17.3                             |
| 84141 Prostate NAT (OD04410)                | 15.7                             |
| 87073 Prostate Cancer (OD04720-01)          | 41.2                             |
| 87074 Prostate NAT (OD04720-02)             | 22.8                             |
| Normal Lung GENPAK 061010                   | 2.8                              |
| 83239 Lung Met to Muscle (ODO4286)          | 0                                |
| 83240 Muscle NAT (ODO4286)                  | 66                               |
| 84136 Lung Malignant Cancer (OD03126)       | 3.5                              |
| 84137 Lung NAT (OD03126)                    | 2.9                              |
| 84871 Lung Cancer (OD04404)                 | 46                               |
| 84872 Lung NAT (OD04404)                    | 16.6                             |
| 84875 Lung Cancer (OD04565)                 | 100                              |
| 84876 Lung NAT (OD04565)                    | 3                                |
| 85950 Lung Cancer (OD04237-01)              | 2.6                              |
| 85970 Lung NAT (OD04237-02)                 | 0.6                              |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 1                                |

|                                                         |      |
|---------------------------------------------------------|------|
| 83256 Liver NAT (ODO4310)                               | 0    |
| 84139 Melanoma Mets to Lung (OD04321)                   | 3.5  |
| 84138 Lung NAT (OD04321)                                | 0.8  |
| Normal Kidney GENPAK 061008                             | 11.3 |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)              | 6.2  |
| 83787 Kidney NAT (OD04338)                              | 3.6  |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339)             | 23.8 |
| 83789 Kidney NAT (OD04339)                              | 15   |
| 83790 Kidney Ca, Clear cell type (OD04340)              | 3.2  |
| 83791 Kidney NAT (OD04340)                              | 11.9 |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)              | 1.3  |
| 83793 Kidney NAT (OD04348)                              | 12.2 |
| 87474 Kidney Cancer (OD04622-01)                        | 4.9  |
| 87475 Kidney NAT (OD04622-03)                           | 3.1  |
| 85973 Kidney Cancer (OD04450-01)                        | 0.5  |
| 85974 Kidney NAT (OD04450-03)                           | 7.4  |
| Kidney Cancer Clontech 8120607                          | 3    |
| Kidney NAT Clontech 8120608                             | 1.1  |
| Kidney Cancer Clontech 8120613                          | 0.9  |
| Kidney NAT Clontech 8120614                             | 2    |
| Kidney Cancer Clontech 9010320                          | 13.1 |
| Kidney NAT Clontech 9010321                             | 11.5 |
| Normal Uterus GENPAK 061018                             | 2.9  |
| Uterus Cancer GENPAK 064011                             | 21.3 |
| Normal Thyroid Clontech A+ 6570-1                       | 0.8  |
| Thyroid Cancer GENPAK 064010                            | 2.5  |
| Thyroid Cancer INVITROGEN A302152                       | 3    |
| Thyroid NAT INVITROGEN A302153                          | 0    |
| Normal Breast GENPAK 061019                             | 44.1 |
| 84877 Breast Cancer (OD04566)                           | 5.3  |
| 85975 Breast Cancer (OD04590-01)                        | 10.8 |
| 85976 Breast Cancer Mets (OD04590-03)                   | 6.4  |
| 87070 Breast Cancer Metastasis (OD04655-05)             | 1.4  |
| GENPAK Breast Cancer 064006                             | 13.1 |
| Breast Cancer Res. Gen. 1024                            | 62   |
| Breast Cancer Clontech 9100266                          | 10   |
| Breast NAT Clontech 9100265                             | 12.9 |
| Breast Cancer INVITROGEN A209073                        | 25.2 |
| Breast NAT INVITROGEN A2090734                          | 61.1 |
| Normal Liver GENPAK 061009                              | 5.4  |
| Liver Cancer GENPAK 064003                              | 2.6  |
| Liver Cancer Research Genetics RNA 1025                 | 1    |
| Liver Cancer Research Genetics RNA 1026                 | 0.9  |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 9.7  |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 3.1  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 0    |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0    |
| Normal Bladder GENPAK 061001                            | 9    |
| Bladder Cancer Research Genetics RNA 1023               | 2.4  |
| Bladder Cancer INVITROGEN A302173                       | 21.8 |

|                                            |      |
|--------------------------------------------|------|
| 87071 Bladder Cancer (OD04718-01)          | 46.7 |
| 87072 Bladder Normal Adjacent (OD04718-03) | 4.1  |
| Normal Ovary Res. Gen.                     | 0    |
| Ovarian Cancer GENPAK 064008               | 65.1 |
| 87492 Ovary Cancer (OD04768-07)            | 33   |
| 87493 Ovary NAT (OD04768-08)               | 0    |
| Normal Stomach GENPAK 061017               | 2.4  |
| Gastric Cancer Clontech 9060358            | 1.5  |
| NAT Stomach Clontech 9060359               | 1.4  |
| Gastric Cancer Clontech 9060395            | 2.3  |
| NAT Stomach Clontech 9060394               | 0.8  |
| Gastric Cancer Clontech 9060397            | 6.6  |
| NAT Stomach Clontech 9060396               | 0    |
| Gastric Cancer GENPAK 064005               | 4.5  |

Table 16. Panel 2D (Ag888)

| Tissue Name                                 | Rel. Expr., %<br>2dtm2313f ag888 | Rel. Expr., %<br>2Dtm2409f ag888 |
|---------------------------------------------|----------------------------------|----------------------------------|
| Normal Colon GENPAK 061003                  | 10.7                             | 5.6                              |
| 83219 CC Well to Mod Diff (ODO3866)         | 0.5                              | 0.5                              |
| 83220 CC NAT (ODO3866)                      | 0                                | 0                                |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 0.7                              | 0.2                              |
| 83222 CC NAT (ODO3868)                      | 0.6                              | 0.7                              |
| 83235 CC Mod Diff (ODO3920)                 | 2                                | 0.7                              |
| 83236 CC NAT (ODO3920)                      | 1.1                              | 1.1                              |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 0.3                              | 0                                |
| 83238 CC NAT (ODO3921)                      | 0.8                              | 0.9                              |
| 83241 CC from Partial Hepatectomy (ODO4309) | 0.7                              | 0.2                              |
| 83242 Liver NAT (ODO4309)                   | 0.9                              | 0                                |
| 87472 Colon mets to lung (OD04451-01)       | 0.7                              | 0.4                              |
| 87473 Lung NAT (OD04451-02)                 | 0.6                              | 0.2                              |
| Normal Prostate Clontech A+ 6546-1          | 29.3                             | 21                               |
| 84140 Prostate Cancer (OD04410)             | 9.3                              | 5.2                              |
| 84141 Prostate NAT (OD04410)                | 8.9                              | 12.2                             |
| 87073 Prostate Cancer (OD04720-01)          | 37.9                             | 41.2                             |
| 87074 Prostate NAT (OD04720-02)             | 37.1                             | 33.2                             |
| Normal Lung GENPAK 061010                   | 4.5                              | 3                                |
| 83239 Lung Met to Muscle (ODO4286)          | 1.3                              | 1.3                              |
| 83240 Muscle NAT (ODO4286)                  | 24                               | 16.7                             |
| 84136 Lung Malignant Cancer (OD03126)       | 4.4                              | 2.4                              |
| 84137 Lung NAT (OD03126)                    | 1.8                              | 0.2                              |
| 84871 Lung Cancer (OD04404)                 | 100                              | 30.4                             |
| 84872 Lung NAT (OD04404)                    | 5.9                              | 1.7                              |
| 84875 Lung Cancer (OD04565)                 | 65.5                             | 100                              |
| 84876 Lung NAT (OD04565)                    | 0.8                              | 2                                |
| 85950 Lung Cancer (OD04237-01)              | 0.9                              | 1.2                              |
| 85970 Lung NAT (OD04237-02)                 | 0.9                              | 0.2                              |



|                                                         |      |      |
|---------------------------------------------------------|------|------|
| 83255 Ocular Mel Met to Liver (ODO4310)                 | 0.7  | 0.9  |
| 83256 Liver NAT (ODO4310)                               | 0    | 0    |
| 84139 Melanoma Mets to Lung (OD04321)                   | 1.1  | 0.3  |
| 84138 Lung NAT (OD04321)                                | 1.2  | 0.5  |
| Normal Kidney GENPAK 061008                             | 10.3 | 3    |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)              | 2.3  | 2.4  |
| 83787 Kidney NAT (OD04338)                              | 3.4  | 1.4  |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339)             | 4.4  | 3.3  |
| 83789 Kidney NAT (OD04339)                              | 5.8  | 5.5  |
| 83790 Kidney Ca, Clear cell type (OD04340)              | 1    | 2.4  |
| 83791 Kidney NAT (OD04340)                              | 9.8  | 4    |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)              | 2    | 1.9  |
| 83793 Kidney NAT (OD04348)                              | 2.7  | 3    |
| 87474 Kidney Cancer (OD04622-01)                        | 2.5  | 4.8  |
| 87475 Kidney NAT (OD04622-03)                           | 3.2  | 4.4  |
| 85973 Kidney Cancer (OD04450-01)                        | 1.6  | 0.1  |
| 85974 Kidney NAT (OD04450-03)                           | 3    | 0.8  |
| Kidney Cancer Clontech 8120607                          | 2.7  | 0.4  |
| Kidney NAT Clontech 8120608                             | 0.4  | 1.9  |
| Kidney Cancer Clontech 8120613                          | 0    | 0.4  |
| Kidney NAT Clontech 8120614                             | 0    | 0.3  |
| Kidney Cancer Clontech 9010320                          | 2.4  | 0.9  |
| Kidney NAT Clontech 9010321                             | 2.3  | 3.1  |
| Normal Uterus GENPAK 061018                             | 0.1  | 1.1  |
| Uterus Cancer GENPAK 064011                             | 23.2 | 21.2 |
| Normal Thyroid Clontech A+ 6570-1                       | 0.7  | 0.7  |
| Thyroid Cancer GENPAK 064010                            | 3.2  | 1.5  |
| Thyroid Cancer INVITROGEN A302152                       | 0.7  | 1.5  |
| Thyroid NAT INVITROGEN A302153                          | 0.4  | 0.5  |
| Normal Breast GENPAK 061019                             | 9.2  | 16.6 |
| 84877 Breast Cancer (OD04566)                           | 1.7  | 3.8  |
| 85975 Breast Cancer (OD04590-01)                        | 1.2  | 1.2  |
| 85976 Breast Cancer Mets (OD04590-03)                   | 3.1  | 3.3  |
| 87070 Breast Cancer Metastasis (OD04655-05)             | 0.2  | 1.4  |
| GENPAK Breast Cancer 064006                             | 13.7 | 5.5  |
| Breast Cancer Res. Gen. 1024                            | 55.9 | 23.3 |
| Breast Cancer Clontech 9100266                          | 22.4 | 14.4 |
| Breast NAT Clontech 9100265                             | 36.6 | 28.5 |
| Breast Cancer INVITROGEN A209073                        | 43.8 | 44.8 |
| Breast NAT INVITROGEN A2090734                          | 100  | 20.7 |
| Normal Liver GENPAK 061009                              | 0    | 0.4  |
| Liver Cancer GENPAK 064003                              | 1    | 0    |
| Liver Cancer Research Genetics RNA 1025                 | 0.4  | 0.3  |
| Liver Cancer Research Genetics RNA 1026                 | 0    | 0    |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 0    | 0    |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 0.6  | 0.2  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 0.3  | 0.3  |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0    | 0    |
| Normal Bladder GENPAK 061001                            | 2.5  | 3.1  |
| Bladder Cancer Research Genetics RNA 1023               | 0.4  | 0.3  |

|                                            |      |      |
|--------------------------------------------|------|------|
| Bladder Cancer INVITROGEN A302173          | 33.4 | 11.9 |
| 87071 Bladder Cancer (OD04718-01)          | 75.3 | 68.3 |
| 87072 Bladder Normal Adjacent (OD04718-03) | 1.6  | 0.5  |
| Normal Ovary Res. Gen.                     | 0.4  | 0    |
| Ovarian Cancer GENPAK 064008               | 91.4 | 50.3 |
| 87492 Ovary Cancer (OD04768-07)            | 17.9 | 10.8 |
| 87493 Ovary NAT (OD04768-08)               | 0    | 0.2  |
| Normal Stomach GENPAK 061017               | 2.1  | 1.6  |
| Gastric Cancer Clontech 9060358            | 0.7  | 0    |
| NAT Stomach Clontech 9060359               | 0.4  | 0.4  |
| Gastric Cancer Clontech 9060395            | 0.4  | 0.2  |
| NAT Stomach Clontech 9060394               | 0.3  | 0.7  |
| Gastric Cancer Clontech 9060397            | 2.8  | 0.8  |
| NAT Stomach Clontech 9060396               | 0    | 0.2  |
| Gastric Cancer GENPAK 064005               | 1.5  | 0.3  |

### NOV3

Expression of gene NOV3 was assessed using the primer-probe set Ag784, described  
 5 in Table 17. Results from RTQ-PCR runs are shown in Tables 12, 13, 14, 15 and 16.

**Table 17. Probe and Primer Ag784**

| Primers | Sequences                                          | TM   | Length | Start Position | SEQ ID NO: |
|---------|----------------------------------------------------|------|--------|----------------|------------|
| Forward | 5'-GTCCTGGGATGTGTGAGAGAT-3'                        | 59   | 21     | 1147           | 59         |
| Probe   | FAM-5'-<br>CAGAGAGACGCAGCTCCTCCAAGAA<br>G-3'-TAMRA | 69.8 | 26     | 1174           | 60         |
| Reverse | 5'-GAACAACCTCACAGAGCTTCAG-3'                       | 59.1 | 22     | 1223           | 61         |

10

**Table 18. Panel 1.2**

| Tissue Name              | Rel. Expr., %<br>1.2tm924f ag784 | Rel. Expr., %<br>1.2tm1115f ag784 |
|--------------------------|----------------------------------|-----------------------------------|
| Endothelial cells        | 0                                | 0                                 |
| Heart (fetal)            | 0.4                              | 13.1                              |
| Pancreas                 | 0                                | 0                                 |
| Pancreatic ca. CAPAN 2   | 7.3                              | 0                                 |
| Adrenal Gland (new lot*) | 0                                | 0                                 |
| Thyroid                  | 22.5                             | 0                                 |
| Salivary gland           | 15.2                             | 15.6                              |
| Pituitary gland          | 100                              | 14                                |
| Brain (fetal)            | 2.5                              | 0                                 |
| Brain (whole)            | 11.3                             | 0                                 |
| Brain (amygdala)         | 0                                | 0                                 |
| Brain (cerebellum)       | 20.4                             | 26.2                              |

|                                     |      |      |
|-------------------------------------|------|------|
| Brain (hippocampus)                 | 0.3  | 0    |
| Brain (thalamus)                    | 3.6  | 0    |
| Cerebral Cortex                     | 0.2  | 0    |
| Spinal cord                         | 0    | 0    |
| CNS ca. (glio/astro) U87-MG         | 0    | 0    |
| CNS ca. (glio/astro) U-118-MG       | 0    | 0    |
| CNS ca. (astro) SW1783              | 0    | 0    |
| CNS ca.* (neuro; met) SK-N-AS       | 0    | 0    |
| CNS ca. (astro) SF-539              | 0    | 0    |
| CNS ca. (astro) SNB-75              | 0    | 0    |
| CNS ca. (glio) SNB-19               | 0    | 0    |
| CNS ca. (glio) U251                 | 0    | 0    |
| CNS ca. (glio) SF-295               | 0    | 0    |
| Heart                               | 5.4  | 2.1  |
| Skeletal Muscle (new lot*)          | 0    | 0    |
| Bone marrow                         | 0    | 0    |
| Thymus                              | 0    | 0    |
| Spleen                              | 5.7  | 0    |
| Lymph node                          | 0    | 0    |
| Colorectal                          | 0    | 1.3  |
| Stomach                             | 0    | 0    |
| Small intestine                     | 0    | 0    |
| Colon ca. SW480                     | 19.1 | 18.7 |
| Colon ca.* (SW480 met)SW620         | 56.6 | 8.5  |
| Colon ca. HT29                      | 0    | 0    |
| Colon ca. HCT-116                   | 0    | 0    |
| Colon ca. CaCo-2                    | 0    | 0    |
| 83219 CC Well to Mod Diff (ODO3866) | 0    | 0.9  |
| Colon ca. HCC-2998                  | 1.6  | 0    |
| Gastric ca.* (liver met) NCI-N87    | 20.7 | 21.3 |
| Bladder                             | 0    | 0    |
| Trachea                             | 9.7  | 11.3 |
| Kidney                              | 0    | 0    |
| Kidney (fetal)                      | 0    | 0    |
| Renal ca. 786-0                     | 0    | 0    |
| Renal ca. A498                      | 0    | 0    |
| Renal ca. RXF 393                   | 0    | 0    |
| Renal ca. ACHN                      | 0    | 0    |
| Renal ca. UO-31                     | 0    | 0    |
| Renal ca. TK-10                     | 0    | 0    |
| Liver                               | 0    | 0    |
| Liver (fetal)                       | 0    | 0    |
| Liver ca. (hepatoblast) HepG2       | 0    | 0    |
| Lung                                | 1.2  | 0    |
| Lung (fetal)                        | 0    | 0    |
| Lung ca. (small cell) LX-1          | 45.4 | 20.9 |
| Lung ca. (small cell) NCI-H69       | 28.1 | 55.9 |
| Lung ca. (s.cell var.) SHP-77       | 0    | 0    |
| Lung ca. (large cell)NCI-H460       | 0    | 0    |
| Lung ca. (non-sm. cell) A549        | 27.4 | 49   |

|                                  |      |      |
|----------------------------------|------|------|
| Lung ca. (non-s.cell) NCI-H23    | 0    | 0    |
| Lung ca (non-s.cell) HOP-62      | 0    | 0    |
| Lung ca. (non-s.cl) NCI-H522     | 0    | 0    |
| Lung ca. (squam.) SW 900         | 6.4  | 0.5  |
| Lung ca. (squam.) NCI-H596       | 64.6 | 100  |
| Mammary gland                    | 16   | 19.6 |
| Breast ca.* (pl. effusion) MCF-7 | 0    | 0    |
| Breast ca.* (pl.ef) MDA-MB-231   | 0    | 0    |
| Breast ca.* (pl. effusion) T47D  | 0    | 0    |
| Breast ca. BT-549                | 0    | 0    |
| Breast ca.MDA-N                  | 0    | 0    |
| Ovary                            | 0    | 0    |
| Ovarian ca.OVCAR-3               | 0.2  | 0    |
| Ovarian ca. OVCAR-4              | 0    | 0    |
| Ovarian ca. OVCAR-5              | 0.6  | 0    |
| Ovarian ca. OVCAR-8              | 0    | 0    |
| Ovarian ca. IGROV-1              | 0    | 0    |
| Ovarian ca.* (ascites) SK-OV-3   | 1    | 0    |
| Uterus                           | 0    | 0    |
| Placenta                         | 0    | 0    |
| Prostate                         | 2.3  | 7.7  |
| Prostate ca.* (bone met)PC-3     | 0    | 0    |
| Testis                           | 0    | 0    |
| Melanoma Hs688(A).T              | 0    | 0    |
| Melanoma* (met) Hs688(B).T       | 0    | 0    |
| Melanoma UACC-62                 | 0    | 0    |
| Melanoma M14                     | 0    | 0    |
| Melanoma LOX IMVI                | 0    | 0    |
| Melanoma* (met) SK-MEL-5         | 0    | 0    |
| Adipose                          | 0    | 0    |

Table 19. Panel 2D

| Tissue Name                                 | Rel. Expr., %<br>2dtm2311f ag784 |
|---------------------------------------------|----------------------------------|
| Normal Colon GENPAK 061003                  | 23.8                             |
| 83219 CC Well to Mod Diff (ODO3866)         | 22.1                             |
| 83220 CC NAT (ODO3866)                      | 12.5                             |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 12                               |
| 83222 CC NAT (ODO3868)                      | 1.7                              |
| 83235 CC Mod Diff (ODO3920)                 | 8.1                              |
| 83236 CC NAT (ODO3920)                      | 9                                |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 3.1                              |
| 83238 CC NAT (ODO3921)                      | 1.3                              |
| 83241 CC from Partial Hepatectomy (ODO4309) | 69.7                             |
| 83242 Liver NAT (ODO4309)                   | 4.5                              |
| 87472 Colon mets to lung (OD04451-01)       | 21.2                             |
| 87473 Lung NAT (OD04451-02)                 | 12.2                             |

|                                             |      |
|---------------------------------------------|------|
| Normal Prostate Clontech A+ 6546-1          | 32.1 |
| 84140 Prostate Cancer (OD04410)             | 8.3  |
| 84141 Prostate NAT (OD04410)                | 69.3 |
| 87073 Prostate Cancer (OD04720-01)          | 11.7 |
| 87074 Prostate NAT (OD04720-02)             | 40.3 |
| Normal Lung GENPAK 061010                   | 47   |
| 83239 Lung Met to Muscle (ODO4286)          | 0    |
| 83240 Muscle NAT (ODO4286)                  | 2.2  |
| 84136 Lung Malignant Cancer (OD03126)       | 31   |
| 84137 Lung NAT (OD03126)                    | 21.9 |
| 84871 Lung Cancer (OD04404)                 | 3.2  |
| 84872 Lung NAT (OD04404)                    | 24.5 |
| 84875 Lung Cancer (OD04565)                 | 3.1  |
| 84876 Lung NAT (OD04565)                    | 7.9  |
| 85950 Lung Cancer (OD04237-01)              | 37.9 |
| 85970 Lung NAT (OD04237-02)                 | 15.6 |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 0    |
| 83256 Liver NAT (ODO4310)                   | 12.4 |
| 84139 Melanoma Mets to Lung (OD04321)       | 2.5  |
| 84138 Lung NAT (OD04321)                    | 47.3 |
| Normal Kidney GENPAK 061008                 | 13.3 |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)  | 0    |
| 83787 Kidney NAT (OD04338)                  | 11.5 |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339) | 1.3  |
| 83789 Kidney NAT (OD04339)                  | 5.6  |
| 83790 Kidney Ca, Clear cell type (OD04340)  | 4.2  |
| 83791 Kidney NAT (OD04340)                  | 18.3 |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)  | 1.9  |
| 83793 Kidney NAT (OD04348)                  | 7.8  |
| 87474 Kidney Cancer (OD04622-01)            | 4.1  |
| 87475 Kidney NAT (OD04622-03)               | 3.8  |
| 85973 Kidney Cancer (OD04450-01)            | 2.1  |
| 85974 Kidney NAT (OD04450-03)               | 8.3  |
| Kidney Cancer Clontech 8120607              | 0    |
| Kidney NAT Clontech 8120608                 | 3.7  |
| Kidney Cancer Clontech 8120613              | 0    |
| Kidney NAT Clontech 8120614                 | 7.2  |
| Kidney Cancer Clontech 9010320              | 3.5  |
| Kidney NAT Clontech 9010321                 | 5    |
| Normal Uterus GENPAK 061018                 | 0    |
| Uterus Cancer GENPAK 064011                 | 5.9  |
| Normal Thyroid Clontech A+ 6570-1           | 54.3 |
| Thyroid Cancer GENPAK 064010                | 7    |
| Thyroid Cancer INVITROGEN A302152           | 9.9  |
| Thyroid NAT INVITROGEN A302153              | 32.3 |
| Normal Breast GENPAK 061019                 | 76.3 |
| 84877 Breast Cancer (OD04566)               | 1.3  |
| 85975 Breast Cancer (OD04590-01)            | 2.2  |
| 85976 Breast Cancer Mets (OD04590-03)       | 10.2 |
| 87070 Breast Cancer Metastasis (OD04655-05) | 2.1  |

|                                                         |      |
|---------------------------------------------------------|------|
| GENPAK Breast Cancer 064006                             | 16.5 |
| Breast Cancer Res. Gen. 1024                            | 69.3 |
| Breast Cancer Clontech 9100266                          | 32.3 |
| Breast NAT Clontech 9100265                             | 45.7 |
| Breast Cancer INVITROGEN A209073                        | 39.5 |
| Breast NAT INVITROGEN A2090734                          | 100  |
| Normal Liver GENPAK 061009                              | 6.2  |
| Liver Cancer GENPAK 064003                              | 3.1  |
| Liver Cancer Research Genetics RNA 1025                 | 4.1  |
| Liver Cancer Research Genetics RNA 1026                 | 5.6  |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 8.4  |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 3.5  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 9.9  |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 7    |
| Normal Bladder GENPAK 061001                            | 2.4  |
| Bladder Cancer Research Genetics RNA 1023               | 12.5 |
| Bladder Cancer INVITROGEN A302173                       | 4.3  |
| 87071 Bladder Cancer (OD04718-01)                       | 6.7  |
| 87072 Bladder Normal Adjacent (OD04718-03)              | 2.1  |
| Normal Ovary Res. Gen.                                  | 7.5  |
| Ovarian Cancer GENPAK 064008                            | 84.7 |
| 87492 Ovary Cancer (OD04768-07)                         | 1.4  |
| 87493 Ovary NAT (OD04768-08)                            | 2.5  |
| Normal Stomach GENPAK 061017                            | 9.9  |
| Gastric Cancer Clontech 9060358                         | 2.2  |
| NAT Stomach Clontech 9060359                            | 2.3  |
| Gastric Cancer Clontech 9060395                         | 84.7 |
| NAT Stomach Clontech 9060394                            | 25.5 |
| Gastric Cancer Clontech 9060397                         | 17   |
| NAT Stomach Clontech 9060396                            | 2.6  |
| Gastric Cancer GENPAK 064005                            | 3.8  |

#### NOV4

Expression of gene NOV4 was assessed using the primer-probe set Ag273, described  
 5 in Table 20. Results from RTQ-PCR runs are shown in Tables 21 and 22.

**Table 20. Probe and Primer Ag273**

| Primers | Sequences                                                | TM | Length | Start Position | SEQ ID NO: |
|---------|----------------------------------------------------------|----|--------|----------------|------------|
| Forward | 5'-CGGCTTGACGATGCTTCAC-3'                                |    | 19     |                | 62         |
| Probe   | FAM-5'-<br>TGACTTTTCTGGGCTTACCAATGCTAT<br>TTCAA-3'-TAMRA |    | 32     |                | 63         |
| Reverse | 5'-<br>GCACCTATCTCAATATCTGCAATATT                        |    | 27     |                | 64         |

|  |      |  |  |  |  |
|--|------|--|--|--|--|
|  | G-3' |  |  |  |  |
|--|------|--|--|--|--|

Table 21: Panel 1

| Tissue Name                   | Rel. Expr., %<br>tm379f | Rel. Expr., %<br>tm444f | Rel. Expr., %<br>tm566f_ag273b |
|-------------------------------|-------------------------|-------------------------|--------------------------------|
| Endothelial cells             | 0                       | 0                       | 0                              |
| Endothelial cells (treated)   | 0                       | 0                       | 0                              |
| Pancreas                      | 0                       | 0                       | 0                              |
| Pancreatic ca. CAPAN 2        | 0                       | 0                       | 0                              |
| Adipose                       | 0                       | 1.1                     | 26.6                           |
| Adrenal gland                 | 0                       | 0                       | 0                              |
| Thyroid                       | 0                       | 0                       | 0                              |
| Salivary gland                | 10                      | 14                      | 12.9                           |
| Pituitary gland               | 0                       | 0                       | 0                              |
| Brain (fetal)                 | 0                       | 0.2                     | 0                              |
| Brain (whole)                 | 0                       | 0.2                     | 0.2                            |
| Brain (amygdala)              | 0                       | 0                       | 0                              |
| Brain (cerebellum)            | 2.6                     | 11.3                    | 1.6                            |
| Brain (hippocampus)           | 0                       | 0                       | 0                              |
| Brain (substantia nigra)      | 0                       | 0.2                     | 0                              |
| Brain (thalamus)              | 0                       | 2.3                     | 2.9                            |
| Brain (hypothalamus)          | 0                       | 0                       | 0                              |
| Spinal cord                   | 0                       | 0                       | 0                              |
| CNS ca. (glio/astro) U87-MG   | 0                       | 0                       | 0                              |
| CNS ca. (glio/astro) U-118-MG | 0                       | 0                       | 0                              |
| CNS ca. (astro) SW1783        | 0                       | 0                       | 0                              |
| CNS ca.* (neuro; met) SK-N-AS | 2.7                     | 5                       | 6.6                            |
| CNS ca. (astro) SF-539        | 0                       | 0                       | 0                              |
| CNS ca. (astro) SNB-75        | 3.4                     | 16.3                    | 10.2                           |
| CNS ca. (glio) SNB-19         | 21.5                    | 24.1                    | 24.3                           |
| CNS ca. (glio) U251           | 0.2                     | 2.2                     | 4.2                            |
| CNS ca. (glio) SF-295         | 19.9                    | 22.7                    | 37.6                           |
| Heart                         | 0                       | 0.8                     | 1.5                            |
| Skeletal muscle               | 0                       | 0                       | 0                              |
| Bone marrow                   | 0                       | 0.3                     | 0                              |
| Thymus                        | 0                       | 0                       | 0.4                            |
| Spleen                        | 0                       | 0                       | 0                              |
| Lymph node                    | 0                       | 0                       | 0                              |
| Colon (ascending)             | 1                       | 8.6                     | 9.9                            |
| Stomach                       | 3.1                     | 6                       | 0.4                            |
| Small intestine               | 2.1                     | 5.7                     | 4.2                            |
| Colon ca. SW480               | 0                       | 0                       | 0                              |
| Colon ca.* (SW480 met)SW620   | 0                       | 0                       | 0                              |
| Colon ca. HT29                | 12                      | 10.4                    | 34.4                           |
| Colon ca. HCT-116             | 0                       | 0                       | 0                              |
| Colon ca. CaCo-2              | 0                       | 0                       | 0                              |
| Colon ca. HCT-15              | 0                       | 0                       | 0                              |

|                                  |      |      |      |
|----------------------------------|------|------|------|
| Colon ca. HCC-2998               | 0    | 0    | 0    |
| Gastric ca.* (liver met) NCI-N87 | 3.1  | 6.9  | 1.3  |
| Bladder                          | 2.4  | 14   | 0.1  |
| Trachea                          | 0.4  | 1.7  | 8.9  |
| Kidney                           | 0    | 0    | 0.2  |
| Kidney (fetal)                   | 0    | 1.5  | 1.3  |
| Renal ca. 786-0                  | 0    | 0    | 0    |
| Renal ca. A498                   | 0    | 0    | 0    |
| Renal ca. RXF 393                | 0    | 0    | 0    |
| Renal ca. ACHN                   | 0    | 0    | 0    |
| Renal ca. UO-31                  | 0    | 0    | 0    |
| Renal ca. TK-10                  | 0    | 0    | 0    |
| Liver                            | 0.1  | 2.3  | 0    |
| Liver (fetal)                    | 0    | 0.8  | 0    |
| Liver ca. (hepatoblast) HepG2    | 0    | 0    | 0    |
| Lung                             | 0    | 2    | 0.5  |
| Lung (fetal)                     | 0.9  | 6.7  | 2.2  |
| Lung ca. (small cell) LX-1       | 0    | 0    | 0    |
| Lung ca. (small cell) NCI-H69    | 0    | 1.8  | 2.7  |
| Lung ca. (s.cell var.) SHP-77    | 100  | 100  | 44.1 |
| Lung ca. (large cell) NCI-H460   | 0    | 0    | 0    |
| Lung ca. (non-sm. cell) A549     | 0    | 0.4  | 0    |
| Lung ca. (non-s.cell) NCI-H23    | 0    | 5.2  | 14.7 |
| Lung ca (non-s.cell) HOP-62      | 0    | 2.5  | 12.2 |
| Lung ca. (non-s.cl) NCI-H522     | 0    | 0    | 0.2  |
| Lung ca. (squam.) SW 900         | 8.4  | 9.8  | 11.9 |
| Lung ca. (squam.) NCI-H596       | 0    | 1.9  | 2.5  |
| Mammary gland                    | 0    | 1.3  | 4.8  |
| Breast ca.* (pl. effusion) MCF-7 | 0    | 0.2  | 0.4  |
| Breast ca.* (pl.ef) MDA-MB-231   | 0    | 0    | 0    |
| Breast ca.* (pl. effusion) T47D  | 0.1  | 4.6  | 7.2  |
| Breast ca. BT-549                | 0    | 0.7  | 0    |
| Breast ca. MDA-N                 | 0    | 0    | 0    |
| Ovary                            | 0    | 0    | 0    |
| Ovarian ca. OVCAR-3              | 0    | 0    | 0    |
| Ovarian ca. OVCAR-4              | 0    | 0    | 0    |
| Ovarian ca. OVCAR-5              | 8.8  | 7.2  | 6.2  |
| Ovarian ca. OVCAR-8              | 0    | 0    | 0    |
| Ovarian ca. IGROV-1              | 0    | 0    | 0    |
| Ovarian ca.* (ascites) SK-OV-3   | 0    | 0    | 0    |
| Uterus                           | 0    | 0    | 0    |
| Placenta                         | 0    | 0.2  | 0.8  |
| Prostate                         | 2.8  | 5.2  | 3.6  |
| Prostate ca.* (bone met) PC-3    | 24.5 | 21.9 | 100  |
| Testis                           | 0    | 0.4  | 0    |
| Melanoma Hs688(A).T              | 0    | 0    | 0    |
| Melanoma* (met) Hs688(B).T       | 0    | 0    | 0    |
| Melanoma UACC-62                 | 1.2  | 2.7  | 0.3  |
| Melanoma M14                     | 0    | 0    | 0    |
| Melanoma LOX IMVI                | 0    | 0    | 0    |



|                          |   |   |     |
|--------------------------|---|---|-----|
| Melanoma* (met) SK-MEL-5 | 0 | 0 | 0   |
| Melanoma SK-MEL-28       | 0 | 0 | 0.2 |

Table 22: Panel 2D

| Tissue Name                                 | Rel. Expr., %<br>2Dtm2301f ag273 | Rel. Expr., %<br>2Dtm3156f ag273 |
|---------------------------------------------|----------------------------------|----------------------------------|
| Normal Colon GENPAK 061003                  | 13.4                             | 14.4                             |
| 83219 CC Well to Mod Diff (ODO3866)         | 0.2                              | 0.2                              |
| 83220 CC NAT (ODO3866)                      | 2.9                              | 1.5                              |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 0                                | 0                                |
| 83222 CC NAT (ODO3868)                      | 0.2                              | 0.2                              |
| 83235 CC Mod Diff (ODO3920)                 | 0.3                              | 0.2                              |
| 83236 CC NAT (ODO3920)                      | 0.8                              | 0.6                              |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 3.3                              | 2.7                              |
| 83238 CC NAT (ODO3921)                      | 1.8                              | 3                                |
| 83241 CC from Partial Hepatectomy (ODO4309) | 0                                | 0.2                              |
| 83242 Liver NAT (ODO4309)                   | 0.2                              | 0.4                              |
| 87472 Colon mets to lung (OD04451-01)       | 0                                | 0.2                              |
| 87473 Lung NAT (OD04451-02)                 | 2                                | 1.3                              |
| Normal Prostate Clontech A+ 6546-1          | 7.5                              | 4                                |
| 84140 Prostate Cancer (OD04410)             | 2.8                              | 2.2                              |
| 84141 Prostate NAT (OD04410)                | 7.7                              | 8.4                              |
| 87073 Prostate Cancer (OD04720-01)          | 5.7                              | 6.4                              |
| 87074 Prostate NAT (OD04720-02)             | 17.9                             | 18.2                             |
| Normal Lung GENPAK 061010                   | 4                                | 4.2                              |
| 83239 Lung Met to Muscle (ODO4286)          | 0                                | 0.2                              |
| 83240 Muscle NAT (ODO4286)                  | 0                                | 0                                |
| 84136 Lung Malignant Cancer (OD03126)       | 11                               | 8.9                              |
| 84137 Lung NAT (OD03126)                    | 2.1                              | 2.3                              |
| 84871 Lung Cancer (OD04404)                 | 19.9                             | 21.6                             |
| 84872 Lung NAT (OD04404)                    | 3.5                              | 1.6                              |
| 84875 Lung Cancer (OD04565)                 | 0.6                              | 1                                |
| 84876 Lung NAT (OD04565)                    | 0.5                              | 0.6                              |
| 85950 Lung Cancer (OD04237-01)              | 21.9                             | 14.4                             |
| 85970 Lung NAT (OD04237-02)                 | 1.4                              | 1.2                              |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 0                                | 0                                |
| 83256 Liver NAT (ODO4310)                   | 0.4                              | 0.3                              |
| 84139 Melanoma Mets to Lung (OD04321)       | 0.6                              | 0.6                              |
| 84138 Lung NAT (OD04321)                    | 3.3                              | 2.3                              |
| Normal Kidney GENPAK 061008                 | 0.2                              | 0.2                              |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)  | 0                                | 0                                |
| 83787 Kidney NAT (OD04338)                  | 0.3                              | 0.3                              |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339) | 0                                | 0                                |
| 83789 Kidney NAT (OD04339)                  | 0                                | 0.2                              |
| 83790 Kidney Ca, Clear cell type (OD04340)  | 0.6                              | 0.3                              |
| 83791 Kidney NAT (OD04340)                  | 0.2                              | 0.1                              |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)  | 0                                | 0                                |

|                                                         |      |     |
|---------------------------------------------------------|------|-----|
| 83793 Kidney NAT (OD04348)                              | 0    | 0.2 |
| 87474 Kidney Cancer (OD04622-01)                        | 0.4  | 0.4 |
| 87475 Kidney NAT (OD04622-03)                           | 0    | 0   |
| 85973 Kidney Cancer (OD04450-01)                        | 0    | 0   |
| 85974 Kidney NAT (OD04450-03)                           | 0.2  | 0   |
| Kidney Cancer Clontech 8120607                          | 0.4  | 0.6 |
| Kidney NAT Clontech 8120608                             | 0    | 0   |
| Kidney Cancer Clontech 8120613                          | 0    | 0   |
| Kidney NAT Clontech 8120614                             | 0    | 0   |
| Kidney Cancer Clontech 9010320                          | 0    | 0   |
| Kidney NAT Clontech 9010321                             | 0    | 0   |
| Normal Uterus GENPAK 061018                             | 0.6  | 0   |
| Uterus Cancer GENPAK 064011                             | 0.8  | 0.6 |
| Normal Thyroid Clontech A+ 6570-1                       | 0.9  | 0.3 |
| Thyroid Cancer GENPAK 064010                            | 0.1  | 0.1 |
| Thyroid Cancer INVITROGEN A302152                       | 0    | 0   |
| Thyroid NAT INVITROGEN A302153                          | 0.6  | 0.6 |
| Normal Breast GENPAK 061019                             | 11.4 | 7   |
| 84877 Breast Cancer (OD04566)                           | 0.8  | 0.6 |
| 85975 Breast Cancer (OD04590-01)                        | 5.1  | 3.9 |
| 85976 Breast Cancer Mets (OD04590-03)                   | 2.9  | 1.6 |
| 87070 Breast Cancer Metastasis (OD04655-05)             | 100  | 100 |
| GENPAK Breast Cancer 064006                             | 3.9  | 2.7 |
| Breast Cancer Res. Gen. 1024                            | 1.1  | 0.5 |
| Breast Cancer Clontech 9100266                          | 6.2  | 3.5 |
| Breast NAT Clontech 9100265                             | 5.2  | 4   |
| Breast Cancer INVITROGEN A209073                        | 0.9  | 0.7 |
| Breast NAT INVITROGEN A2090734                          | 2    | 1.2 |
| Normal Liver GENPAK 061009                              | 5.9  | 1.7 |
| Liver Cancer GENPAK 064003                              | 0    | 0   |
| Liver Cancer Research Genetics RNA 1025                 | 0.2  | 0.2 |
| Liver Cancer Research Genetics RNA 1026                 | 0    | 0   |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 0.4  | 0   |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 0    | 0   |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 0    | 0   |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0    | 0   |
| Normal Bladder GENPAK 061001                            | 0.3  | 0.2 |
| Bladder Cancer Research Genetics RNA 1023               | 3.9  | 2.8 |
| Bladder Cancer INVITROGEN A302173                       | 1.5  | 1.2 |
| 87071 Bladder Cancer (OD04718-01)                       | 0.1  | 0   |
| 87072 Bladder Normal Adjacent (OD04718-03)              | 6.2  | 4.6 |
| Normal Ovary Res. Gen.                                  | 0    | 0   |
| Ovarian Cancer GENPAK 064008                            | 1    | 1.2 |
| 87492 Ovary Cancer (OD04768-07)                         | 0    | 0   |
| 87493 Ovary NAT (OD04768-08)                            | 0    | 0   |
| Normal Stomach GENPAK 061017                            | 1.2  | 1.7 |
| Gastric Cancer Clontech 9060358                         | 0    | 0   |
| NAT Stomach Clontech 9060359                            | 0.2  | 0.4 |
| Gastric Cancer Clontech 9060395                         | 1.1  | 1.1 |
| NAT Stomach Clontech 9060394                            | 0.4  | 0.3 |

|                                 |     |     |
|---------------------------------|-----|-----|
| Gastric Cancer Clontech 9060397 | 0.2 | 0.3 |
| NAT Stomach Clontech 9060396    | 0   | 0   |
| Gastric Cancer GENPAK 064005    | 1   | 1.9 |

**NOV5**

Expression of gene NOV5 was assessed using the primer-probe set Ag819, described  
 5 in Table 23. Results from RTQ-PCR runs are shown in Tables 12, 13, 14, 15 and 16.

**Table 23. Probe and Primer Ag819**

| Primers | Sequences                                          | TM   | Length | Start Position | SEQ ID NO: |
|---------|----------------------------------------------------|------|--------|----------------|------------|
| Forward | 5'-GGTCCAACAGGGCTATCAAT-3'                         | 58.9 | 20     | 1105           | 65         |
| Probe   | TET-5'-<br>CCAAACCACGACTGTCGTAGCAGGTA-3'-<br>TAMRA | 69.1 | 26     | 1156           | 66         |
| Reverse | 5'-<br>GCACCTATCTCAATATCTGCAATATTG-3'              | 59.5 | 21     | 1182           | 67         |

10

**Table 24. Panel 1.2**

| Tissue Name                   | Rel. Expr., %<br>1.2tm959t ag819 | Rel. Expr., %<br>1.2tm1100t ag819 |
|-------------------------------|----------------------------------|-----------------------------------|
| Endothelial cells             | 0                                | 0                                 |
| Heart (fetal)                 | 0.4                              | 0.8                               |
| Pancreas                      | 43.8                             | 48.3                              |
| Pancreatic ca. CAPAN 2        | 8.1                              | 17.9                              |
| Adrenal Gland (new lot*)      | 0.2                              | 0.2                               |
| Thyroid                       | 11.8                             | 12.9                              |
| Salivary gland                | 63.3                             | 63.7                              |
| Pituitary gland               | 0.9                              | 0.5                               |
| Brain (fetal)                 | 37.1                             | 41.5                              |
| Brain (whole)                 | 4.6                              | 6.3                               |
| Brain (amygdala)              | 1.5                              | 2.3                               |
| Brain (cerebellum)            | 0.9                              | 1.5                               |
| Brain (hippocampus)           | 3.4                              | 4                                 |
| Brain (thalamus)              | 1.9                              | 2.6                               |
| Cerebral Cortex               | 1.2                              | 2.7                               |
| Spinal cord                   | 1.2                              | 1.9                               |
| CNS ca. (glio/astro) U87-MG   | 0                                | 0                                 |
| CNS ca. (glio/astro) U-118-MG | 0                                | 0                                 |
| CNS ca. (astro) SW1783        | 0                                | 0                                 |
| CNS ca.* (neuro; met) SK-N-AS | 0.3                              | 0                                 |
| CNS ca. (astro) SF-539        | 0                                | 0                                 |
| CNS ca. (astro) SNB-75        | 0                                | 0                                 |
| CNS ca. (glio) SNB-19         | 0                                | 0                                 |

|                                     |      |      |
|-------------------------------------|------|------|
| CNS ca. (glio) U251                 | 0    | 0.1  |
| CNS ca. (glio) SF-295               | 0    | 0    |
| Heart                               | 8.1  | 9.5  |
| Skeletal Muscle (new lot*)          | 2.6  | 3.7  |
| Bone marrow                         | 0.6  | 1.2  |
| Thymus                              | 0    | 0    |
| Spleen                              | 0.5  | 0    |
| Lymph node                          | 1.4  | 0.2  |
| Colorectal                          | 0.3  | 1.8  |
| Stomach                             | 10.7 | 23.3 |
| Small intestine                     | 10.4 | 18.9 |
| Colon ca. SW480                     | 0    | 0    |
| Colon ca.* (SW480 met)SW620         | 9    | 11.7 |
| Colon ca. HT29                      | 32.5 | 40.9 |
| Colon ca. HCT-116                   | 5.9  | 7.9  |
| Colon ca. CaCo-2                    | 100  | 100  |
| 83219 CC Well to Mod Diff (ODO3866) | 4.7  | 5.4  |
| Colon ca. HCC-2998                  | 2.5  | 3    |
| Gastric ca.* (liver met) NCI-N87    | 0    | 0.2  |
| Bladder                             | 39.2 | 49.7 |
| Trachea                             | 29.7 | 34.4 |
| Kidney                              | 27.4 | 25.7 |
| Kidney (fetal)                      | 17.7 | 19.1 |
| Renal ca. 786-0                     | 0    | 0    |
| Renal ca. A498                      | 0    | 0    |
| Renal ca. RXF 393                   | 0    | 0    |
| Renal ca. ACHN                      | 0    | 0    |
| Renal ca. UO-31                     | 1    | 1.6  |
| Renal ca. TK-10                     | 0    | 0    |
| Liver                               | 8    | 3.3  |
| Liver (fetal)                       | 2.8  | 2.7  |
| Liver ca. (hepatoblast) HepG2       | 12.8 | 20.2 |
| Lung                                | 5.7  | 4.2  |
| Lung (fetal)                        | 9.5  | 7.4  |
| Lung ca. (small cell) LX-1          | 39   | 33.4 |
| Lung ca. (small cell) NCI-H69       | 7.4  | 10.5 |
| Lung ca. (s.cell var.) SHP-77       | 0.5  | 0.6  |
| Lung ca. (large cell)NCI-H460       | 0    | 0    |
| Lung ca. (non-sm. cell) A549        | 0    | 0.1  |
| Lung ca. (non-s.cell) NCI-H23       | 0    | 0    |
| Lung ca (non-s.cell) HOP-62         | 0    | 0.2  |
| Lung ca. (non-s.cl) NCI-H522        | 0    | 0    |
| Lung ca. (squam.) SW 900            | 0.6  | 0.8  |
| Lung ca. (squam.) NCI-H596          | 14.6 | 22.1 |
| Mammary gland                       | 33   | 46.3 |
| Breast ca.* (pl. effusion) MCF-7    | 0    | 0    |
| Breast ca.* (pl.ef) MDA-MB-231      | 0    | 0    |
| Breast ca.* (pl. effusion) T47D     | 0.8  | 1.3  |
| Breast ca. BT-549                   | 0    | 0    |
| Breast ca. MDA-N                    | 0.4  | 0.6  |

|                                |  |      |      |
|--------------------------------|--|------|------|
| Ovary                          |  | 4.6  | 0.2  |
| Ovarian ca. OVCAR-3            |  | 3.3  | 4    |
| Ovarian ca. OVCAR-4            |  | 27.9 | 54   |
| Ovarian ca. OVCAR-5            |  | 37.4 | 51   |
| Ovarian ca. OVCAR-8            |  | 0    | 0    |
| Ovarian ca. IGROV-1            |  | 3.2  | 5.5  |
| Ovarian ca.* (ascites) SK-OV-3 |  | 0    | 0    |
| Uterus                         |  | 1.4  | 1.2  |
| Placenta                       |  | 23.2 | 22.5 |
| Prostate                       |  | 2.6  | 2.7  |
| Prostate ca.* (bone met)PC-3   |  | 0    | 0    |
| Testis                         |  | 19.8 | 21.9 |
| Melanoma Hs688(A).T            |  | 1.7  | 0    |
| Melanoma* (met) Hs688(B).T     |  | 0.7  | 0    |
| Melanoma UACC-62               |  | 1.8  | 1.7  |
| Melanoma M14                   |  | 0    | 0.2  |
| Melanoma LOX IMVI              |  | 0    | 0    |
| Melanoma* (met) SK-MEL-5       |  | 0.5  | 1    |
| Adipose                        |  | 0.1  | 0.2  |

Table 25. Panel 2D

| Tissue Name                                 | Rel. Expr., %<br>2Dtm2318t ag819 | Rel. Expr., %<br>2Dtm2649t ag819 |
|---------------------------------------------|----------------------------------|----------------------------------|
| Normal Colon GENPAK 061003                  | 17                               | 20.7                             |
| 83219 CC Well to Mod Diff (ODO3866)         | 0.9                              | 5.3                              |
| 83220 CC NAT (ODO3866)                      | 9.5                              | 6                                |
| 83221 CC Gr.2 rectosigmoid (ODO3868)        | 5.8                              | 3.9                              |
| 83222 CC NAT (ODO3868)                      | 0                                | 0.2                              |
| 83235 CC Mod Diff (ODO3920)                 | 0.7                              | 0.9                              |
| 83236 CC NAT (ODO3920)                      | 2.8                              | 2.1                              |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 26.2                             | 37.4                             |
| 83238 CC NAT (ODO3921)                      | 4.4                              | 7                                |
| 83241 CC from Partial Hepatectomy (ODO4309) | 13.1                             | 20.4                             |
| 83242 Liver NAT (ODO4309)                   | 0.1                              | 0.2                              |
| 87472 Colon mets to lung (OD04451-01)       | 8.5                              | 6.2                              |
| 87473 Lung NAT (OD04451-02)                 | 2.1                              | 1.7                              |
| Normal Prostate Clontech A+ 6546-1          | 1.2                              | 0.3                              |
| 84140 Prostate Cancer (OD04410)             | 0.5                              | 0.7                              |
| 84141 Prostate NAT (OD04410)                | 0.8                              | 0.6                              |
| 87073 Prostate Cancer (OD04720-01)          | 0.4                              | 0.4                              |
| 87074 Prostate NAT (OD04720-02)             | 2                                | 2                                |
| Normal Lung GENPAK 061010                   | 4.6                              | 4.7                              |
| 83239 Lung Met to Muscle (ODO4286)          | 0                                | 0                                |
| 83240 Muscle NAT (ODO4286)                  | 0.2                              | 0.3                              |
| 84136 Lung Malignant Cancer (OD03126)       | 8.7                              | 6.5                              |
| 84137 Lung NAT (OD03126)                    | 1.4                              | 1.6                              |

|                                             |      |      |
|---------------------------------------------|------|------|
| 84871 Lung Cancer (OD04404)                 | 0    | 0.2  |
| 84872 Lung NAT (OD04404)                    | 3.1  | 1.2  |
| 84875 Lung Cancer (OD04565)                 | 0.2  | 0    |
| 84876 Lung NAT (OD04565)                    | 1    | 0.9  |
| 85950 Lung Cancer (OD04237-01)              | 100  | 74.7 |
| 85970 Lung NAT (OD04237-02)                 | 1.7  | 1.5  |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 0.1  | 0.3  |
| 83256 Liver NAT (ODO4310)                   | 0.6  | 0.2  |
| 84139 Melanoma Mets to Lung (OD04321)       | 14.8 | 12.2 |
| 84138 Lung NAT (OD04321)                    | 1.7  | 1.5  |
| Normal Kidney GENPAK 061008                 | 23.2 | 17.4 |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)  | 4.2  | 5.1  |
| 83787 Kidney NAT (OD04338)                  | 8    | 11.3 |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339) | 65.5 | 69.3 |
| 83789 Kidney NAT (OD04339)                  | 6.7  | 6    |
| 83790 Kidney Ca, Clear cell type (OD04340)  | 0    | 0.1  |
| 83791 Kidney NAT (OD04340)                  | 13.8 | 12   |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)  | 0    | 0    |
| 83793 Kidney NAT (OD04348)                  | 9.2  | 6.2  |
| 87474 Kidney Cancer (OD04622-01)            | 0.7  | 0.4  |
| 87475 Kidney NAT (OD04622-03)               | 1.1  | 1.2  |
| 85973 Kidney Cancer (OD04450-01)            | 32.5 | 24.5 |
| 85974 Kidney NAT (OD04450-03)               | 22.1 | 16   |
| Kidney Cancer Clontech 8120607              | 4.4  | 4.2  |
| Kidney NAT Clontech 8120608                 | 3.9  | 2    |
| Kidney Cancer Clontech 8120613              | 0    | 0    |
| Kidney NAT Clontech 8120614                 | 1.2  | 0.8  |
| Kidney Cancer Clontech 9010320              | 7.7  | 8    |
| Kidney NAT Clontech 9010321                 | 7.8  | 6    |
| Normal Uterus GENPAK 061018                 | 0    | 0    |
| Uterus Cancer GENPAK 064011                 | 24.1 | 18.8 |
| Normal Thyroid Clontech A+ 6570-1           | 4.7  | 2.4  |
| Thyroid Cancer GENPAK 064010                | 4    | 2.2  |
| Thyroid Cancer INVITROGEN A302152           | 0    | 0    |
| Thyroid NAT INVITROGEN A302153              | 2.9  | 2.7  |
| Normal Breast GENPAK 061019                 | 16.6 | 7.4  |
| 84877 Breast Cancer (OD04566)               | 0.6  | 0.4  |
| 85975 Breast Cancer (OD04590-01)            | 0.8  | 0.5  |
| 85976 Breast Cancer Mets (OD04590-03)       | 0    | 0    |
| 87070 Breast Cancer Metastasis (OD04655-05) | 0.1  | 0    |
| GENPAK Breast Cancer 064006                 | 15.7 | 11.7 |
| Breast Cancer Res. Gen. 1024                | 12.1 | 11.6 |
| Breast Cancer Clontech 9100266              | 1.2  | 0.6  |
| Breast NAT Clontech 9100265                 | 3    | 2    |
| Breast Cancer INVITROGEN A209073            | 6.5  | 4.6  |
| Breast NAT INVITROGEN A2090734              | 25   | 9    |
| Normal Liver GENPAK 061009                  | 0.6  | 0.5  |
| Liver Cancer GENPAK 064003                  | 0    | 0    |
| Liver Cancer Research Genetics RNA 1025     | 0.2  | 0.3  |
| Liver Cancer Research Genetics RNA 1026     | 0.2  | 0.1  |

|                                                         |      |      |
|---------------------------------------------------------|------|------|
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 0.2  | 0.1  |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 1.6  | 1.7  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 0.1  | 0.2  |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0    | 0.2  |
| Normal Bladder GENPAK 061001                            | 14.8 | 18.7 |
| Bladder Cancer Research Genetics RNA 1023               | 6.9  | 6.4  |
| Bladder Cancer INVITROGEN A302173                       | 0.2  | 0.1  |
| 87071 Bladder Cancer (OD04718-01)                       | 0.1  | 0    |
| 87072 Bladder Normal Adjacent (OD04718-03)              | 0.2  | 0.4  |
| Normal Ovary Res. Gen.                                  | 0    | 0    |
| Ovarian Cancer GENPAK 064008                            | 68.8 | 100  |
| 87492 Ovary Cancer (OD04768-07)                         | 0.5  | 1    |
| 87493 Ovary NAT (OD04768-08)                            | 0    | 0.1  |
| Normal Stomach GENPAK 061017                            | 5    | 4.5  |
| Gastric Cancer Clontech 9060358                         | 2.5  | 2.6  |
| NAT Stomach Clontech 9060359                            | 5.6  | 7    |
| Gastric Cancer Clontech 9060395                         | 1.7  | 1.3  |
| NAT Stomach Clontech 9060394                            | 3.4  | 6.4  |
| Gastric Cancer Clontech 9060397                         | 26.1 | 39.8 |
| NAT Stomach Clontech 9060396                            | 2.7  | 2.7  |
| Gastric Cancer GENPAK 064005                            | 15.5 | 22.1 |

## NOV6

Expression of gene NOV6 was assessed using the primer-probe set Ag1395, described  
 5 in Table 26. Results from RTQ-PCR runs are shown in Tables 12, 13, 14, 15 and 16.

**Table 26. Primer and Probe Ag1395**

| Primers | Sequences                                          | TM   | Length | Start Position | SEQ ID NO: |
|---------|----------------------------------------------------|------|--------|----------------|------------|
| Forward | 5'-CCTCCTGCAGGATAAAGTCAT-3'                        | 58.3 | 21     | 1518           | 68         |
| Probe   | TET-5'-<br>CCCCAAGGCTCCAGCTACTCTAAATT<br>-3'-TAMRA | 66.6 | 26     | 1539           | 69         |
| Reverse | 5'-CTCCTGGAGCAGCAATAACTTA-3'                       | 58.7 | 22     | 1577           | 70         |

10

**Table 27. Panel 1.2**

| Tissue Name            | Rel. Expr., %<br>1.2tm1618t ag1389 | Rel. Expr., %<br>1.2tm1729t ag1389* |
|------------------------|------------------------------------|-------------------------------------|
| Endothelial cells      | 0                                  | 0                                   |
| Heart (fetal)          | 3.4                                | 6.8                                 |
| Pancreas               | 2.4                                | 0.5                                 |
| Pancreatic ca. CAPAN 2 | 0                                  | 0                                   |

|                                     |      |      |
|-------------------------------------|------|------|
| Adrenal Gland (new lot*)            | 33.9 | 15.6 |
| Thyroid                             | 2    | 0.5  |
| Salivary gland                      | 8.7  | 3.3  |
| Pituitary gland                     | 3.9  | 1.7  |
| Brain (fetal)                       | 0.2  | 0.1  |
| Brain (whole)                       | 12.6 | 0.4  |
| Brain (amygdala)                    | 0.5  | 0.5  |
| Brain (cerebellum)                  | 4    | 1.6  |
| Brain (hippocampus)                 | 0.4  | 0.9  |
| Brain (thalamus)                    | 0.2  | 0.4  |
| Cerebral Cortex                     | 2.3  | 3.3  |
| Spinal cord                         | 0.2  | 0.1  |
| CNS ca. (glio/astro) U87-MG         | 0    | 0    |
| CNS ca. (glio/astro) U-118-MG       | 0    | 0    |
| CNS ca. (astro) SW1783              | 1.2  | 1    |
| CNS ca.* (neuro; met ) SK-N-AS      | 0.5  | 0.1  |
| CNS ca. (astro) SF-539              | 3.8  | 3.1  |
| CNS ca. (astro) SNB-75              | 0    | 0    |
| CNS ca. (glio) SNB-19               | 0    | 0    |
| CNS ca. (glio) U251                 | 0    | 0    |
| CNS ca. (glio) SF-295               | 0    | 0.3  |
| Heart                               | 6.7  | 29.5 |
| Skeletal Muscle (new lot*)          | 3.6  | 9.2  |
| Bone marrow                         | 0.3  | 0.5  |
| Thymus                              | 0.7  | 0.2  |
| Spleen                              | 3.4  | 2.3  |
| Lymph node                          | 0.6  | 0.2  |
| Colorectal                          | 0.3  | 0.5  |
| Stomach                             | 4.1  | 1.8  |
| Small intestine                     | 18.9 | 17.1 |
| Colon ca. SW480                     | 0    | 0.3  |
| Colon ca.* (SW480 met)SW620         | 1.8  | 1.9  |
| Colon ca. HT29                      | 0    | 0    |
| Colon ca. HCT-116                   | 0.2  | 0.2  |
| Colon ca. CaCo-2                    | 0.2  | 0.2  |
| 83219 CC Well to Mod Diff (ODO3866) | 5.2  | 2.3  |
| Colon ca. HCC-2998                  | 1    | 1.5  |
| Gastric ca.* (liver met) NCI-N87    | 13.8 | 6.2  |
| Bladder                             | 12.2 | 15.5 |
| Trachea                             | 0.8  | 0.5  |
| Kidney                              | 6.1  | 9.8  |
| Kidney (fetal)                      | 0.5  | 1.8  |
| Renal ca. 786-0                     | 0    | 0    |
| Renal ca. A498                      | 0.1  | 0.2  |
| Renal ca. RXF 393                   | 4.5  | 6.8  |
| Renal ca. ACHN                      | 0    | 0.2  |
| Renal ca. UO-31                     | 2.4  | 7    |
| Renal ca. TK-10                     | 1.2  | 2.1  |
| Liver                               | 3.5  | 10.9 |
| Liver (fetal)                       | 2.9  | 5.3  |



|                                  |      |      |
|----------------------------------|------|------|
| Liver ca. (hepatoblast) HepG2    | 2.6  | 1.8  |
| Lung                             | 0.7  | 0.4  |
| Lung (fetal)                     | 0.9  | 2.8  |
| Lung ca. (small cell) LX-1       | 4.8  | 6.5  |
| Lung ca. (small cell) NCI-H69    | 0.1  | 0.2  |
| Lung ca. (s.cell var.) SHP-77    | 0    | 0    |
| Lung ca. (large cell) NCI-H460   | 0.7  | 1.6  |
| Lung ca. (non-sm. cell) A549     | 0.2  | 0.4  |
| Lung ca. (non-s.cell) NCI-H23    | 1.3  | 3.4  |
| Lung ca. (non-s.cell) HOP-62     | 1.9  | 10.6 |
| Lung ca. (non-s.cl) NCI-H522     | 1.4  | 3.2  |
| Lung ca. (squamous) SW 900       | 0.5  | 0.8  |
| Lung ca. (squamous) NCI-H596     | 0    | 0    |
| Mammary gland                    | 76.8 | 7.3  |
| Breast ca.* (pl. effusion) MCF-7 | 0.5  | 0.2  |
| Breast ca.* (pl.ef) MDA-MB-231   | 0.5  | 0.4  |
| Breast ca.* (pl. effusion) T47D  | 0.3  | 0.2  |
| Breast ca. BT-549                | 100  | 55.9 |
| Breast ca. MDA-N                 | 0.2  | 0.3  |
| Ovary                            | 11.1 | 19.9 |
| Ovarian ca. OVCAR-3              | 0.1  | 0.3  |
| Ovarian ca. OVCAR-4              | 0    | 0    |
| Ovarian ca. OVCAR-5              | 0.6  | 0.7  |
| Ovarian ca. OVCAR-8              | 4.1  | 1.7  |
| Ovarian ca. IGROV-1              | 0.1  | 0    |
| Ovarian ca.* (ascites) SK-OV-3   | 1.2  | 1.4  |
| Uterus                           | 13   | 19.8 |
| Placenta                         | 3.9  | 1.3  |
| Prostate                         | 67.4 | 100  |
| Prostate ca.* (bone met) PC-3    | 0    | 0    |
| Testis                           | 0.5  | 0.2  |
| Melanoma Hs688(A).T              | 2.9  | 8.8  |
| Melanoma* (met) Hs688(B).T       | 1.1  | 3.1  |
| Melanoma UACC-62                 | 0.2  | 0.3  |
| Melanoma M14                     | 10.4 | 42.6 |
| Melanoma LOX IMVI                | 0.1  | 0.4  |
| Melanoma* (met) SK-MEL-5         | 0    | 0.1  |
| Adipose                          | 3.6  | 6.6  |

Table 28. Panel 2D

| Tissue Name                          | Rel. Expr., %<br>2Dtm2491t ag1389 | Rel. Expr., %<br>2Dtm2507t ag1389 |
|--------------------------------------|-----------------------------------|-----------------------------------|
| Normal Colon GENPAK 061003           | 1                                 | 1.8                               |
| 83219 CC Well to Mod Diff (ODO3866)  | 1.6                               | 3.1                               |
| 83220 CC NAT (ODO3866)               | 0.5                               | 0.5                               |
| 83221 CC Gr.2 rectosigmoid (ODO3868) | 0.4                               | 0.6                               |

|                                             |      |      |
|---------------------------------------------|------|------|
| 83222 CC NAT (ODO3868)                      | 0.2  | 0.2  |
| 83235 CC Mod Diff (ODO3920)                 | 0.3  | 0.3  |
| 83236 CC NAT (ODO3920)                      | 0.4  | 0.5  |
| 83237 CC Gr.2 ascend colon (ODO3921)        | 1.7  | 1.4  |
| 83238 CC NAT (ODO3921)                      | 0.7  | 0.5  |
| 83241 CC from Partial Hepatectomy (ODO4309) | 1.1  | 0.5  |
| 83242 Liver NAT (ODO4309)                   | 0.8  | 0.5  |
| 87472 Colon mets to lung (OD04451-01)       | 0.2  | 0.2  |
| 87473 Lung NAT (OD04451-02)                 | 0.2  | 0.4  |
| Normal Prostate Clontech A+ 6546-1          | 4.9  | 36.6 |
| 84140 Prostate Cancer (OD04410)             | 100  | 100  |
| 84141 Prostate NAT (OD04410)                | 14.9 | 10.9 |
| 87073 Prostate Cancer (OD04720-01)          | 1.1  | 1    |
| 87074 Prostate NAT (OD04720-02)             | 2.9  | 2    |
| Normal Lung GENPAK 061010                   | 0.6  | 0.7  |
| 83239 Lung Met to Muscle (ODO4286)          | 0.3  | 0.1  |
| 83240 Muscle NAT (ODO4286)                  | 0.3  | 0.5  |
| 84136 Lung Malignant Cancer (OD03126)       | 1.9  | 1.4  |
| 84137 Lung NAT (OD03126)                    | 0.7  | 0.7  |
| 84871 Lung Cancer (OD04404)                 | 0.8  | 0.5  |
| 84872 Lung NAT (OD04404)                    | 0.7  | 1.5  |
| 84875 Lung Cancer (OD04565)                 | 0.5  | 0.4  |
| 84876 Lung NAT (OD04565)                    | 0.1  | 0.3  |
| 85950 Lung Cancer (OD04237-01)              | 2.2  | 2.5  |
| 85970 Lung NAT (OD04237-02)                 | 0.9  | 1.4  |
| 83255 Ocular Mel Met to Liver (ODO4310)     | 0    | 0    |
| 83256 Liver NAT (ODO4310)                   | 1.1  | 0.6  |
| 84139 Melanoma Mets to Lung (OD04321)       | 0.8  | 0.3  |
| 84138 Lung NAT (OD04321)                    | 1.5  | 0.4  |
| Normal Kidney GENPAK 061008                 | 0.8  | 0.4  |
| 83786 Kidney Ca, Nuclear grade 2 (OD04338)  | 7    | 3.7  |
| 83787 Kidney NAT (OD04338)                  | 0.8  | 0.4  |
| 83788 Kidney Ca Nuclear grade 1/2 (OD04339) | 2.6  | 5.9  |
| 83789 Kidney NAT (OD04339)                  | 0.4  | 0.5  |
| 83790 Kidney Ca, Clear cell type (OD04340)  | 0.7  | 0.5  |
| 83791 Kidney NAT (OD04340)                  | 0.6  | 0.9  |
| 83792 Kidney Ca, Nuclear grade 3 (OD04348)  | 0.4  | 0.3  |
| 83793 Kidney NAT (OD04348)                  | 0.6  | 0.5  |
| 87474 Kidney Cancer (OD04622-01)            | 8.5  | 8.4  |
| 87475 Kidney NAT (OD04622-03)               | 0.2  | 0.2  |
| 85973 Kidney Cancer (OD04450-01)            | 10.7 | 5.1  |
| 85974 Kidney NAT (OD04450-03)               | 0.5  | 0.3  |
| Kidney Cancer Clontech 8120607              | 0.2  | 0.2  |
| Kidney NAT Clontech 8120608                 | 0.4  | 0.3  |
| Kidney Cancer Clontech 8120613              | 0.4  | 0.3  |
| Kidney NAT Clontech 8120614                 | 0.4  | 0.2  |
| Kidney Cancer Clontech 9010320              | 1.7  | 5    |
| Kidney NAT Clontech 9010321                 | 2.1  | 3.3  |
| Normal Uterus GENPAK 061018                 | 2    | 1.6  |
| Uterus Cancer GENPAK 064011                 | 1.6  | 1.2  |

|                                                         |     |      |
|---------------------------------------------------------|-----|------|
| Normal Thyroid Clontech A+ 6570-1                       | 0.3 | 1.8  |
| Thyroid Cancer GENPAK 064010                            | 0   | 0    |
| Thyroid Cancer INVITROGEN A302152                       | 0.1 | 0    |
| Thyroid NAT INVITROGEN A302153                          | 0.5 | 0.2  |
| Normal Breast GENPAK 061019                             | 1.8 | 1.4  |
| 84877 Breast Cancer (OD04566)                           | 0.2 | 0.4  |
| 85975 Breast Cancer (OD04590-01)                        | 1   | 2.2  |
| 85976 Breast Cancer Mets (OD04590-03)                   | 1.1 | 2.9  |
| 87070 Breast Cancer Metastasis (OD04655-05)             | 0.2 | 0.2  |
| GENPAK Breast Cancer 064006                             | 1   | 0.9  |
| Breast Cancer Res. Gen. 1024                            | 2   | 5.8  |
| Breast Cancer Clontech 9100266                          | 0.4 | 0.4  |
| Breast NAT Clontech 9100265                             | 0.9 | 1.1  |
| Breast Cancer INVITROGEN A209073                        | 1.3 | 1.4  |
| Breast NAT INVITROGEN A2090734                          | 0.9 | 0.5  |
| Normal Liver GENPAK 061009                              | 0.2 | 0.3  |
| Liver Cancer GENPAK 064003                              | 1.1 | 2.5  |
| Liver Cancer Research Genetics RNA 1025                 | 0.2 | 0.3  |
| Liver Cancer Research Genetics RNA 1026                 | 4.1 | 3.2  |
| Paired Liver Cancer Tissue Research Genetics RNA 6004-T | 0.4 | 1.5  |
| Paired Liver Tissue Research Genetics RNA 6004-N        | 0.6 | 1.7  |
| Paired Liver Cancer Tissue Research Genetics RNA 6005-T | 3.8 | 7.2  |
| Paired Liver Tissue Research Genetics RNA 6005-N        | 0.7 | 1.2  |
| Normal Bladder GENPAK 061001                            | 1.6 | 2.4  |
| Bladder Cancer Research Genetics RNA 1023               | 0.2 | 0.2  |
| Bladder Cancer INVITROGEN A302173                       | 0.2 | 0.1  |
| 87071 Bladder Cancer (OD04718-01)                       | 1   | 1.2  |
| 87072 Bladder Normal Adjacent (OD04718-03)              | 0.5 | 1.4  |
| Normal Ovary Res. Gen.                                  | 1   | 1.7  |
| Ovarian Cancer GENPAK 064008                            | 3.5 | 3    |
| 87492 Ovary Cancer (OD04768-07)                         | 0.1 | 0.4  |
| 87493 Ovary NAT (OD04768-08)                            | 1   | 1.2  |
| Normal Stomach GENPAK 061017                            | 0.3 | 0.8  |
| Gastric Cancer Clontech 9060358                         | 0.2 | 0.5  |
| NAT Stomach Clontech 9060359                            | 0.3 | 0.9  |
| Gastric Cancer Clontech 9060395                         | 1.1 | 2.7  |
| NAT Stomach Clontech 9060394                            | 1   | 1.6  |
| Gastric Cancer Clontech 9060397                         | 2.8 | 10.6 |
| NAT Stomach Clontech 9060396                            | 0.2 | 0.6  |
| Gastric Cancer GENPAK 064005                            | 0.9 | 2    |

**Example 2: SAGE analysis for NOVX**

Serial Analysis of Gene Expression, or SAGE, is an experimental technique designed to gain a quantitative measure of gene expression. The SAGE technique itself includes several steps utilizing molecular biological, DNA sequencing and bioinformatics techniques. These steps (reviewed in Adams MD, "Serial analysis of gene expression: ESTs get smaller." Bioessays. 18(4):261-2 (1996)) have been used to produce 9 or 10 base "tags", which are then, in some manner, assigned gene descriptions. For experimental reasons, these tags are immediately adjacent to the 3' end of the 3'-most NlaIII restriction site in cDNA sequences.

The Cancer Genome Anatomy Project, or CGAP, is an NCI-initiated and sponsored project, which hopes to delineate the molecular fingerprint of the cancer cell. It has created a database of those cancer-related projects that used SAGE analysis in order to gain insight into the initiation and development of cancer in the human body. The SAGE expression profiles reported in this invention are generated by first identifying the Unigene accession ID associated with the given MTC gene by querying the Unigene database at <http://www.ncbi.nlm.nih.gov/UniGene/>. This page has then a link to the SAGE : Gene to Tag mapping (<http://www.ncbi.nlm.nih.gov/SAGE/SAGEcid.cgi?cid='unigeneID'>).

This generated the reports that are included in this application, which list the number of tags found for the given gene in a given sample along with the relative expression. This information is then used to understand whether the gene has a more general role in tumorigenesis and/or tumor progression. A list of the SAGE libraries generated by CGAP and used in the analysis can be found at <http://www.ncbi.nlm.nih.gov/SAGE/sage1b.cgi>.

**NOV2 SAGE Data**

| CGAGAGGGAG                        |  | Tags per million | Tag counts | Total tags |
|-----------------------------------|--|------------------|------------|------------|
| Library name                      |  |                  |            |            |
| SAGE Duke BB542 normal cerebellum |  | 313              | 13         | 41450      |
| SAGE Duke cerebellum              |  | 434              | 3          | 6899       |
| SAGE Panc 91-18113                |  | 29               | 1          | 34159      |
| SAGE OVT-7                        |  | 18               | 1          | 55476      |
| SAGE normal cerebellum            |  | 399              | 18         | 45078      |
| SAGE Duke H1043                   |  | 25               | 2          | 77449      |
| GCATTTCGAG                        |  | Tags per million | Tag counts | Total tags |
| Library name                      |  |                  |            |            |
| SAGE normal pool(6th)             |  | 15               | 1          | 64138      |
| SAGE normal cerebellum            |  | 22               | 1          | 45079      |
| SAGE ML10-10                      |  | 17               | 1          | 57326      |
| SAGE IOSE28-11                    |  | 20               | 1          | 48876      |

**NOV3 SAGE Data**

SAGE library data and reliable tag summary:

Reliable tags found in SAGE libraries:

| CATAAAGACT | Library name                  | Tags per million | Tag counts | Total tags |
|------------|-------------------------------|------------------|------------|------------|
|            | <u>SAGE Duke thalamus</u>     | 40               | 1          | 24671      |
|            | <u>SAGE Chen LNCaP</u>        | 15               | 1          | 62681      |
|            | <u>SAGE Duke GBM H1110</u>    | 14               | 1          | 71138      |
|            | <u>SAGE SW837</u>             | 16               | 1          | 61280      |
|            | <u>SAGE Tu102</u>             | 17               | 1          | 58190      |
|            | <u>SAGE OVT-8</u>             | 23               | 1          | 43074      |
|            | <u>SAGE H1126</u>             | 56               | 1          | 17756      |
|            | <u>SAGE normal cerebellum</u> | 22               | 1          | 45079      |
|            | <u>SAGE OVT-8</u>             | 117              | 4          | 34096      |

**NOV4 SAGE Data**UniGene cluster: Hs.  Hs.255372 : hypothetical protein DKFZp564O1278SAGE library data and reliable tag summary:

Reliable tags found in SAGE libraries:

| <u>CTGAACCTGA</u> | <u>Library name</u>                     | <u>Tags per million</u> | <u>Tag counts</u> | <u>Total tags</u> |
|-------------------|-----------------------------------------|-------------------------|-------------------|-------------------|
|                   | <u>SAGE HCT116</u>                      | 16                      | 1                 | 60322             |
|                   | <u>SAGE Caco 2</u>                      | 16                      | 1                 | 61601             |
|                   | <u>SAGE Chen Tumor Pr</u>               | 14                      | 1                 | 68384             |
|                   | <u>SAGE HX</u>                          | 93                      | 3                 | 32157             |
|                   | <u>SAGE H126</u>                        | 185                     | 6                 | 32420             |
|                   | <u>SAGE Duke H392</u>                   | 17                      | 1                 | 57529             |
|                   | <u>SAGE SW837</u>                       | 16                      | 1                 | 80986             |
|                   | <u>SAGE RKO</u>                         | 96                      | 5                 | 52064             |
|                   | <u>SAGE PR317 normal prostate</u>       | 16                      | 1                 | 59419             |
|                   | <u>SAGE NC1</u>                         | 19                      | 1                 | 50115             |
|                   | <u>SAGE Tu98</u>                        | 61                      | 3                 | 49005             |
|                   | <u>SAGE SciencePark MCF7 Control 0h</u> | 16                      | 1                 | 61079             |
|                   | <u>SAGE LNCaP</u>                       | 44                      | 1                 | 22637             |
|                   | <u>SAGE OVT-7</u>                       | 18                      | 1                 | 54914             |
|                   | <u>SAGE MDA453</u>                      | 52                      | 1                 | 18924             |
|                   | <u>SAGE mammary epithelium</u>          | 20                      | 1                 | 49167             |
|                   | <u>SAGE OVT-8</u>                       | 29                      | 1                 | 33575             |
|                   | <u>SAGE Duke-H988</u>                   | 35                      | 1                 | 28015             |

Reliable tags **NOT** found in SAGE libraries:

## NOV5 SAGE Data

| TCAGATTC | Library name            | Tags per million | Tag counts | Total tags |
|----------|-------------------------|------------------|------------|------------|
|          | SAGE Caco 2             | 32               | 2          | 61898      |
|          | SAGE Duke GBM H1110     | 14               | 1          | 71138      |
|          | SAGE SW837              | 18               | 1          | 81280      |
|          | SAGE NHA(6th)           | 18               | 1          | 53218      |
|          | SAGE NC2                | 88               | 5          | 50128      |
|          | SAGE Panc 81-16113      | 58               | 2          | 34158      |
|          | SAGE Panc 88-8252       | 27               | 1          | 38087      |
|          | SAGE Tu102              | 34               | 2          | 58180      |
|          | SAGE Tu88               | 40               | 2          | 48527      |
|          | SAGE Duke H341          | 66               | 3          | 44883      |
|          | SAGE OVT-8              | 23               | 1          | 43074      |
|          | SAGE OVT-7              | 18               | 1          | 55476      |
|          | SAGE mammary epithelium | 40               | 2          | 48782      |
|          | SAGE DCIS               | 144              | 8          | 41540      |
|          | SAGE OVT-8              | 58               | 2          | 34088      |
|          | SAGE Duke 88-348        | 705              | 4          | 5668       |
|          | SAGE Duke H988          | 35               | 1          | 28103      |
|          | SAGE DCIS 2             | 34               | 1          | 29201      |
|          | SAGE Br N               | 28               | 1          | 38274      |
|          | SAGE Duke H1043         | 12               | 1          | 77449      |

## OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting  
5 with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the  
10 embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.



**WHAT IS CLAIMED IS:**

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, and 12; and
  - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, and 12.
3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11.
4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12;
  - (d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, and 12, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
  - (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 12, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
  - (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.
7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.
8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11.

9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11;
  - (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, and 11, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
  - (c) a nucleic acid fragment of (a); and
  - (d) a nucleic acid fragment of (b).
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting SEQ ID NOS:1, 3, 5, 7, 9, and 11, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
  - (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
  - (b) an isolated second polynucleotide that is a complement of the first polynucleotide; and
  - (c) a nucleic acid fragment of (a) or (b).
12. A vector comprising the nucleic acid molecule of claim 11.
13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. A cell comprising the vector of claim 12.
15. An antibody that binds immunospecifically to the polypeptide of claim 1.

16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
  - (a) providing the sample;
  - (b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
  - (c) determining the presence or amount of antibody bound to said polypeptide,thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
  - (a) providing the sample;
  - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
  - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. The method of claim 20 wherein the cell or tissue type is cancerous.
22. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising:
  - (a) contacting said polypeptide with said agent; and
  - (b) determining whether said agent binds to said polypeptide.
23. The method of claim 22 wherein the agent is a cellular receptor or a downstream effector.

24. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising:
- (a) providing a cell expressing said polypeptide;
  - (b) contacting the cell with said agent, and
  - (c) determining whether the agent modulates expression or activity of said polypeptide,
- whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.
25. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
26. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
27. The method of claim 26 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.
28. The method of claim 26 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
29. The method of claim 26, wherein said subject is a human.
30. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 5 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
31. The method of claim 30 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.

32. The method of claim 30 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
33. The method of claim 30, wherein said subject is a human.
34. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 15 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
35. The method of claim 34 wherein the disorder is diabetes.
36. The method of claim 34 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
37. The method of claim 34, wherein the subject is a human.
38. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
39. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
41. A kit comprising in one or more containers, the pharmaceutical composition of claim 38.
42. A kit comprising in one or more containers, the pharmaceutical composition of claim 39.

43. A kit comprising in one or more containers, the pharmaceutical composition of claim 40.
44. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
- (a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
  - (b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease;
- wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
45. The method of claim 44 wherein the predisposition is to a cancer.
46. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
  - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
47. The method of claim 46 wherein the predisposition is to a cancer.

48. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 10, and 12, or a biologically active fragment thereof.
49. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.
50. The method of claim 49, wherein the pathological state is cancer related.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**